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Abstract 
Aggrecan is one of the most abundant components of the articular cartilage 
matrix and its degradation by aggrecanases is considered to be a key early event 
in the development of osteoarthritis.  This study investigates whether the 
extracellular level of ADAMTS-4 (a disintegrin and metalloproteinase with 
thrombospondin type 1 motifs-4), one of the most studied aggrecanases, can be 
regulated by receptor-mediated endocytosis.   
 
Exogenously-added ADAMTS-4 disappeared from the medium of HTB94 cells 
and TCA-soluble degradation products of ADAMTS-4 increased in the medium 
over time.  Fluorescent-labeled ADAMTS-4 could be detected within the cell by 
confocal microscopy.  ADAMTS-4 clearance by HTB94 cells and chondrocytes 
could be inhibited by more than 70 % by heparin and another sulfated glycan, 
calcium pentosan polysulfate, suggesting that the cellular uptake of ADAMTS-4 
was via a mechanism involving cell surface heparan sulfate proteoglycans 
(HSPGs).  GM6001 also inhibited ADAMTS-4 clearance by 50 %, suggesting that 
cell surface metalloprotease-mediated degradation played a contributory role.  
However, ADAMTS-4 clearance was reduced by 50 % in a HSPG-deficient cell 
line compared to wild-type cells, further supporting a HSPG-dependent 
mechanism of ADAMTS-4 cellular uptake and preliminary studies using Timp-3-
null fibroblasts suggest that ADAMTS-4 may be endocytosed in a complex with 
TIMP-3.  In HTB94 cells and chondrocytes, the appearance of TCA-soluble 
degradation products was also inhibited by at least 50 % by receptor-associated 
protein (RAP), an antagonist for members of the low-density lipoprotein receptor 
(LDL-R) family. However, siRNA knockdown of LDL-receptor-related protein 
(LRP-1), a member of the LDL-R family, in HTB94 cells and the use of an LRP-1-
deficient cell line had no affect on the clearance of ADAMTS-4.  These results 
suggest that another member of the LDL-R family may be involved.  Taken 
together, this research has revealed a novel RAP-sensitive and/or HSPG-
sensitive mechanism of ADAMTS-4 regulation which may have a role in the 
degradation of the cartilage matrix.   
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Introduction 
The ADAMTSs (a disintegrin and metalloproteinase with thrombospondin motifs) 
are a group of 19 secreted proteases.  Since their discovery in 1997, the function 
of many of these proteases remains largely unknown, although several members 
of the ADAMTS family have been named aggrecanases due to their ability to 
cleave the proteoglycan aggrecan at several sites.  Aggrecan is one of the most 
abundant components of the articular cartilage matrix and its degradation is 
considered to be a key early event in the development of osteoarthritis.  The 
activity of ADAMTS-4, one of the most studied aggrecanases, can be regulated 
in several ways, including transcriptional regulation, prodomain removal, C-
terminal processing and by endogenous tissue inhibitor of metalloproteinase-3 
(TIMP-3).   A further mechanism which may serve to control ADAMTS-4 activity 
is receptor-mediated endocytosis.  Endocytosis of ADAMTS-4 would reduce its 
activity in the matrix by promoting intracellular degradation.  The aim of this 
thesis was to investigate whether the extracellular level of ADAMTS-4 is 
regulated by endocytic clearance.  This work may identify a further mechanism 
regulating ADAMTS-4 activity in the cartilage matrix which could also be 
applicable to other substrates of ADAMTS-4.     
 
This chapter reviews the structure and function of the cartilage matrix before 
describing the enzymes involved in cartilage matrix degradation and the 
mechanisms known to regulate their activity.   
 
1.1. Articular cartilage composition 
Cartilage is a tissue which is aneural, avascular and alymphatic (Mankin and 
Lippiello, 1970).  There are 3 types of cartilage found within the body:  elastic, 
hyaline and fibrocartilage.  Each type of cartilage is classified according to its 
exact biochemical composition.  Elastic cartilage is rich in elastin and is found in 
the ear and epiglottis, where it provides a rigid but flexible framework.  
Fibrocartilage is very rigid due to the abundance of type 1 collagen and is found 
within intervertebral discs and where tendons and ligaments connect to bones.   
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Hyaline cartilage is found in the nose, larynx, between the ribs and the sternum 
and also in articular cartilage lining the surface of synovial joints such as the 
knee or hip.  The role of articular cartilage is to provide a framework for bone 
deposition and a smooth surface for the frictionless movement of articulating 
joints.  Additionally, articular cartilage has the ability to compress and in doing so 
can effectively absorb and distribute loads. 
 
Articular cartilage consists of chondrocytes and an extensive extracellular matrix 
(ECM).  The chondrocytes are relatively sparse in number, constituting less than 
2 % of its total volume.  They are the only cell type found in cartilage and they 
are responsible for synthesizing and degrading components of the ECM.  The 
matrix consists of 65-80 % water, 10-30 % collagen, 5-10 % proteoglycans 
(Walsh et al., 1997).  Type II collagen is the most abundant collagen and its 
function is to provide articular cartilage with tensile strength.  Aside from type II 
collagen, collagens VI, IX, X and XI are also cartilage specific (Martel-Pelletier et 
al., 2008).  Proteoglycans consist of a core protein covalently attached to one or 
more glycosaminoglycan (GAG) chain.  GAG chains are long unbranched 
polymers consisting of repeating disaccharides; an amino sugar N-
acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc) and an uronic 
acid (glucuronic acid, GlcA, or iduronic acid, IdoA) (Varki et al., 2002).  The major 
GAGs are chondroitin sulfate (CS), keratan sulfate (KS), heparin, heparan sulfate 
(HS), dermatan sulfate (DS) and hylauronan (HA).  Each GAG differs in the type 
and arrangement of their disaccharide units.  For example, CS is composed of 
alternating GalNAc and GlcA disaccharides, whereas the most common 
disaccharide unit within HS is composed of GlcNAc and GlcA.  At least one of the 
sugars in the repeating unit has a negatively charged sulfate or carboxylate 
group and therefore each GAG chain bears many negative charges.  It is this 
feature of cartilage which draws in water from the surrounding areas to maintain 
a hydrated matrix and enable it to withstand compression.  The major 
proteoglycan found in cartilage is aggrecan, although the matrix also contains 
other proteoglycans which play important roles in its assembly and function.     
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Aggrecan is composed of a core protein with KS and CS polysaccharide chains 
attached (Figure 1).  The core protein is approximately 230 kDa and contains 3 
globular domains: G1, G2 and G3 (Doege et al., 1991).  Two globular domains 
(G1 and G2) are located towards the N-terminus and a third globular domain 
(G3) is located towards the C-terminus.  Up to 100 aggrecan monomers can bind 
to hyaluronan via the G1 domain of aggrecan (Watanabe et al., 1997) and the 
interaction between aggrecan and hylauronan is stabilized by link protein, a small 
glycoprotein homologous with the G1 domain of aggrecan (Hardingham, 1979).  
Hyaluronan binds to chondrocytes via the CD44 cell surface receptor (Knudson, 
1993).  This interaction anchors proteoglycan aggregates within the pericellular 
matrix and they become trapped within the network of collagen fibres 
(Hardingham and Muir, 1972).   The G2 domain of aggrecan has no hylauronan 
binding activity (Watanabe et al., 1997) and its function is unknown whereas the 
G3 domain of aggrecan mediates binding to other ECM molecules such as 
tenascin-C, via its C-type lectin module (Day et al., 2004; Tompson et al., 2009).  
The G1 and G2 domains of aggrecan are separated a region known as the 
interglobular domain (IGD).  The G2 domain is followed by a long region where 
KS and CS side chains are attached (Doege et al., 1991).  There are 2 CS-rich 
regions; CS-1 and CS-2, and the number of CS chains in the CS-1-rich region of 
human aggrecan can vary due to a polymorphism in the aggrecan gene (Doege 
et al., 1997). 
 
Other proteoglycans of the cartilage matrix include decorin, biglycan, lumican 
and fibromodulin.  These proteoglycans are members of the small leucine-rich 
proteins (SLRPs).  They contain multiple leucine-rich repeat (LRR) motifs which 
are flanked by two conserved cysteine-rich regions (Hocking et al., 1998).  
Decorin consists of a core protein of 38 kDa together with one CS or DS side 
chain attached towards the N-terminus.  Aside from binding to type I and type II 
collagen (Hedbom and Heinegard, 1989; Vogel et al., 1984), decorin binds to 
other molecules of the cartilage matrix including type VI collagen (Bidanset et al., 
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1992), fibronectin (Gendelman et al., 2003), C1q (Krumdieck et al., 1992) and 
TGF-β (Hildebrand et al., 1994).  Decorin is essential for proper collagen 
fibrillogenesis as decorin-null mice present with fragile skin and tendons and 
abnormalities in both collagen size and morphology (Danielson et al., 1997).  The 
core protein of biglycan is approximately 43 kDa with two CS or DS side chains 
attached towards the N-terminus.  Biglycan also binds a number of molecules 
including type I collagen (Schonherr et al., 1995) and TGF-β (Hildebrand et al., 
1994; Yamaguchi et al., 1990) and is thought to play a role in neuronal survival 
(Kappler et al., 1997).   Although normal at birth, biglycan deficient mice have a 
reduced growth rate and develop an osteoporosis-like phenotype of decreased 
bone mass (Xu et al., 1998).  These results suggest that biglycan regulates bone 
formation and bone mass.  Lumican and fibromodulin are KS proteoglycans.  
Lumican-null mice present with defects in corneal transparency and skin fragility 
and have larger than normal collagen fibrils (Chakravarti, 2002), indicating that 
lumican is involved in the regulation of collagen fibril growth.  Fibromodulin 
carries up to four KS chains and binds type I and type II collagen with high affinity 
(Hedbom and Heinegard, 1989).  Fibromodulin-null mice have increased 
susceptibility to OA and their tendons contain an increased frequency of small 
diameter collagen fibrils compared to wild-type mice (Chakravarti, 2002), 
showing that fibromodulin is involved in collagen fibrillogenesis.   
 
A number of heparan sulfate proteoglycans (HSPGs) are found in cartilage, 
including perlecan and members of the syndecan family of cell surface receptors.  
Perlecan was originally isolated from a mouse Engelbreth-Holm-Swarm (EHS) 
tumour (Hassell et al., 1980).  It is approximately 470 kDa and in addition to 
being expressed in cartilage is also expressed in almost all basement 
membranes (Clement et al., 1989; Handler et al., 1997; Hayashi et al., 1992; 
SundarRaj et al., 1995).  Perlecan is a CS/HS hybrid proteoglycan and is 
essential for normal cartilage development as perlecan-null mice are embryonic 
lethal and present with severe skeletal defects (Arikawa-Hirasawa et al., 1999).  
Mutations in the human perlecan gene result in a skeletal disorder known as 
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Schwartz-Jampel syndrome and dyssegmental dysplasia, Silverman-Handmaker 
type (DDSH) (Arikawa-Hirasawa et al., 2002; Arikawa-Hirasawa et al., 2001).  
Members of the transmembrane family of syndecans as well as the glycosyl 
phosphatidylinositol-linked HSPGs, glypicans are also expressed on the surface 
of chondrocytes (Knudson and Knudson, 2001).   
Other proteins found in the cartilage matrix include versican, chondroadherin, 
matrilins, thrombospondins such as cartilage oligomeric protein (COMP) and 
fibronectin.   
 
1.2. Articular cartilage degradation 
Proteolytic degradation of the cartilage ECM is an early and important event in 
the development of osteoarthritis (OA).  OA is a disease characterized by 
progressive loss of cartilage from the surface of articulating joints and cartilage 
erosion eventually leads to loss of joint function (Felson and Zhang, 1998). 
Degradation of the cartilage matrix involves cleavage of both aggrecan and 
collagen fibres and aggrecan is one of the first components of the ECM to be 
degraded in arthritic disease (Mankin and Lippiello, 1970).   Aggrecan 
degradation precedes collagen degradation in cartilage cultured with the 
proinflammatory cytokine interleukin-1 (IL-1) (Kozaci et al., 1997) and the 
presence of aggrecan in the cartilage matrix may even protect against collagen 
degradation (Pratta et al., 2003b).    
 
Members of the matrix metalloproteinase (MMP) family which can cleave 
collagen at neutral pH include MMP-1, MMP-8, MMP-13, MMP-2 and MMP-
14/MT1-MMP (see Nagase et al., 2006 for review).   Whilst MMP-13 seems to 
have a significant role the degradation of collagen in OA (Billinghurst et al., 1997; 
Dahlberg et al., 2000; Mitchell et al., 1996), there is debate as to which 
enzyme(s) are responsible for aggrecan degradation in vivo.  Aggrecan can be 
cleaved by a number of matrix metalloproteinases in vitro, including MMP-2, 
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MMP-3, MMP-7 and MMP-9, although the activity of MMP-9 against aggrecan is 
very weak (Fosang et al., 1991; 1992).  MMPs can cleave aggrecan at a number 
of sites within the IGD and CS-2 regions (Figure 1) although they primarily cleave 
within the IGD domain between Asn341-Phe342 (Flannery et al., 1992; Fosang et 
al., 1991; Sandy et al., 1991).  Additionally, the IGD of aggrecan can be cleaved 
by the cysteine protease, cathepsin B (Fosang et al., 1992).   
 
Figure 1: The domain structure of aggrecan with MMP and aggrecanase 
cleavage sites shown.   
Aggrecan contains 3 globular domains – G1, G2 and G3. The N-terminal G1 domain 
interacts with hylauronan and is stabilised by link protein.  Aggrecanase cleavage sites 
are indicated by letter (A-E), whilst MMP cleavage sites are indicated by number (1-4).  
Amino acids in brackets indicate bovine sequence.  KS - keratan sulfate-rich region, CS-
1- 1st chondroitin sulfate-rich region, CS-2 – 2nd chondroitin sulfate-rich region.  Adapted 
from Nagase and Kashiwagi (2003).   
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Another cleavage site within the IGD domain of aggrecan between Glu373-Ala374 
was identified by N-terminal sequencing of fragments derived from bovine 
cartilage explant cultures stimulated with IL-1 (Sandy et al., 1991).  The 
unidentified enzyme(s) responsible for cleavage at the Glu373-Ala374 bond were 
termed ’aggrecanases’.  Subsequently, aggrecanase-1 (ADAMTS-4 (a disintegrin 
and metalloproteinase with thrombospondin motifs-4)) (Tortorella et al., 1999) 
and aggrecanase-2 (ADAMTS-5) (Abbaszade et al., 1999) were purified from IL-
1α-stimulated cartilage explants and were the first members of the ADAMTS 
family shown to cleave the Glu373-Ala374 bond.  They also cleave at a number of 
sites in the KS-rich and CS-2-rich regions of aggrecan (Figure 1) (Tortorella et 
al., 2000).   Cleavage within the IGD is thought to be of greater functional 
significance than cleavage in the C-terminal KS-rich and CS-rich regions of 
aggrecan because cleavage in the IGD liberates the extensive GAG attachment 
region from the tissue and reduces its ability to draw in water.  
 
Aggrecan fragments resulting from cleavage between residues Glu373-Ala374 are 
detected in the synovial fluid of OA patients (Lohmander et al., 1993; Sandy et 
al., 1992).  However, at high concentrations, MMP-8 and MMP-14 can also 
cleave at Glu373-Ala374 (Buttner et al., 1998; Fosang et al., 1994) and in addition 
to cleavage at the Glu373-Ala374 site, ADAMTS-4 has been shown to cleave 
aggrecan at the Asn341-Phe342 site, although at a much slower rate (Westling et 
al., 2002).  Furthermore, both MMP- and aggrecanase-generated fragments were 
detected by immunohistochemistry in cartilage from OA patients, indicating that 
both MMPs and aggrecanases cleave aggrecan in vivo (Lark et al., 1997).  
 
 
1.3. The ADAMTS family members  
The ADAMTSs belong to the M12 family in the MEROPS database (Rawlings et 
al., 2008).  They are a subfamily of the adamalysin family, which includes the 
snake venom metalloproteinases (reprolysins) and ADAMs (a disintegrin and 
metalloproteinase).  The adamalysins along with other related families including 
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the MMPs, astacins, serralysins, snapalysins, leishmanolysins and pappalysins 
(Bode et al., 1993; Gomis-Ruth, 2009; Hooper, 1994; Kaushal and Shah, 2000; 
Stocker et al., 1995) all require zinc for catalytic activity and each contain a zinc 
binding motif (H-E-X-X-H-X-X-G-X-X-H/D) within their catalytic domain.  They are 
all classified as metzincins as they also contain a conserved methionine residue 
which supports the catalytic site (Bode et al., 1993).  This residue is known as 
the ‘Met turn’ and is located downstream of the zinc binding motif. 
 
1.3.1. ADAMTSs domain structure 
ADAMTSs are a group of 19 secreted enzymes (see Porter et al., 2005 for 
review) which generally consist of a signal peptide, pro-domain, catalytic 
metalloproteinase domain, disintegrin-like domain, a thrombospondin type I-like 
domain, a cysteine-rich domain and a spacer domain.  Unlike the ADAMs, they 
are soluble proteinases due to the absence of a transmembrane domain.  All 
ADAMTSs, except ADAMTS-4, have a second thrombospondin type 1-like motif 
of variable length towards the C-terminal.  The functions of each domain are 
discussed below.  The domain composition of the entire ADAMTS family and 
known substrates to date are detailed in Table 1.    
 
The signal peptide is a hydrophobic sequence that directs a protein to be 
secreted across the ER membrane (Blobel et al., 1979).  The signal peptide is 
absent from mature proteins because it is cleaved by a signal peptidase on the 
ER membrane. 
 
ADAMTSs are synthesized as inactive zymogens and most ADAMTSs require 
proteolytic cleavage and removal of the prodomain for activity.  ADAMTSs 
contain a conserved furin consensus cleavage site between the prodomain and 
the catalytic motif (R-K-K-R235) suggesting that furin and/or other proprotein 
convertases (PCs) are responsible for prodomain cleavage (Rodriguez-
Manzaneque et al., 2000).   
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The mechanism of ADAMTS catalytic activity is thought to be the same as that 
described for the MMPs (Spurlino et al., 1994; Stocker et al., 1995).   The 
catalytic domain of all MMPs contain the zinc binding motif H-E-X-G-H-X-X-G-X-
X-H and the 3 histidines within this motif co-ordinate a Zn2+ ion.  The glutamic 
acid polarizes a zinc-bound water molecule whereas the conserved methionine 
residue downstream of the zinc binding domain, a second Zn2+ ion and two to 
three Ca2+ ions stabilize the structure.  When a substrate binds to the catalytic 
domain, the polarized water (OH-) promotes a nucleophilic attack on the carbonyl 
carbon of the scissile peptide bond.      
 
The exact function of the disintegrin-like domain is not known.  One possible role 
of this domain is in mediating cellular adhesion, although there have been no 
reports to date that ADAMTSs associate with integrins.  However, the disintegrin-
like domain of related proteinases, the ADAMs has been implicated in cellular 
adhesion events such as sperm-egg fusion (Schlondorff and Blobel, 1999).  
Additionally, the disintegrin-like domain of both ADAM7 and ADAM28 have been 
reported to interact with α4β1, α4β7 and α9β1 integrins whereas the disintegrin-
like domain of ADAM33 interacts only with α9β1 integrin (Bridges et al., 2005; 
Bridges et al., 2002).  The disintegrin domain of ADAMTS-1 is required for 
protease activity against α2-macroglobulin (α2-M) (Wei et al., 2002) whilst the 
disintegrin domain of ADAMTS-4 and ADAMTS-5 enhances their activity against 
a variety of substrates compared to the catalytic domain alone (Gendron et al., 
2007; Kashiwagi et al., 2004).   
 
The precise function of the thrombospondin type-1 like domain of the ADAMTSs 
is also unknown.  The thrombospondin type-1 like domain of ADAMTS-1 contains 
a heparan sulfate binding motif W-G-P-W-G-P-W and the potential CD36 cell 
surface binding sequence C-S-(R/K)-T-C-G (Iruela-Arispe et al., 1999; Kuno and 
Matsushima, 1998; Lawler, 2000).  The thrombospondin type-1 like domain has 
been shown to be involved in the adhesion of ADAMTS-1 to the cell membrane 
and/or the ECM (Kuno and Matsushima, 1998).   
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The cysteine-rich and spacer domains are involved in ADAMTS localization and 
activity.  In the case of ADAMTS-1, both domains are required for binding to the 
ECM (Kuno and Matsushima, 1998).  The spacer domain of ADAMTS-4 interacts 
with the cell surface and ECM (Kashiwagi et al., 2004).    Removal of the spacer 
domain of ADAMTS-4 liberates ADAMTS-4 from the matrix and reduces its 
activity towards aggrecan but increases its ability to cleave other substrates such 
as carboxymethylated transferrin (Fushimi et al., 2008; Kashiwagi et al., 2004).  
Additionally, the spacer domain of ADAMTS-4 binds to the C-terminal domain of 
fibronectin and this interaction inhibits ADAMTS-4 activity (Hashimoto et al., 
2004) whilst the catalytic activity of ADAMTS-13 requires both the spacer and 
cysteine rich domains (Soejima et al., 2003; Zheng et al., 2003).   
 
The C-terminal thrombospondin repeats of ADAMTS-7 are separated by a 
mucin-like domain rich in chondroitin sulfate.  The addition of the mucin-like 
domain renders ADAMTS-7 a proteoglycan and may affect its cellular localization 
and substrate specificity.  The mucin-like domain is also predicted to exist in 
ADAMTS-12 (Somerville et al., 2004).  
 
The protease and lacunin (PLAC) domain is found at the C-terminus of 
ADAMTS-2, -3, -7, -10, -12, -14, -17 and -19.  This domain was first identified in 
lacunin, an extracellular matrix protein found in the moth Manduca sexta (Nardi 
et al., 1999).  Removal of the PLAC domain from ADAMTS-2 increased its N-
procollagen I peptidase activity 3.5-fold, suggesting that the PLAC domain is a 
negative regulator of N-terminal procollagen processing (Colige et al., 2005).   
 
ADAMTS-20 and the long isoforms of ADAMTS-9 each have a gon-1-like 
domain.  This domain was first described in GON-1, a secreted 
metalloproteinase which controls gonadal development in Caenorhabditis 
elegans (Blelloch and Kimble, 1999).  However, the function of the gon-1-like 
domain in members of the ADAMTS family has not been determined. 
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Unlike other family members, ADAMTS-13 contains two C-terminal CUB 
[complement subcomponent C1r/C1s/embryonic sea urchin protein Uegf (urchin 
epidermal growth factor)/bone morphogenic protein 1] domains of unknown 
function.  The CUB domain is found in many proteins involved in developmental 
processes such as embryogenesis and organogenesis (Bork and Beckmann, 
1993).  The CUB domain may be involved in substrate recognition as the CUB 
domain of procollagen C-proteinase-2 can bind immobilized procollagen type I 
(Sieron et al., 2000). 
 
1.3.2. ADAMTS functions  
Substrates of several members of the ADAMTSs have been identified, including 
the N-propeptide of procollagen, von Willebrand factor, aggrecan and COMP.  
However, there are a number of ADAMTSs whose proteolytic activities have not 
yet been discovered. 
 
1.3.2.1. Procollagen N-proteinases (ADAMTS-2, -3 and -14) 
Collagens I, II and III are synthesized as procollagens with both NH2 and COOH 
terminal propeptides which must be removed before mature collagen fibrils can 
be formed (Olsen, 1995).  The C-terminal propeptide is cleaved by procollagen 
C-proteinases such as BMP-1 (Kessler et al., 1996; Lee et al., 1997; Li et al., 
1996) whilst ADAMTS-2, -3 and -14 cleave the N-terminal propeptide (Colige et 
al., 1997; 2002; Fernandes et al., 2001).  Mutations within the ADAMTS-2 gene, 
resulting in a premature stop codon, cause Ehlers-Danlos syndrome type VII C in 
humans.  This disease is characterized by symptoms including severe joint 
hyperextensibility, stretchable and easily bruised skin, short stature and a 
depressed nasal bridge (Colige et al., 1999).  Mutations within the ADAMTS-2 
gene of cattle and sheep cause dermatosparaxis, a connective tissue disease 
similar to human Ehlers-Danlos syndrome type VII C. 
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Table 1: Domain composition of ADAMTSs and their known substrates.   
 
Abbreviations - SS, signal peptide; Pro, pro-domain; Cat, metalloproteinase domain; Dis, 
disintegrin domain; TS-1, thrombospondin type-1 motif; Cys, cysteine-rich domain; Sp, 
spacer domain; TS-1 rp, C-terminal thrombospondin type 1 repeats; Muc, mucin-like 
domain; PLAC, protease and lacunin motif; gon-1, gon-1-like motif; CUB, complement 
subcomponent C1r/C1s/embryonic sea urchin protein Uegf (urchin epidermal growth 
factor)/bone morphogenic protein 1; Cm-Tf, carboxymethylated transferrin; COMP, 
cartilage oligomeric matrix protein; α2M, α2-macroglobulin.  * mucin domain resides 
between 3rd and 4th C-terminal TS-1 repeats.   
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1.3.2.2. von Willebrand factor cleaving proteinase (ADAMTS-13) 
von Willebrand factor (vWF) is a large plasma glycoprotein present in plasma 
and produced constitutively in platelets and vascular endothelial cells.  Its role is 
to support platelet aggregation and platelet adhesion to damaged blood vessels 
by forming a bridge between platelet surface glycoproteins and the damaged 
endothelium.  Von Willebrand factor is synthesized by vascular endothelial cells 
and assembles into homodimers and ‘ultra large’ multimers (UL-vWF) through 
the formation of disulfide bonds.  Under conditions of shear stress in the 
circulation, UL-vWF becomes more susceptible to proteolysis and is cleaved 
between residues Tyr1605-Met1606 in the A2 domain of vWF by ADAMTS-13 (vWF 
cleaving proteinase) (Fujikawa et al., 2001; Soejima et al., 2001; Zheng et al., 
2001).  The absence or inactivation of ADAMTS-13 causes thrombocytic 
thrombocytopenic purpura (TTP), a condition characterized by the accumulation 
of UL-vWF multimers which form platelet-rich microthrombi in the small vessels 
of multiple organs.  These clots eventually lead to organ ischemia and hemolytic 
anemia.  Genetic mutations in ADAMTS-13 cause TTP (Levy et al., 2001).  
Additionally, auto-antibodies against ADAMTS-13 cause acquired TTP (Furlan et 
al., 1998).    
 
1.3.2.3. Aggrecanases (ADAMTS-1, -4, -5, -8, -9 -15, -16 and -18) 
As previously mentioned, ADAMTS-4 and ADAMTS-5 both cleave the IGD of 
aggrecan between residues Glu373-Ala374 although ADAMTS-5 is a 22-33-fold 
more active aggrecanase than ADAMTS-4 (Abbaszade et al., 1999; Gendron et 
al., 2007; Kashiwagi et al., 2004; Tortorella et al., 1999).  In addition, several 
other members of the ADAMTS family have been reported to have aggrecanase 
activity in vitro:  ADAMTS-1 (Rodriguez-Manzaneque et al., 2002), ADAMTS-8 
(Collins-Racie et al., 2004), ADAMTS-9 (Somerville et al., 2003), ADAMTS-16 
(Zeng et al., 2006) and ADAMTS-18 (Zeng et al., 2006).  According to a 
European patent approved in 2004, ADAMTS-15 is also an aggrecanase (Yamaji 
et al., 2004).  However, aside from ADAMTS-4 and ADAMTS-5, the 
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aggrecanases have very weak activity against aggrecan and the significance of 
this activity in vivo is not understood.       
ADAMTS-1 was the first member of the ADAMTS family to be identified and was 
initially discovered as a gene selectively expressed in cachexigenic colon 26 
adenocarcinoma cells (Kuno et al., 1997).   ADAMTS-1-null mice present with 
renal abnormalities and female infertility (Shindo et al., 2000) although they are 
not protected from aggrecan degradation in an inflammatory model of arthritis or 
in an in vitro model of early cartilage degradation (Little et al., 2005).    
 
ADAMTS-5 knockout mice, but not ADAMTS-4 knockout mice, are protected 
from cartilage degradation upon challenge in either inflammatory or surgically 
induced models of arthritis (Glasson et al., 2004; Majumdar et al., 2007; Stanton 
et al., 2005).   However, Malfait et al showed that both ADAMTS-4 and ADAMTS-
5 were expressed in human OA tissue and that inhibition of these enzymes using 
a synthetic aggrecanase inhibitor blocked aggrecan degradation in vitro (Malfait 
et al., 2002).  Additionally, knockdown of either ADAMTS-4, ADAMTS-5 or both 
enzymes simultaneously by small interfering RNA (siRNA) reduced aggrecan 
degradation in both OA and normal human cartilage stimulated with a 
combination of TNFα and oncostatin M (Song et al., 2007).  This suggests that 
both ADAMTS-4 and ADAMTS-5 may contribute to aggrecanolysis in humans.  
Together, these results show that ADAMTS-5 is the major aggrecanase in mouse 
cartilage and infer that the specific aggrecanase(s) responsible for aggrecan 
cleavage in vivo may differ between species.     
A recent paper suggested that another aggrecanase, induced by retinoic acid but 
not IL-1α, caused aggrecan catabolism in cartilage explants derived from mice 
deficient in both ADAMTS-4 and ADAMTS-5 (TS-4/TS-5 Δ-cat) (Rogerson et al., 
2008).  A low level of cleavage at SELE1279-1280GRG was detected upon 
stimulation of TS-4/TS-5 Δ-cat cartilage with retinoic acid.  In addition, a major 
cleavage at FREEE1467-1468GLG was detected, although the level of the 
FREEE1467 neoepitope detected in the tissue immediately ex-vivo was minor 
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compared to the amount detected in wild-type tissue.  Nonetheless, this suggests 
that even in the mouse, aggrecan degradation may be more complex. 
 
1.3.2.3.1. Other substrates of ADAMTS-1, -4, and -5  
Several of the aggrecanases have activity towards other substrates.  For 
example, ADAMTS-1 and ADAMTS-4 can additionally cleave versican V1 in the 
human aorta between the Glu441-Ala442 bond (Sandy et al., 2001) whilst 
ADAMTS-1 has been reported to cleave thrombospondin-1 and thrombospondin-
2 (Lee et al., 2006).  Recently, ADAMTS-5 has also been shown to cleave 
versican (Longpre et al., 2009).  ADAMTS-4 and ADAMTS-5 can cleave the brain 
specific protein, brevican between residues Glu395-Ser396 and both are 
overexpressed in human glioblastomas compared to normal brain tissue (Held-
Feindt et al., 2006; Matthews et al., 2000; Nakada et al., 2005).  COMP has also 
been reported to be cleaved by ADAMTS-4 in vitro (Dickinson et al., 2003).  
  
Other substrates of ADAMTS-4 and ADAMTS-5 include decorin, biglycan, 
fibronectin, fibromodulin and gelatin, although fibronectin and gelatin are 
degraded at slow rates (Gendron et al., 2007; Kashiwagi et al., 2004).  
 
1.3.2.3.2. Other roles of ADAMTS-1, -8, -9, -15 and -18 
In addition to their ability to cleave aggrecan, both ADAMTS-1 and ADAMTS-8 
inhibit angiogenesis as well as endothelial cell proliferation (Vazquez et al., 
1999).  The anti-angiogenic action of ADAMTS-1 was shown to be due to the 
binding of its C-terminal region to vascular endothelial growth factor (VEGF) 165 
(Luque et al., 2003).  Additionally, ADAMTS-1-mediated cleavage of 
thrombospondin-1 releases fragments with anti-angiogenic properties (Lee et al., 
2006).  The expression of ADAMTS-8 is downregulated in brain tumours (Dunn 
et al., 2006) whereas hypermethylation of the promoter region of the ADAMTS-9 
gene was detected in 15 out of 16 esophageal carcinoma cell lines (Lo et al., 
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2007).  This suggests that ADAMTS-9 can be epigenetically silenced in tumours.  
Similarly, ADAMTS-1 (Lind et al., 2006) and ADAMTS-18 (Jin et al., 2007) genes 
have been reported to be hypermethylated in colorectal carcinomas.  A recent 
study reported that the presence of ADAMTS-15 in human colorectal tumours 
showed a negative correlation with the differentiation grade of the tumour (Viloria 
et al., 2009).  These studies suggest that ADAMTS-1, -9, -15 and -18 may 
function as tumour suppressor genes.   
 
1.3.2.4. COMP is cleaved by ADAMTS-7 and ADAMTS-12 
Both ADAMTS-7 and ADAMTS-12 degrade COMP in vitro (Liu et al., 2006a; 
2006b) and their activity towards COMP can be inhibited by α2M (Luan et al., 
2008) and granulin-epithelin precursor (GEP), a chondrogenic growth factor (Liu, 
2009).  The expression of ADAMTS-12 was found to be significantly upregulated 
in cartilage from patients with OA compared with normal cartilage (Kevorkian et 
al., 2004).   
 
1.3.2.5. Other ADAMTSs (ADAMTS-6, -10, -17, -19 and -20) 
The function of these remaining ADAMTSs remains largely unknown.  However, 
ADAMTS-17 expression is upregulated in OA synovium compared with fractured 
neck of femur (NOF) cartilage (Davidson et al., 2006) whereas ADAMTS-6 and 
ADAMTS-20 are upregulated in human breast carcinoma (Porter et al., 2004).  
Mutations in the catalytic domain of the ADAMTS-10 gene, each coding for a 
premature stop codon have been described in three families with the autosomal 
recessive form of Weill-Marchesani syndrome (Dagoneau et al., 2004).  Weill-
Marchesani syndrome is a connective tissue disorder characterized by short 
stature, joint stiffness, shortness of the fingers and toes (brachydactyly), eye 
defects, including severe myopia and glaucoma and occasionally heart defects.  
This suggests that ADAMTS-10 may have an important role in the growth and 
development of organs including the eye and heart. 
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1.4. Regulation of ADAMTS activity 
ADAMTSs are subject to various levels of regulation, including gene expression, 
activation and inhibition.  These mechanisms are discussed in further detail 
below, with emphasis on the regulation of ADAMTS-4.   
 
1.4.1. Transcriptional Regulation 
Although aggrecanase activity was first identified in bovine articular cartilage 
treated with IL-1 (Sandy et al., 1991), aggrecanase activity can also be induced 
by other inflammatory cytokines including TNF-α, retinoic acid (Caterson et al., 
2000), TGF-β (Moulharat et al., 2004) and IL-17 (Cai et al., 2001).  Additionally, a 
45 kDa collagen binding fragment of fibronectin has been shown to stimulate the 
release of aggrecanase-generated aggrecan fragments from cartilage explants 
into the conditioned medium (Stanton et al., 2002)  
 
The effect of IL-1 on the expression of ADAMTSs remains debatable.  Several 
studies report that the mRNA expression of ADAMTS-4 is increased by IL-1 in 
human chondrocytes (Bau et al., 2002), bovine chondrocytes (Curtis et al., 
2000), bovine articular cartilage (Curtis et al., 2000; Tortorella et al., 2001) and 
porcine articular cartilage (Little et al., 2002).  However, another study reports 
that the expression of ADAMTS-1, ADAMTS-2, ADAMTS-3, ADAMTS-4, and 
ADAMTS-5 mRNA in human articular cartilage stimulated with IL-1β did not 
change although aggrecanase activity was enhanced (Flannery et al., 1999).  
This suggests that another enzyme aside from the ADAMTSs investigated may 
be responsible for aggrecan cleavage or that the activity of the ADAMTSs 
mediating degradation is not regulated at the level of expression.  Similarly, in 
bovine cartilage and chondrocytes, the activity of ADAMTS-4 was shown to be 
induced by IL-1 with no detectable change in the amount of ADAMTS-4 protein.  
This suggests that ADAMTS-4 is constitutively produced by chondrocytes and is 
activated by an unknown factor (Pratta et al., 2003a). 
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A study by Bau et al (2002) showed that although the expression of ADAMTS-4 
was induced by IL-1β in human chondroctyes, the expression of ADAMTS-5 was 
not enhanced.  However, a recent study reported that IL-1α induced both 
ADAMTS-4 and ADAMTS-5 in human articular chondrocytes although ADAMTS-
4 was more strongly induced than ADAMTS-5 (Sawaji et al., 2008).  In addition, 
the expression of ADAMTS-5 was significantly increased at the 4 h time point but 
was similar to unstimulated chondrocytes at 24 h, suggesting that ADAMTS-5 
expression in response to IL-1α is transient.         
 
Expression profiling studies have reported that the expression of ADAMTS-1, 
ADAMTS-5, ADAMTS-9 and ADAMTS-15 are significantly down-regulated whilst 
the expression of ADAMTS-2, ADAMTS-12, ADAMTS-14 and ADAMTS-16 are 
significantly increased in OA cartilage (Kevorkian et al., 2004).  In a separate 
study, ADAMTS-1, ADAMTS-4, ADAMTS-5 and ADAMTS-9 were down-
regulated whilst ADAMTS-2, ADAMTS-10 and ADAMTS-16 were upregulated in 
both OA cartilage and synovium tissues compared to control samples (Davidson 
et al., 2006).  The decrease in expression of key aggrecanase genes in OA 
tissue is contrary to the dogma that they are involved in cartilage degradation in 
vivo although this could be due to the fact that OA cartilage samples used in 
these studies were from patients with end-stage disease where most of the 
aggrecan has already been lost from the tissue.  Alternatively, it may indicate that 
in vivo, ADAMTSs activity is not regulated at the level of gene expression but is 
regulated by other post-translational modifications such as prodomain removal or 
C-terminal processing.    
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1.4.2. Pro-domain removal  
Many proteins, including a variety of hormones, growth factors, receptors and 
proteases are synthesized as inactive precursor proteins and are proteolytically 
processed into their mature and functionally active forms by the action of 
proprotein convertases (PCs) (see Seidah et al., 2008 for review).  PCs are a 
family of Ca2+-dependent subtilisin-type serine proteases.  Seven PCs cleave 
after basic amino acids:  PC1/3, PC2, PC4, PC5/6 (exists as 2 isoforms A and 
B), PACE4 (paired basic amino acid converting enzyme-4), PC7 and furin.   PCs 
such as furin mainly reside in the trans-Golgi network but can also be found on 
the cell surface or as a soluble form secreted into the extracellular milieu (Klimpel 
et al., 1992; Mayer et al., 2004; Thomas, 2002).  Once cleaved by PCs, the 
exposed carboxyl-terminal basic residues of the substrate are removed by 
metallocarboxypeptidases.   
 
PCs have been shown to activate several metalloproteases in vitro, including 
MMP-11 (Pei and Weiss, 1995), MT1-MMP (Yana and Weiss, 2000) and 
ADAM12 (Loechel et al., 1998).  It is likely that N-terminal processing by furin or 
other PCs also activates ADAMTSs as they also contain a conserved furin 
consensus cleavage site between the prodomain and the catalytic motif (R-K-K-
R235) and several members of the ADAMTS family have been shown to be 
processed upon secretion, including ADAMTS-1 (Kuno et al., 1997; 1999; 
Rodriguez-Manzaneque et al., 2000), ADAMTS-5 (Abbaszade et al., 1999) and 
ADAMTS-9 (Somerville et al., 2003).  The prodomain of ADAMTS-4 can also be 
cleaved (Gao et al., 2004; Kashiwagi et al., 2004; Tortorella et al., 1999; Wang et 
al., 2004a) with the mature form secreted from the cell.  It has also been reported 
that a 100 kDa form of ADAMTS-4 appears on the cell surface of JJ012 
chondrosarcoma cells with the prodomain still intact (Gao et al., 2004).  However, 
this result could be an artifact of transient transfection where the overexpressed 
protein is not processed correctly due to the large amount of protein being 
translated.   
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Further evidence for furin processing of the ADAMTSs arises from studies in 
which a single amino acid substitution in the furin cleavage site of ADAMTS-1 
(R232 > A232) blocked prodomain release and inhibited its proteolytic activity 
against aggrecan (Rodriguez-Manzaneque et al., 2002).   In addition to furin, 
PACE4 and PC5/6A cleave proADAMTS-4 in vitro (Malfait et al., 2008; Tortorella 
et al., 2005; Wang et al., 2004a).  PACE4 also cleaves pro-ADAMTS-5 in vitro 
(Malfait et al., 2008).  Furthermore, the addition of recombinant PACE4 to human 
OA tissue increased the release of ARGS-containing fragments, suggesting that 
cartilage matrix contains proADAMTS-4 and/or proADAMTS-5, which become 
catalytically active upon addition of recombinant PACE4 (Malfait et al., 2008).  
Recently, it was reported that proADAMTS-5 was activated extracellularly by 
furin, although the authors of this study also stated that they can not exclude the 
possibility that pro-ADAMTS-5 may be processed late in the secretory pathway, 
just prior to fusion with the plasma membrane (Longpre et al., 2009). 
 
The mechanism by which ADAMTSs are preserved in their latent proform is not 
thoroughly understood.  In MMPs, a cysteine residue within the conserved 
sequence P-R-C-G-V/N-P-D-V/L-A/G of the prodomain co-ordinates with the 
catalytic Zn2+ in the active site (Van Wart and Birkedal-Hansen, 1990).  This 
mechanism is known as the ‘cysteine switch’ and serves to retain the enzyme in 
an inactive state until the propeptide is cleaved by a PC or other MMPs.  
However, only 6 ADAMTSs (ADAMTS-1, -6, -7, -10, -12 and -15) contain a 
cysteine residue in their prodomain, suggesting that the prodomain of the 
ADAMTSs may not function in the same way as reported for MMPs (Porter et al., 
2005).  Additionally, mutation within the furin cleavage site or deletion of its pro-
peptide does not affect the secretion or activity of ADAMTS-13 (Majerus et al., 
2003).  Similarly, ADAMTS-7 can also be catalytically active with its prodomain 
still intact (Somerville et al., 2004).   
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1.4.3. C-terminal processing  
In addition to furin-mediated removal of the prodomain, secondary processing of 
the mature ADAMTS protein can also occur.  For example, active 64 kDa and 50 
kDa fragments of ADAMTS-5 were isolated from conditioned medium collected 
from IL-1-stimulated bovine nasal cartilage (Abbaszade et al., 1999).  In addition, 
a 46 kDa fragment of ADAMTS-4 was identified in IL-1α-treated porcine cartilage 
explants (Kashiwagi et al., 2004).    
 
There have also been several reports that ADAMTS-4 requires cleavage within 
the C-terminal region by MMP-17 in order to cleave aggrecan at the Glu373-Ala374 
bond and that furin-mediated cleavage to generate the p68 form is a prerequisite 
for C-terminal processing by MMP-17 (Gao et al., 2002; 2004; Patwari et al., 
2005).  However, the p68 form, the result of prodomain removal alone, is able to 
cleave within the C-terminal CS-2-region of aggrecan (Kashiwagi et al., 2004).   
 
Our group has also reported that the full-length form of ADAMTS-4 has little 
activity against the Glu373-Ala374 bond in the IGD of aggrecan whereas removal of 
the spacer domain increases the ability of ADAMTS-4 to cleave aggrecan at this 
site (Gendron et al., 2007; Kashiwagi et al., 2004).  In contrast, full-length 
ADAMTS-4 (ADAMTS4-1) and the spacer domain-deleted form (ADAMTS4-2) 
have been shown to have equal activity against the Glu373-Ala374 bond of 
aggrecan, suggesting that the spacer domain is not required for full catalytic 
activity (Hashimoto et al., 2004).   
 
In contrast to previous reports by our laboratory, we recently reported that full-
length ADAMTS-4 is more active than the spacer domain-deleted form of 
ADAMTS-4 at both the IGD and CS-2-rich region cleavage sites of aggrecan but 
is still a 22-33 fold weaker aggrecanase than full-length ADAMTS-5 (Fushimi et 
al., 2008).  However, the activity of ADAMTS-4 against non-aggrecan substrates 
such as carboxymethylated transferrin and fibromodulin is enhanced when the C-
terminal spacer domain is removed (Fushimi et al., 2008).  The discrepancy 
Chapter 1  Introduction                                           
 
  38 
between the results of our two studies was likely due to heparin contamination 
within the preparation of ADAMTS4-1 used in the initial study.  As the spacer 
domain of ADAMTS4-1 interacts with the cell surface and ECM (Kashiwagi et al., 
2004), it therefore seems that processing of the spacer domain of ADAMTS-4 
liberates ADAMTS-4 from the matrix.  Removal of the spacer domain reduces 
ADAMTS-4 activity towards aggrecan but increases its ability to cleave other 
substrates.   
 
Removal of the spacer domain of ADAMTS-5 reduces aggrecanolytic activity but 
has no effect on its general proteolytic activity.  Removal of both CysR and Sp 
domains of ADAMTS-5 further reduces its activity against aggrecan (Gendron et 
al., 2007) but has little effect on its general proteolytic activity. However, the 
catalytic domain of either ADAMTS-4 or ADAMTS-5 alone has little proteolytic 
and aggrecanolytic-activity (Gendron et al., 2007; Kashiwagi et al., 2004).  
 
1.4.4. Endogenous inhibition  
The tissue inhibitor of metalloproteinase (TIMP) family consists of 4 members:  
TIMP-1, TIMP-2, TIMP-3 and TIMP-4.  TIMPs bind tightly and are endogenous 
inhibitors of most MMPs (Murphy and Willenbrock, 1995).  In addition, TIMP-3 
can inhibit ADAMTS-4 and ADAMTS-5 in vitro, with Ki values of 3.3 nM and 0.66 
nM, respectively (Kashiwagi et al., 2001) and is the only TIMP to protect against 
cartilage aggrecan breakdown in explant cultures stimulated with IL-1 or retinoic 
acid (Gendron et al., 2003).  TIMP-3 also differs from other members of the TIMP 
family, in that it binds tightly to the ECM (Kishnani et al., 1995; Staskus et al., 
1991).  It has been reported that TIMP-3 interacts with the ECM via both its N- 
and C-terminal domains and the residues involved in ECM binding are all basic 
amino acids (Lee et al., 2007).     
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Additionally, the activity of ADAMTS-4 and ADAMTS-5 can be irreversibly 
inhibited by the general plasma proteinase inhibitor α2-macrogloblin (Tortorella et 
al., 2004).   
 
1.5. Endocytosis 
Endocytosis is a further mechanism by which the extracellular level of proteases 
can be regulated.  Although there are no reports demonstrating the endocytosis 
of any member of the ADAMTS family, clearance of these enzymes from the 
extracellular milieu would serve to reduce their activity in the matrix by promoting 
intracellular catabolism.  In support of this potential mechanism, the endocytosis 
of many proteinases and proteinase/inhibitor complexes have been reported, 
including the endocytosis of MMP-2 (Emonard et al., 2004; Yang et al., 2001), 
MMP-9 (Hahn-Dantona et al., 2001) and MMP-13 (Barmina et al., 1999).   
 
1.5.1. Clathrin-dependent endocytosis 
Clathrin-mediated mechanisms of endocytosis have been well studied.  The 
process involves the formation of clathrin invaginations around cell surface 
receptors.  The clathrin-coated invaginations bud from the plasma membrane 
and form a clathrin-coated vesicle (Kirchhausen, 2000).  Some receptors are 
constitutive, i.e. they are endocytosed both in the presence and absence of 
ligands, whilst others require ligand binding to initiate the formation of the 
clathrin-coated vesicle.  Once endocytosed, the clathrin-coated vesicle is 
targeted to the early endosome.  In the early endosome, the ligand dissociates 
from the receptor due to acidic pH (~pH 5).  Endocytosed proteins and receptors 
can be recycled to the plasma membrane through recycling endosomes or are 
degraded by hydrolases following transport to late endosomes and lysosomes 
(Figure 2).  Receptors can be recycled back to the cell surface and so the 
turnover of the receptor and its level of expression on the cell surface are factors 
which can regulate the rate of endocytosis of a particular ligand.  Cells possess 
many types of cell surface receptors, each of which is able to bind and 
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endocytose a variety of ligands.  For example, all cell types contain transferrin 
receptors which deliver iron to cells by endocytosis of receptor-bound 
ferrotransferrin (Jandl and Katz, 1963).  However, the receptor also endocytoses 
apotransferrin and receptor internalisation also proceeds in the absence of 
transferrin (Dautry-Varsat et al., 1983; Watts, 1985).  In the early endosome, iron 
dissociates from the transferrin-receptor complex and remains in the cell whilst 
transferrin is not degraded but is secreted intact into the medium (Jandl and 
Katz, 1963; Klausner et al., 1983).  The low-density lipoprotein receptor (LDL-R) 
family is another class of receptors which mediate clathrin-dependent 
endocytosis of a variety of structurally and functionally unrelated ligands (see 
Hussain et al., 1999 for review).  In the case of the LDL-R, the bound ligand 
dissociates from the receptor in the early endosome and is transported to the 
lysosome for degradation.  Members of the LDL-R family are constitutively 
recycling receptors although they bind their ligands with high affinity.   
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Figure 2: Clathrin-mediated endocytosis. 
Ligands are internalised at the plasma membrane in clathrin-coated pits.  Following 
transfer to the early endosome, endocytosed proteins and receptors are recycled to the 
plasma membrane through recycling endosomes or transported to late endosomes and 
then lysosomes.  In the lysosomes they are degraded by hydrolases.  
  
1.5.1.1. LDL-R Family 
The LDL-R family is comprised of several structurally homologous receptors, 7 of 
which are very closely related: LDL receptor (LDL-R), LDL-R-related protein-1 
(LRP-1), LRP-1b, megalin/LRP-2, very-low density lipoprotein receptor (VLDL-R), 
LRP-4/MEGF7 (multiple EGF-like domain) and LRP8/apolipoprotein E receptor 2 
(apoER2) (Figure 3).  The LDL-R family also includes members which are more 
distantly related such as sorting protein-related receptor containing LDL-R class 
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A repeats (SorLa/LRP11), LRP-5 and LRP-6.  All members of the LDL-R family 
are type 1 transmembrane receptors and consist of an extracellular N-terminal 
ligand binding domain, containing cysteine-rich ligand-binding repeats, epidermal 
growth factor (EGF)-like repeats and β-propeller domains, a single 
transmembrane domain and all except LRP-5/-6 contain NPXY motifs in their 
cytoplasmic tail (Marzolo and Bu, 2009).  The NPXY motifs mediate binding of 
the receptor to coated pits and have been shown to bind cytosolic adaptor 
proteins such as mammalian Disabled (mDab1) and FE65.  This indicates that 
they may activate intracellular signaling (Trommsdorff et al., 1998; 1999). 
 
1.5.1.1.1. LDL-R 
The founder member of the receptor family, LDL-R was identified through studies 
demonstrating that fibroblasts bound [125I]-LDL with high affinity and specificity 
(Brown and Goldstein, 1974).  The LDL-R, unlike other members of this family 
appears to function exclusively in lipoprotein metabolism, mediating the 
internalisation and degradation of apoB100-containing lipoproteins as well as 
apoE-containing lipoproteins from plasma (Hussain et al., 1999).  Mutations 
within the LDL-R gene cause familial hypercholesterolemia (see Hobbs et al., 
1990 for review).  In this condition, the clearance of lipoproteins from the 
bloodstream is impaired which results in increased LDL levels in the circulation.  
Physical signs include cholesterol deposits in the tendons (tendon xanthomas) 
and yellow patches around the eye (arcus cornea).  Deposition of cholesterol in 
the arteries leads to atherosclerosis and early onset cardiovascular disease.   
 
1.5.1.1.2. VLDL-R 
The structure of VLDL-R differs from that of LDL-R only by an additional ligand- 
binding repeat at the N terminus.  It is expressed in heart, muscle, brain and 
adipose tissue but not in liver (Hussain et al., 1999).  The VLDL-R endocytoses 
proteins involved in lipoproprotein metabolism such as apoE and VLDL as well 
as several protease/inhibitor complexes including protease/anti-thrombin III and 
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protease/PAI-1 complexes (Hussain et al., 1999).   A polymorphism in the VLDL-
R, due to the absence of an 84 base pair O-glycosylation motif, has been 
described, although this does not affect ligand binding (Martensen et al., 1997; 
Sakai et al., 1994; Webb et al., 1994).  No human disorders have been linked 
with VLDL-R dysfunction.  However, mutations in the chicken homolog of VLDL-
R result in female sterility and severe hyperlipidemia (Bujo et al., 1995).   
 
1.5.1.1.3. LRP-1 
LRP-1, also known as CD91, was first described as the receptor for activated α2-
macroglobulin (α2-M*) (Hanover et al., 1983).  In 1988, Herz et al screened a 
mouse lymphocyte cDNA library and identified a cell surface receptor with 
sequence similarity to the LDL-receptor, naming it LDL-receptor related protein 
(LRP-1) (Herz et al., 1988).  Sequencing of both the α2M receptor and LRP-1 
identified them as the same molecule (Strickland et al., 1990).  LRP-1 is 
synthesized as a 600 kDa precursor which is cleaved in the trans-Golgi by a 
furin-like protease to produce a non-covalently associated receptor of 85 kDa 
and 515 kDa subunits (Willnow et al., 1996b).  The 85 kDa subunit contains a 
small ectodomain, single transmembrane domain and cytoplasmic tail and the 
515 kDa extracellular subunit contains 4 ligand-binding clusters (Herz et al., 
1990; Willnow et al., 1996b).  LRP-1 expression is widespread; it is found 
abundantly in the placenta, liver and brain and is highly expressed in several cell 
types including hepatocytes, fibroblasts and macrophages (Moestrup et al., 1992; 
Zheng et al., 1994).  Aside from α2-M*, LRP-1 binds and internalizes a variety of 
other ligands, including the matrix molecules connective tissue growth factor 
(CTGF) (Segarini et al., 2001), decorin (Brandan et al., 2006) and fibronectin 
(Salicioni et al., 2002).  Many proteases or molecules associated with regulating 
protease activity are also LRP-1 ligands including tissue-type plasminogen 
activator (tPA) (Bu et al., 1992), urinary-type plasminogen activator (uPA) 
(Kounnas et al., 1993), tPA or uPA bound to plasminogen activator inhibitor type 
I (PAI-1) (Nykjaer et al., 1992; Orth et al., 1994), lactoferrin (Willnow et al., 1992), 
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MMP-2 (Emonard et al., 2004; Yang et al., 2001), MMP-9 (Hahn-Dantona et al., 
2001) and MMP-13 (Barmina et al., 1999). LRP-1 is also the endocytic receptor 
for thrombospondin-1 and -2 (Chen et al., 1996; Mikhailenko et al., 1995), 
Pseudomonas exotoxin A (Kounnas et al., 1992b) and the transcriptional 
transactivator HIV-1-Tat (Liu et al., 2000c).  In addition, LRP-1 internalises ApoE-
enriched lipoproteins and lipoprotein lipase (LpL) (Lillis et al., 2009).  Another 
important ligand is receptor associated protein (RAP), a 39 kDa protein which co-
purifies with LRP-1 (Ashcom et al., 1990).  RAP binds to LRP-1 with a Kd of 3.3 
nM (Iadonato et al., 1993) and inhibits the binding and/or uptake of all known 
LRP-1 ligands (Bu et al., 1992; Herz et al., 1992; Nykjaer et al., 1992).  
 
LRP-1 has 4 ligand binding clusters (I-IV) (Figure 3).  The majority of LRP-1-
ligands bind to ligand-binding clusters II and IV and ligands including apoE and 
RAP bind to either domain with equal affinity which suggests functional 
duplication within the gene (Springer, 1998).  Furthermore, high affinity ligand 
binding requires interaction with multiple ligand binding repeats.   
 
1.5.1.1.3.1. α2M endocytosis  
α2M is found at relatively high levels in the plasma (2-4 mg/ml) and is a tetramer 
of 4 identical 185 kDa subunits linked in pairs by disulfide bonds.  The two dimers 
are associated non-covalently (Barrett et al., 1979).   Each subunit has a ‘bait 
region’ which is susceptible to cleavage by proteinases.  Once cleaved, α2M 
undergoes a rapid conformational change and forms an irreversible α2M-
proteinase complex which entraps the proteinase without blocking its active site.  
Although the trapped protease remains active towards low molecular mass 
substrates, protease activity towards large molecular weight substrates is 
inhibited (Barrett and Starkey, 1973; Harpel, 1973).  Early studies reported that 
complexes of α2M with proteinases and not the native molecule were taken up 
preferentially by human fibroblasts (Van Leuven et al., 1979).  This supports 
observations that upon complex formation, α2M undergoes a substantial 
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conformational change, exposing a receptor binding site within α2M.  This form of 
α2M is known as activated-α2M (α2M*).  α2M* can also be generated by reaction 
with methylamine, a small nucleophile which attacks the internal thioester bond 
within the molecule and generates four free thiol groups (Barrett et al., 1979).  
α2M* endocytosis is inhibited by nickel (Hussain et al., 1995; Kancha and 
Hussain, 1997; Odom et al., 1997) although the internalisation of other LRP-1 
ligands including RAP and lactoferrin are not inhibited by nickel.  This suggests 
that Ni2+ is a specific inhibitor of α2M* endocytosis.  
 
1.5.1.1.3.2. MMP endocytosis 
MMP-2, -9 and -13 are endocytosed by LRP-1 (Barmina et al., 1999; Emonard et 
al., 2004; Hahn-Dantona et al., 2001; Yang et al., 2001).  Pro-MMP2 can be 
internalised by LRP-1 in a complex with thrombospondin-2 (Yang et al., 2001) or 
in a complex with TIMP-2 (Emonard et al., 2004).  Binding of pro-MMP-2-TIMP-2 
to the surface of HT1080 cells was not inhibited by RAP, whereas endocytosis 
and lysosomal degradation of pre-bound complex was inhibited by RAP 
(Emonard et al., 2004).  This suggests that an unknown RAP-insensitive co-
receptor may be involved in the initial binding of pro-MMP-2-TIMP-2 to the cell 
surface, followed by transfer to and endocytosis by LRP-1. Blocking the 
interaction of thrombospondin-1 with either LRP-1 or pro-MMP-2 partially 
inhibited LRP-1-mediated endocytosis of pro-MMP-2 but had no affect on the 
endocytosis of the pro-MMP-2-TIMP-2 complex (Emonard et al., 2004).  This 
suggests that complexing pro-MMP2 with thrombospondin-1 can mediate 
proMMP-2 endocytosis whereas endocytosis of pro-MMP-2-TIMP-2 complex is 
via a two step process which is independent of thrombopondin-1.  Similar to pro-
MMP2, MMP-9 can be internalised by LRP-1 alone or in a complex with TIMP-1 
(Hahn-Dantona et al., 2001) although another member of the LDL receptor 
family, megalin has also been shown to internalise MMP-9 (Van den Steen et al., 
2006).  The internalisation of MMP-13 occurs after transfer of the proteinase to 
LRP-1 from an unknown Ca2+-sensitive 170 kDa receptor (Barmina et al., 1999).  
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Furthermore, LRP-1-mediated catabolism of MMP-13 was shown to be impaired 
in human osteoarthritic chondrocytes in vitro (Walling et al., 2003), indicating that 
LRP-1-mediated endocytosis may be an important mechanism regulating the 
extracellular level of MMP-13 in the cartilage matrix.    In this study, the mRNA 
level of LRP-1 was not significantly altered between control and OA 
chondrocytes.  This suggests that other factors such as a change in cell surface 
expression of LRP-1 or altered expression of the unidentified 170 kDa receptor 
may account for the reduced endocytosis of MMP-13 by OA chondrocytes. 
  
1.5.1.1.3.3. Other properties of LRP-1 
LRP-1 can itself be cleaved by proteases on the cell surface.  For example, 
malignant cells down–regulate the expression of LRP-1 and in malignant cells 
MT1-MMP has been shown to cleave the ligand binding domain of LRP-1 into 
several fragments, impairing the internalisation of the 125I-labeled LRP-1-specific 
antibody, 8G1 (Rozanov et al., 2004).  Furthermore, a soluble form of LRP-1, 
arising from cleavage within the 85 kDa subunit of LRP-1, was detected in 
human plasma and is a competitive inhibitor of LRP-1 endocytosis (Quinn et al., 
1997; 1999).  The ectodomain of LRP-1 can also be shed by BACE (β site of 
APP-cleaving enzyme) (von Arnim et al., 2005) and tPA (Polavarapu et al., 
2007).  ADAM-12 has been implicated as the sheddase responsible for cleaving 
LRP-1 in the endometrium, inhibiting endocytosis of MMP-2 and MMP-9.  The 
resulting increase in the extracellular concentration of MMP-2 and MMP-9 
facilitates ECM remodelling during the menstrual cycle (Selvais et al., 2009). 
 
Deletion of the LRP-1 gene is embryonic lethal as LRP-1-null mice die at around 
day 10 in embryo (Herz et al., 1992; 1993).  In addition to its role in fetal 
development, LRP-1 is emerging as having an important role in the development 
of Alzheimer’s disease, a neurodegenerative disorder characterized by neuronal 
loss and the accumulation of extracellular β-amyloid plaques and intracellular 
neurofibrillary tangles.  The main component of amyloid plaques is amyloid-β 
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(Aβ) peptide, which is a cleavage product of the β-amyloid precursor protein 
(APP).  A study by Ulery et al showed that transfection of APP and LRP-1 in 
LRP-1-deficient cells led to a 3-fold increase in Aβ, demonstrating that LRP-1 
promotes APP endocytosis and APP processing to Aβ (Ulery et al., 2000).  
Furthermore, LRP-1 endocytoses APP, apoE, lactoferrin, Aβ and α2M, all of 
which have been genetically associated with Alzheimer’s disease (Herz and 
Bock, 2002).  Studies have also indicated that polymorphisms within the LRP-1 
gene are associated with Alzheimer’s disease and the levels of LRP-1 decrease 
with age (Kang et al., 1997; 2000; Kolsch et al., 2003).     
 
LRP-1 is also emerging as an important signalling molecule.  For example, since 
each α2M* molecule contains four receptor binding sites, α2M* can 
simultaneously bind to several LRP-1 receptors on the cell surface.  This causes 
LRP-1 aggregation and induces a calcium influx via N-methyl-D-aspartate 
(NMDA) receptors in primary neurons (Bacskai et al., 2000).  In addition, binding 
of extracellular ligands may promote secretase-mediated LRP-1 cleavage.  
Cleavage of LRP-1 and the release of the intracellular domain has been shown 
to inhibit Jun N-terminal kinases (JNK) (Hoe et al., 2005) and may also directly 
modulate gene transcription by colocalising with the transcription modulator, 
Tip60, in the nucleus (Kinoshita et al., 2003).  A recent paper reported that ligand 
binding to LRP-1 in neurons resulted in LRP-1 phosphorylation, activation of Src 
family kinase (SFK) and SFK-dependent Trk receptor transactivation (Shi et al., 
2009). 
 
1.5.1.1.4. LRPb 
LRP1b shares 59 % identity with LRP-1.  In contrast with LRP-1, LRP1b contains 
one additional ligand-binding repeat within its fourth ligand-binding domain and 
also has a unique 33 amino acid sequence within its cytoplasmic tail (Liu et al., 
2000b).   LRPb is highly expressed in the brain, thyroid and salivary gland and 
can bind and internalise many LRP-1 ligands including uPA, tPA and PAI-1 
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although it has a slower rate of endocytosis (t1/2 ~ 8 min) compared to LRP-1 (t1/2 
~ 0.5 min) (Liu et al., 2001).  LRP1b was originally named LRP-deleted in 
tumours (LRP-DIT) because it was found to be totally deleted or to contain 
inactivating mutations in 40 % of non small cell lung cancer cell lines (Liu et al., 
2000a).  This suggests that LRPb1 may be a tumour suppressor. 
 
1.5.1.1.5. Megalin/LRP-2 
Megalin is found in many absorptive epithelia and is expressed in a variety of 
tissues including the intestinal brush border (Yammani et al., 2001), uterus and 
oviduct (Argraves and Morales, 2004) and the male reproductive tract (Van Praet 
et al., 2003).  LRP-1 ligands including MMP-9 (Van den Steen et al., 2006), 
lactoferrin and PAI-1 complexes also bind megalin (Willnow et al., 1992).  
Megalin is also expressed in the kidney and is required for the reabsorption of 
vitamins and vitamin/protein complexes including retinol (Christensen et al., 
1999), vitamin B (Moestrup et al., 1996) and vitamin D (Nykjaer et al., 1999).  In 
addition, thyroxine (Sousa et al., 2000) as well as androgens and estrogens 
(Hammes et al., 2005) are endocytosed by megalin.  Circulating antibodies to 
both megalin and RAP cause Heymann nephritis, a rat model of autoimmune 
kidney disease (Kerjaschki and Farquhar, 1982; Orlando et al., 1992; 
Pietromonaco et al., 1990).   
 
Megalin is thought to be required for normal cholesterol transport in the 
developing embryo.  Megalin knockout mice present with developmental 
abnormalities in the lung, kidney and central nervous system and die shortly after 
birth due to respiratory insufficiency (Willnow et al., 1996a). 
 
1.5.1.1.6. MEGF7/LRP4 
MEGF7/LRP4 was identified as a member of the LDL-R family in a motif trap 
screen of large EGF repeat transcripts expressed in mammalian cells 
(Nakayama et al., 1998).  MEGF7/LRP4-null mice present with growth 
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retardation as well as fusion and duplication of the digits (polysyndactyl) 
(Johnson et al., 2005).  MEGF7/LRP4 inhibits Wnt signalling in vitro suggesting 
that it may have a role in modulating signaling pathways controlling limb 
development in the embryo. 
 
1.5.1.1.7. LRP8/apoE receptor 2 
LRP8, also known as apoE receptor 2 was cloned from cDNA libraries of 
humans, mice and chickens (Kim et al., 1996; Novak et al., 1996).   The human 
receptor contains 7 ligand binding repeats and is expressed in the brain, ovaries, 
testis and placenta (Stockinger et al., 1998).   It has broad ligand binding ability, 
similar to that of VLDL-R.  The mouse and chicken receptors contain 8 ligand 
binding repeats, possibly due to alternative splicing (Brandes et al., 1997; 
Schneider et al., 1997). 
 
1.5.1.1.8. SorLa/LRP11 
SorLa/LRP11 is a 250 kDa receptor which is expressed in human brain, spinal 
cord and testis (Jacobsen et al., 1996).  In addition to ligand-binding repeats, 
SorLA/LR11 also possesses a Vps10p domain and is thus classified as a 
member of the Vsp10p-domain receptor family (Hermey, 2009).  SorLa/LRP11 
ligands include RAP, apoE and lipoprotein lipase although it has a slower rate of 
endocytosis compared to LRP-1 (Jacobsen et al., 1996).   
 
1.5.1.1.9. LRP-5 and LRP-6 
LRP-5 and LRP-6 are distantly related members of the LDL-R family and are 
closely related to each other in structure and sequence (Herz and Bock, 2002).  
Unlike other members of the LDL-R family, their cytoplasmic domain does not 
contain an NPXY motif.  Both LRP-5 and LRP-6 are likely to function as co-
receptors in the Wnt signalling pathway (Mao et al., 2001a; 2001b). 
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Figure 3: Structure of LDL receptor family members.   
A, Core members of the LDL-receptor family.  In LRP-1, the ligand binding clusters are 
numbered I-IV.  B, members of the extended family.  Adapted from Lillis et al (2008) and 
Herz and Bock (2002). 
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1.5.1.2. Other functions of RAP 
Aside from its ability to bind LRP-1 and consequently inhibit the endocytosis of all 
its known ligands, RAP also binds to other members of the LDL receptor family 
with high affinity (Kd ~ 1-10 nM) including megalin (Kounnas et al., 1992a), VLDL-
R (Battey et al., 1994), apoER2 (Stockinger et al., 1998) and sorLA/LR11 
(Jacobsen et al., 1996).  In addition, RAP also binds LDL-R with low affinity (Kd ~ 
250 nM) (Medh et al., 1995).  RAP is found in the endoplasmic reticulum (ER), 
where it acts as a molecular chaperone, preventing the premature interaction of 
co-expressed ligands with their receptor and/or improper folding (Bu et al., 1995; 
Bu and Rennke, 1996; Obermoeller et al., 1997; Willnow et al., 1996c).  It is 
expressed in all human tissues examined to date, with very high expression in 
the kidney and brain (Bu et al., 1994; Zheng et al., 1994).  Early binding studies 
showed that each LRP-1 molecule had 2 distinct RAP binding sites (Williams et 
al., 1992).  However, studies using truncated soluble minireceptors of LRP-1 
indicated that 5 independent RAP binding sites are present on LRP-1; 2 on each 
of the second and fourth ligand binding domains of LRP-1 and one on the third 
(Bu and Rennke, 1996).  It has been suggested that RAP may inhibit endocytosis 
by direct ligand competition.  Additionally, the binding of RAP to LRP-1 may 
induce a conformational change in the receptor so that ligand binding sites are 
masked (Horn et al., 1997; Neels et al., 1999). 
 
The ability of RAP to compete with the binding of many diverse ligands is likely 
due to its small size and presence of multiple binding sites.  RAP can also inhibit 
the binding of the same ligand to several members of the LDL-R family, 
suggesting a level of redundancy between these receptors.  For example, RAP 
inhibits the binding of lactoferrin to both LRP-1 and megalin/LRP-2 (Willnow et 
al., 1992). The ability of RAP to act as a universal ligand antagonist to the LDL-R 
family makes it a useful experimental tool to identify new ligands of these 
receptors.   
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In addition to members of the LDL-R family, RAP has been shown to bind and/or 
inhibit other receptors, including lipolysis-stimulated receptor (Troussard et al., 
1995), cubilin (Birn et al., 1997) and sortilin (Petersen et al., 1997; Tauris et al., 
1998).  In hepatocytes, the lipolysis-stimulated receptor clears chylomicron 
remnants (Yen et al., 1994), whereas in the kidney, cubilin facilitates endocytosis 
of intrinsic factor-vitamin B12 (Birn et al., 1997).  Sortilin, related to SorLa/LRP11, 
is a receptor from the Vsp10p domain gene family that lacks LDL-A repeats and 
it endocytoses apolipoprotein A-V (Nilsson et al., 2008).  
 
Ligand blotting experiments using 125I-Labeled Fluoresceinamine-Heparin ([125I]-
F-Hep) have showed that RAP binds directly to heparin.  Unlabeled heparin 
effectively competed for the binding of [125I]-F-Hep to RAP whereas chondroitin 
sulfate had no effect, indicating that heparin binding was specific and not due to 
non-specific charge interactions (Orlando and Farquhar, 1993).  In subsequent 
studies using recombinant RAP fusion proteins, the heparin binding site within 
RAP was mapped to the C-terminus between amino acids 261 and 323 (Orlando 
and Farquhar, 1994).  This suggests that RAP could bind to cell surface HSPGs.   
 
1.5.1.3. HSPGs as co-receptors 
HSPGs have been identified as co-receptors for the endocytosis of several 
ligands of the LDL-R family.  It is hypothesised that HSPGs may concentrate 
ligands on cell surface and facilitate their internalisation and degradation by 
presenting them to a specific receptor.  The availability of HSPGs on the cell 
surface can be regulated by proteolytic cleavage of the core protein as well as by 
cleavage of the HS chains by extracellular heparanase (Vlodavsky et al., 2002).   
 
LDL can be dissociated from the LDL-R by treatment with heparin and other 
sulfated GAGs (Goldstein et al., 1976) whilst the binding of uPA-PAI-1 
complexes to LRP-1 is also heparin-sensitive (Nykjaer et al., 1992).  Similarly, 
cell surface HSPGs are required for LRP-1-mediated binding and degradation of 
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thrombospondin-1 and thrombospondin-2 (Mikhailenko et al., 1995; Murphy-
Ullrich et al., 1988; Yang et al., 2001), suggesting that cell surface HSPG binding 
is a prerequisite for internalisation.  However, a later study showed that the LRP-
1 binding site of thrombospondin-1 differed from its heparin binding domain 
(Wang et al., 2004b).  This suggests that HSPG binding is not necessary for 
thrombospondin-1 to bind LRP-1 at the cell surface but that subsequent 
endocytosis requires high affinity heparin binding (Wang et al., 2004b).   
 
Our laboratory has shown that RAP, heparin and another sulfated glycan, 
calcium pentosan polysulfate (CaPPS), cause accumulation of TIMP-3 in the 
conditioned medium of HTB94 human chondrosarcoma cells (Troeberg et al., 
2008).  These agents also increase TIMP-3 accumulation by chondrocytes and 
matrix of porcine cartilage explants suggesting that a member of the LDL-R 
family may mediate TIMP-3 internalisation and that HSPGs may act as a co-
receptor for ligand transfer.  TIMP-3 has been reported to sequester to the ECM 
by association with HSPGs (Yu et al., 2000).  Perlecan may be the HSPG 
involved in TIMP-3 binding to the matrix since in a review article, Knox and 
Whitelock quote an unpublished study where TIMP-3 reportedly binds perlecan 
and is localized pericellulary (Knox and Whitelock, 2006).  
 
1.5.1.4. HSPGs as independent receptors 
There have been several studies proposing that HSPGs may also function as 
ligand receptors by mechanisms independent to their function as a co-receptor.  
Any molecule bound to HSPGs on the cell surface could be internalised with the 
HSPG as part of normal HSPG turnover on the cell surface.  Following 
internalisation, HSPGs are degraded rapidly by the lysosomal pathway or 
recycled back to the cell surface (Egeberg et al., 2001).  On the cell surface, 
HSPGs typically have a half-life of 3 – 8 h (Egeberg et al., 2001; Yanagishita and 
Hascall, 1992) 
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HSPGs have been shown to sequester BMP2 at the cell surface and mediate its 
internalisation in C2C12 myoblasts (Jiao et al., 2007).  In addition to basic 
fibroblast growth factor (bFGF) internalisation via FGF receptor 1 (FGFR-1) or 
FGF receptor 2 (FGFR-2) (Dionne et al., 1990), bFGF is also internalised 
independently through its interaction with cell surface HSPGs (Roghani and 
Moscatelli, 1992).  The heparan sulfate pathway of bFGF internalisation was 
shown to be heparin-sensitive and binding was not efficiently competed by 
unlabeled bFGF, indicating that bFGF bound to cell surface HSPGs with low 
affinity.  Further studies using electron microscopy revealed that the FGFR-
independent mechanism of FGF internalisation was by calveolae, flask-shaped 
non-coated membrane invaginations (Gleizes et al., 1996).  Additionally, 
fibronectin matrix turnover occurs through a calveolin-1-dependent mechanism 
(Sottile and Chandler, 2005) although soluble fibronectin has been shown to be 
endocytosed by an LRP-1-dependent mechanism in mouse embryonic 
fibroblasts (Salicioni et al., 2002).   
 
The syndecan family of proteoglycans have been reported to mediate the binding 
and internalisation of lipoprotein lipase (LpL)-enriched low density lipoprotein 
(LDL) via an LRP-1-independent pathway (Fuki et al., 1997).  Endocytosis of 
LpL-enriched LDL was triggered by ligand clustering and was sensitive to 
cytochalasin B.  Syndecan-mediated internalisation of LpL-enriched LDL was 
reported to be independent of coated pits and was found to be mediated via 
detergent-insoluble, cholesterol-rich membrane rafts (Fuki et al., 2000b).  A 
further study by the same group reported that endocytosis of LpL-enriched LDL 
can be independent of both LRP-1 and syndecan, proceeding with a slower half-
life (t½) of internalisation of 6 h, compared to 1 h via the syndecan pathway (Fuki 
et al., 2000a).  Cells expressing perlecan but no other proteoglycans bound and 
internalised LpL-enriched LDL (Fuki et al., 2000a).  Internalisation was 
unaffected by cytochalasin D but was inhibited by the tyrosine kinase inhibitor, 
genistein.  Perlecan has also been reported to mediate the uptake of HIV-1 Tat, a 
transcriptional transactivator of the HIV-1 virus, although only a small amount of 
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HIV-1 Tat was degraded by lysosomes.  This suggests that perlecan uptake of 
HIV-1 Tat is not a major cellular clearance mechanism for this protein (Argyris et 
al., 2004).     
 
1.6. Aims of thesis 
Our laboratory recently suggested that HTB94 chondrosarcoma cells and primary 
chondrocytes may endocytose TIMP-3 (Troeberg et al., 2008).  This work raised 
the hypothesis that TIMP-3-sensitive enzymes such as ADAMTS-4 may also be 
endocytosed.  The aim of this thesis is to determine whether ADAMTS-4 can be 
cleared from the medium of HTB94 chondrosarcoma cells and primary 
chondrocytes via cellular uptake and intracellular degradation. Investigating 
whether the extracellular level of ADAMTS-4 could be regulated by endocytic 
clearance may identify a further mechanism regulating ADAMTS-4 activity in the 
matrix.     
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2.1. Reagents  
2.1.1. Cells/Tissue 
Human chondrosarcoma cells (HTB94) and CHO-K1 cells were from American 
Culture Type Collection (Manassas, VA, USA).   psgA-745 CHO cells, deficient in 
both chondroitin sulfate and heparan sulfate proteoglycans (Esko et al., 1985) 
were a kind gift from Professor Jeffrey Esko (San Diego, USA).  Human epithelial 
kidney (HEK-293/EBNA) cells were from Invitrogen (Paisley, UK).  HEK-
293/EBNA cells transfected with pCEP4-ADAMTS-4 constructs were obtained 
from frozen laboratory stocks prepared by Dr Christine Gendron.  A schematic 
diagram of full-length ADAMTS-4 and the domain deletion mutants used in this 
study are shown in Figure 4.   
 
 
 
Figure 4: Schematic diagram of full-length ADAMTS-4 and domain deletion 
mutants used in this study.   
The predicted molecular mass is based on the amino acid composition.  Each protein 
contains a C-terminal FLAG sequence epitope (D-K-Y-D-D-D-D-K).  The arrow indicates 
the position of the potential furin cleavage site.  Abbreviations - Pro, pro-domain; Cat, 
catalytic metalloproteinase domain; Dis, disintegrin domain; TS-1, thrombospondin type 
1 motif; Cys, cysteine-rich domain; Sp, spacer domain.  Adapted from Gendron et al 
(2007). 
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MEF-1, PEA-10 (heterozygous LRP-1-deficient) and PEA-13 cells (homozygous 
LRP-1 deficient) cells were a kind gift from Professor D Strickland (Maryland, 
USA) and were isolated by repeated selection of mouse embryonic fibroblasts 
heterozygous for a disrupted LRP-1 allele with the LRP-1 ligand Pseudomonas 
exotoxin A (Kounnas et al., 1992b; Willnow and Herz, 1994).  Porcine 
metacarpophalangeal joints of 3-9 month-old-pigs were from Fresh Tissue 
(London, UK) and were used within 24 hours of slaughter.  Human articular 
cartilage was obtained with informed patient consent and ethical approval from 
the Royal National Orthopedic Hospital (Stanmore, UK).  Human chondrocytes 
were isolated by Mr Brendan Thomas at the Kennedy Institute of Rheumatology 
and were a kind gift.  Wild-type and Timp-3-null mouse dermal fibroblasts were 
obtained from frozen laboratory stocks prepared by Dr Linda Troeberg. 
 
2.1.2. Cell and tissue culture reagents 
Materials were from the following sources:  Dulbecco’s modified eagle’s medium 
(DMEM), DMEM without L-glutamine or phenol red, L-glutamine, HEPES and 
penicillin/streptomycin from Biowhittaker (Berkshire, UK); Ham’s F12 medium, 
fetal calf serum (FCS), G418, hygromycin B and trypsin-versene from PAA 
Laboratories (Sommerset, UK); amphotericin B from Gibco (Paisley, UK);  DMEM 
without L-glutamine, cysteine, methionine or cystine from MP Biomedicals (CA, 
USA); Pronase E from BDH (Dorset, UK); lactalbumin enzymatic hydrolysate, 
type 1A bacterial collagenase, heparin, de-N-sulfated heparin, chondroitin 
sulfate, cytochalasin D, Protease Inhibitor Cocktail for mammalian cell and tissue 
extracts, 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), 
GM6001 and L-trans-epoxysuccinyl-leucyl amido(4-guanidio)butane (E-64) from 
Sigma-Aldrich (Dorset, UK); CT1746 from Celltech (Slough, UK); dermatan 
sulfate from Calbiochem (Nottingham, UK); calcium pentosan polysulfate from 
Arthropharm (Sydney, Australia).  AEBSF and each of the GAGs were dissolved 
in serum-free DMEM to a stock concentration of 100 mM and 50 mg/ml, 
respectively.  Cytochalasin D, E-64, GM6001, CT1746 and phosphoramidon 
Chapter 2  Materials and Methods                                             
 
 59 
were all dissolved in dimethyl sulfoxide (DMSO) to a stock concentration of 10 
mM. 
 
2.1.3. SDS-PAGE and Western blotting reagents 
Materials were from the following sources:  Polyvinylidene difluoride membrane 
(PVDF), ECL Plus, ECL Advance Western Blotting Detection System and Reblot 
Plus Strong Solution from Chemicon (CA, USA); photographic Hyperfilm from GE 
Healthcare (Buckinghamshire, UK); pre-stained and unstained Precision Protein 
Standards Precision Protein StandardsTM from Bio-Rad (Hemel Hempstead, UK);  
30 % (w/v) acrylamide/bis-acrylamide from Severn Biotech (Worcestershire, UK); 
2-amino-2-methyl-1,3-propanediol (ammediol) and Tween20 from Sigma-Aldrich 
(Dorset, UK); Western Blue stabilized substrate for alkaline phosphatase (AP) 
from Promega (Southampton, UK).  
 
2.1.4. Proteins and antibodies 
Materials were from the following sources:  anti-mouse AP-linked antibody and 
anti-rabbit AP-linked antibody from Promega (Southampton, UK); anti-rabbit 
horseradish peroxidase (HRP)-linked antibody and anti-mouse HRP-linked 
antibody from GE Healthcare (Buckinghamshire, UK); mouse anti-low-density 
lipoprotein receptor-related protein-1 (LRP-1) antibody (8G1) and Azocoll > 100 
mesh from Calbiochem (Nottingham, UK); mouse monoclonal anti-FLAG M2-
antibody and anti-FLAG M2-agarose from Sigma-Aldrich Ltd (Dorset, UK); TIMP-
3 monoclonal antibody 183551 from R&D Systems (Minneapolis, USA); FLAG 
peptide (D-K-Y-D-D-D-D-K) from Advanced Biotechnology Centre (Imperial 
College, London, UK); recombinant glutathione S-transferase (GST)-tagged 
interglobular domain (IGD) aggrecan substrate (GST-IGD-FLAG) and N-TIMP-3 
from Dr Linda Troeberg in this laboratory; ADAMTS4-1 from Dr Kasu Fushimi in 
this laboratory, ADAMTS4-2 (for iodination) from Dr Christine Gendron in this 
laboratory. 
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The rabbit anti-ADAMTS-4 antibody was raised in this laboratory against the 
purified recombinant catalytic domain of human ADAMTS-4.  Rabbit anti-LRP-1 
antibody (2629) was a kind gift from Professor Dudley Strickland (Maryland, 
USA).  Recombinant His-tagged receptor-associated protein (RAP) was a kind 
gift from Dr Hérve Emonard (Christian de Duve Institute of Cellular Pathology 
and Université Catholique de Louvain, Brussels, Belgium).  Human α2-
macroglobulin (α2M) was a kind gift from Professor Jan Enghild (University of 
Aarhus, Denmark). 
 
2.1.5. Radiochemical Reagents 
Materials were from the following sources: Redivue™ Pro-Mix™ L-[35S] in vitro 
Cell Labeling Mix from GE Healthcare (Buckinghamshire, UK); Goldstar 
Multipurpose Liquid Scintillation Cocktail from Meridian (Surrey, UK); Iodine-125 
was from MP Biomedicals (CA, USA); IODO-BEADS Iodination Reagent from 
Pierce Biotechnology (Illinois, USA). 
 
2.1.6. Molecular Biology Reagents 
Materials were from the following sources: Lipofectamine™, RNAiMAX and 
Optimem 1 + GlutaMax medium from Invitrogen (Paisley, UK); siRNAs (double-
stranded RNA targeting LRP-1 (forward, GACUUGCAGCCCCAAGCAGUU; 
reverse, CUGCUUGGGGCUGCAAGUCUU) and control) (Dedieu et al., 2008) 
were kind gifts from Dr Hérve Emonard (Christian de Duve Institute of Cellular 
Pathology and Université Catholique de Louvain, Brussels, Belgium). 
 
2.1.7. Fluorescent Microscopy Reagents 
Materials were from the following sources: Alexa Fluor 488 and Alexa Fluor 568 
Succinimidyl Esters and ProLong Gold antifade reagent from Molecular Probes, 
Invitrogen (Oregon, USA); concanavalin A and N, N-Dimethylformamide (DMF) 
from Sigma-Aldrich (Dorset, UK).   
Chapter 2  Materials and Methods                                             
 
 61 
2.1.8. Other reagents 
Materials were from the following sources: 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) from Molecular Probes, Invitrogen (Oregon, 
USA); Vivaspin Ultrafiltration Spin Columns (MWCO 3000) from Sartorius Ltd 
(Epsom, UK); Slide-A-Lyzer Dialysis Casettes (MWCO 3500) from Thermo 
Scientific (Illinois, USA); PD-10 Desalting Columns, G-50 Micro Columns and 
Sephacryl S-200 from GE Healthcare (Buckinghamshire, UK); Sephadex G-50 
from Pharmacia Fine Chemicals (Uppsala, Sweden);  methylamine-
hydrochloride, Brij35 solution 30 % (w/v) and sodium nitroprusside from Sigma-
Aldrich (Dorset, UK). 
 
2.2. Cell culture 
2.2.1. Cell line culture 
Cells (HEK-293/EBNA, HTB94, MEF-1, PEA-10, PEA-13, wild-type and Timp-3-
null mouse dermal fibroblasts) were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin 
and 10 % (v/v) FCS.  HEK-293/EBNA cells transfected with pCEP4-ADAMTS-4 
constructs were cultured with the addition of 250 µg/ml G418 and 100 µg/ml 
hygromycin B.  Wild-type and psgA-745 CHO cells were grown in Ham’s F12 
medium supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin and 10 % 
(v/v) FCS.  Cells were passaged every 3-5 days and detached from the culture 
dish by incubation with trypsin-versene.  
 
2.2.2. Porcine chondrocyte isolation and culture 
Porcine metacarpophalangeal joints were dissected into DMEM containing 10 % 
FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mg/ml fungizone and 10 mM 
HEPES.  The cartilage was washed thrice with medium to remove synovial fluid.  
Cartilage (1 g) was incubated overnight with 10 ml DMEM containing 0.25 mg/ml 
type 1A bacterial collagenase (37 ºC with shaking).  The chondrocytes were 
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isolated from undigested material by passing the solution through a cell strainer 
into a 50 ml Falcon tube.  The medium was centrifuged at 327 g for 5 min and 
the cell pellet was washed with 10 ml of DMEM.  The wash step was repeated 
and the chondrocytes were re-suspended in 10 ml of DMEM.  Cell yield and 
viability was determined by diluting a sample with an equal volume of trypan blue 
and counting the number of live and dead cells under a light microscope.  The 
isolated chondrocytes were plated in DMEM supplemented with 100 U/ml 
penicillin, 100 µg/ml streptomycin and 10 % (v/v) FCS and rested for 2-3 days 
before use. 
 
2.3. SDS-PAGE and Western blots 
2.3.1. SDS-PAGE 
Proteins were resolved by SDS-PAGE with reduction using a modification of the 
ammediol/glycine/HCl buffer system of Wyckoff et al. (Wyckoff et al., 1977) or the 
Tris-glycine buffer system according to Laemmli (Laemmli, 1970).  
Polyacrylamide gels were made with 6-12 % total acrylamide, depending on the 
size of the proteins to be separated.  Samples were diluted with an equal volume 
of 2 x reducing sample buffer [42 mM ammediol or 0.125 mM Tris-HCl, 0.01 % 
(w/v) sodium azide, 2 % SDS, 0.1 % (w/v) bromophenol blue, 50 % (w/v) 
glycerol, 1 % β-mercaptoethanol] and boiled for 5 min prior to SDS-PAGE.  
Typically, ammediol gels were run at 150 V for 45-60 min and Tris-glycine gels 
were run at 150 V for 90 min. 
 
2.3.2. Gel staining 
2.3.2.1. Coomassie Brilliant Blue R-250 staining  
SDS-PAGE gels were stained with Coomassie Brilliant Blue R-250 stain [0.1 % 
(w/v) Coomassie Brilliant Blue R-250, 50 % (v/v) methanol and 20 % (v/v) acetic 
acid] for 30 min before several 30 min washes with destaining solution [30 % 
(v/v) methanol and 1 % (v/v) formic acid].   
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2.3.2.2. Silver staining 
SDS-PAGE gels were stained using silver stain (Shevchenko et al., 1996).  Gels 
were incubated with fixing solution [50 % (v/v) methanol and 5 % (v/v) acetic 
acid] for 20 min and washed for 10 min with 50 % (v/v) methanol.   Next, gels 
were washed for at least an hour (usually overnight) with dH20 and then 
incubated with sensitizer [0.02 % (w/v) sodium thiosulfate] for 1 min.  After 
washing twice with dH20, gels were incubated with cold silver reagent [0.1 % 
(w/v) silver nitrate] for 30 min at 4 ºC.  Following this, gels were washed twice 
with dH20 and protein bands were detected by addition of developer [0.04 % (v/v) 
formalin and 2 % (w/v) sodium carbonate].  The developer was discarded and 
replaced as soon as it turned yellow so that protein bands were developed in an 
absolutely transparent solution.  Once protein bands could be detected, the 
developing reaction was stopped using 5 % (v/v) acetic acid. 
 
2.3.3. Western blotting 
Proteins separated by SDS-PAGE were analysed by Western blotting using 
Novex Mini-cell (Invitrogen) or Mini-Trans-Blot cell (BIO-RAD) systems.  The 
proteins were transferred to PVDF at 200 mA for 2.5 h (Invitrogen) or 350 mA for 
1 h (BIO-RAD) in transfer buffer [20 % (v/v) methanol, 12.6 mM Tris, 96 mM 
glycine and 0.1 % (w/v) SDS].  Following transfer, the membranes were blocked 
with either 5 % BSA in TBS or 5 % dry skim milk in TBS for 1 h at room 
temperature.  In general, membranes were incubated overnight with primary 
antibodies in either 1 % BSA-TBS or 1 % dry milk-TBS at 4 ºC.  Antibody 
dilutions were as follows:  anti-ADAMTS-4-catalytic 1:500, anti-FLAG M2 1:1000, 
anti-LRP-1 (2629) and anti-LRP-1 (8G1) 1:5000, anti-TIMP-3 (183551) 1:2500.  
Membranes were then washed thrice with TBS containing 0.1 % Tween 20 and 
incubated with AP-linked secondary antibody (1:5000) or HRP-linked secondary 
antibody (1:5000) for 1 h at room temperature.  Membranes were subsequently 
washed thrice with TBS containing 0.1 % Tween 20 before development.  
However, in the case of LRP-1 detection using the mouse anti-LRP-1 antibody 
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(8G1), membranes were blocked with 5 % dry skim milk in 20 mM Tris (pH 7.5), 
0.5 M NaCl, 0.05 % Tween 20 for 2 h at room temperature.  They were also 
washed extensively with 20 mM Tris (pH 7.5), 0.5 M NaCl, 0.05 % Tween 20 and 
incubated with both primary and secondary antibodies in 0.5 % milk in 20 mM 
Tris (pH 7.5), 0.5 M NaCl, 0.05 % Tween 20.  Western blots were developed as 
follows:  AP Western blots developed with Western Blue AP substrate until bands 
appeared.  The AP reaction was then stopped with AP stop solution [20 mM Tris-
HCl (pH 7.5), 10 mM EDTA]; HRP Western blots were incubated according to the 
manufacturers instructions (GE Healthcare) with either ECL-Plus or ECL-
Advance chemiluminescence substrate for 1 or 5 min, respectively.  Protein 
bands developed by HRP were detected by exposure to photographic film. 
 
2.3.4. Densitometry 
Gels and Western blots were scanned using a BioRad GS-710 imaging 
densitometer.  The pixel intensity of the protein bands were quantified using 
Phoretix 1D software (Nonlinear Dynamics, Newcastle-upon-Tyne, UK).  
Unmodified 16-bit TIFF images were analysed and the background pixel intensity 
was subtracted using the ‘rolling ball’ method. 
 
2.4. Protein purification 
2.4.1. ADAMTS4-2 purification 
HEK-293/EBNA cells stably transfected with pCEP4-ADAMTS4-2 were grown to 
confluence in the presence of hygromycin B (200 µg/ml) and G418 (250 µg/ml).  
Upon reaching confluence, the cells were washed once with serum-free DMEM 
to remove serum and then incubated in serum-free DMEM containing 0.2 % 
lactalbumin enzymatic hydrolysate.   The conditioned medium was collected after 
3-5 days and centrifuged to remove cell debris.   
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The conditioned medium was applied to a 2 ml anti-FLAG M2-agarose column at 
room temperature.  The column was washed with 10 column volumes of 1 M 
NaCl buffer [50 mM Tris-HCl (pH 7.5), 1 M NaCl, 10 mM CaCl2, 0.02 % sodium 
azide, 0.02 % Brij-35] to remove non-specifically bound proteins.  The column 
was then washed with 5 column volumes of Tris-buffered-saline (TBS, pH 7.4).  
The protein was eluted with 200 µg/ml FLAG peptide in TNC-Brij buffer [50 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 10 mM CaCl2, 0.02 % sodium azide, 0.02 % 
Brij-35].  Fractions were run on SDS-PAGE and proteins were silver stained.     
 
Fractions containing the protein were pooled and concentrated to a volume of 2.5 
ml using a Vivaspin ultrafiltration spin column (MWCO 3000).  The protein was 
applied to a Sephacryl S-200 gel filtration column (1.6 cm X 100 cm) equilibrated 
with TNC-Brij.  This step removed the FLAG peptide from the protein.  Fractions 
were run on SDS-PAGE and proteins were silver stained.  Fractions containing 
the protein were pooled, divided into aliquots and stored at -80 ºC. 
 
2.4.2. Metabolic labeling and purification of recombinant ADAMTS-4 
constructs 
HEK-293/EBNA cells stably transfected with pCEP4-ADAMTS4-2 or pCEP4-
ADAMTS4-5 constructs were grown to confluence in a 150 cm2 flask, washed 
once with serum-free DMEM without L-glutamine, cysteine, methionine or cystine 
to remove serum and then incubated in serum-free DMEM without L-glutamine, 
cysteine, methionine or cystine containing 0.2 % lactalbumin enzymatic 
hydrolysate and [35S]Met/[35S]Cys (25 µCi/ml).   The conditioned medium was 
collected after 3-5 days and centrifuged to remove cell-debris.  Conditioned 
media was applied to a 2 ml anti-FLAG M2-agarose column and eluted with 
FLAG peptide as described above.       
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2.4.3. Titration of ADAMTS4-2 using GST-IGD-FLAG substrate 
The concentration of active ADAMTS4-2 was determined by titration with N-
TIMP-3, using a recombinant GST-IGD-FLAG substrate.  The GST-IGD-FLAG 
substrate was designed in-house by Dr Masa Kashiwagi and characterized by Dr 
Ngee Han Lim.  The substrate is based on the IGD sequence of aggrecan core 
protein with a GST-tag at the N-terminus and a FLAG-tag at the C-terminus 
(Figure 5) and contains both MMP and aggrecanase cleavage sites.  ADAMTS4-
2 (2.5 µl) was incubated with 2.5 µl of N-TIMP-3 (0-400 nM) for 1 h at 37 ºC.  The 
enzyme and inhibitor complex was incubated with 2.4 mg/ml GST-IGD-FLAG 
substrate (5 µl) for 90 min at 37 ºC.  The reaction was stopped with 2 x reducing 
sample buffer containing 10 mM EDTA (10 µl).  Each sample (10 µl) was 
analysed by SDS-PAGE (10 % acrylamide) and Coomassie Brilliant Blue R-250 
staining.  
  
 
Figure 5: Schematic diagram of recombinant aggrecan IGD substrate. 
The recombinant substrate was constructed in this laboratory by Dr Masa Kashiwagi and 
is composed of the IGD domain of aggrecan with a GST-tag at the N-terminus and a 
FLAG-tag at the C-terminus.    The substrate contains both the MMP and aggrecanase 
cleavage sites.  It is expressed in E.coli and purified using glutathione Sepharose.  
Figure adapted from Christine Gendron’s thesis (2005). 
 
2.4.4. Determination of ADAMTS4-5 concentration using BSA standard 
curve 
ADAMTS4-5 has essentially no aggrecanase activity (Kashiwagi et al., 2004).  
Therefore, to determine the approximate concentration of [35S]ADAMTS4-5, the 
amount of protein was determined by standard curve against BSA.  Increasing 
amounts of BSA (ng) and an aliquot of [35S]ADAMTS4-5 (5 µl) were analysed by 
SDS-PAGE and silver staining.  The gel was scanned and the pixel volume of 
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each band was determined using Phoretix software.  The concentration of 
[35S]ADAMTS4-5 was calculated from the standard curve using the equation y = 
mx + c.   
 
2.5. Assays to monitor ADAMTS-4 clearance/cellular uptake  
2.5.1. Western blot assay  
Cells were plated at a density of 1 x 106 cells/well (6-well plate).  After resting 
overnight, cells were washed thrice with serum-free DMEM before incubation for 
1 h at 37 ºC with DMEM containing 0.1 % BSA with or without GM6001 (10 µM), 
E-64 (10 µM), AEBSF (100 µM), heparin (5-500 µg/ml), chondroitin sulfate, de-N-
sulfated heparin or dermatan sulfate (all at 100 µg/ml).  Following this, 
conditioned medium, containing ADAMTS4-2 (1.5 nM), was added and incubated 
for up to 24 h in a final volume of 2 ml.  After incubation, the conditioned medium 
was removed and the protein was precipitated with TCA (3.3 %) overnight at 4 
ºC.  The TCA-soluble fraction was separated from the TCA-insoluble fraction by 
centrifugation at 14170 g for 15 min at 4 ºC and the TCA-insoluble fraction was 
re-suspended in 60 µl of 2 x reducing sample buffer.  In order to detect the 
enzyme within the cell, the cell layer was washed with ice-cold PBS and lysed 
with 60 µl of 2 x reducing sample buffer.  The wash fractions were also 
precipitated with TCA (3.3 %) as described above.  All samples (15 µl) were 
analysed by SDS-PAGE (7.5 % acrylamide) and Western blotting using the anti-
ADAMTS-4 catalytic domain antibody.  
 
2.5.2. Radioactivity-based assay  
Cells were plated at a density of 1x106 cells/well (6-well plate) or 0.5 x 106 
cells/well (12-well plate).  After resting overnight, cells were washed thrice with 
serum-free DMEM before incubation for 1 h at 37 ºC with DMEM containing 0.1 
% BSA with or without the following agents: GM6001 (1-50 µM), CT1746 (1-20 
µM), E-64 (10 µM), AEBSF (100 µM), phosphoramidon (10 µM), cytochalasin D 
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(10 µM), heparin (5-500 µg/ml), chondroitin sulfate, de-N-sulfated heparin, 
dermatan sulfate, calcium pentosan polysulfate or hylauronan (all at 250 µg/ml), 
RAP (500 nM).  As a control for agents diluted in DMSO, the equivalent dilution 
of DMSO was added to separate wells.  Following this, [35S]ADAMTS-4 
constructs or [125I]-α2M* (see section 2.11.) were added and cultured for up to 24 
h in a final volume of 2 ml (6-well plate) or 1 ml (12-well plate).  After incubation, 
the conditioned medium was removed and the protein was precipitated with TCA 
(3.3 %) overnight at 4 ºC.  The TCA-soluble fraction was separated from the 
TCA-insoluble fraction by centrifugation at 14170 g for 15 min at 4 ºC.  The cells 
were placed on ice and washed thrice with ice-cold PBS.  The wash fractions 
were transferred into a scintillation vial and counted directly.  The cell layer was 
incubated with 0.1 % pronase in DMEM for 10 min on ice.  The cells were then 
pipetted into an Eppendorf tube.  Each well was then washed once with DMEM 
and the wash was added to each cell suspension.  The surface bound (pronase-
sensitive) fraction was separated from the intracellular fraction (pronase-
resistant) fraction by centrifugation at 755 g for 5 min at 4 ºC.  Both the TCA-
insoluble pellet and the cell pellet were dissolved in 1 M NaOH (500 µl).  In some 
experiments, the surface bound and intracellular fractions were harvested 
together (cell-associated fraction) by lysis with 1 M NaOH.  Radioactivities in 
each fraction were counted as follows: [35S] using a 1410 Liquid Scintillation 
Counter (Wallac, Pharmacia) and [125I] using a 1282 COMPUGAMMA Universal 
Gamma Counter (Wallac, Pharmacia).  The amount of TCA-soluble radioactivity 
in the preparation of labeled protein prior to incubation with cells was subtracted 
from the amount of TCA-soluble radioactivity in the sample at the time of harvest.  
This corrected for any TCA-soluble radioactivity in the starting material.    
 
2.6. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
assay for measuring cell viability 
HTB94 cells were plated at a density of 1 x 106 cells/well (6-well plate) or 0.5 x 
106 cells/well (12-well plate).  After resting overnight, cells were washed thrice 
with serum-free DMEM.  To examine cell viability, cells were incubated in DMEM 
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containing 0.1 % serum and treated with either GM6001 (100 µM), heparin (500 
µg/ml), cytochalasin D (10 µM) or RAP (500 nM) or DMSO carrier control at the 
appropriate dilution for up to 24 h.  Sodium nirtroprusside (2 mM) was used as a 
positive control for cell death in all experiments (Del Carlo and Loeser, 2002).  
Cell viability was then determined by the MTT assay, described by Mosmann et 
al. (Mosmann, 1983).  The conditioned medium was removed and the cells were 
washed once with phenol red-free DMEM before incubation with 975 µl phenol 
red-free DMEM and 25 µl of MTT reagent (5 mg/ml in PBS) for 45 min at 37 ºC.  
One ml of 10 % SDS in 10 mM HCl was added to solubilise the formazan 
crystals.  After overnight incubation at 37 ºC, 200 µl of each well was transferred 
to a 96-well plate and the absorbance was read at 574 nm using a FLUOstar 
Omega (BMG Labtech) plate reader. 
 
2.7. siRNA knockdown of LRP-1 protein expression in HTB94 cells 
siRNAs (double-stranded RNA targeting LRP-1 or control) were transiently 
transfected into HTB94 cells using Lipofectamine RNAiMAX (Invitrogen).  
Throughout the transfection procedure, penicillin and streptomycin were not 
added to the medium because these antibiotics reduce transfection efficiency.   
HTB94 cells were plated overnight at a density of 1.5x104 cells/well (12-well 
plate) in DMEM containing 10 % FCS.  Immediately before transfection, the 
medium on the cells was replaced with 1 ml of serum-free DMEM.  For each 
transfection, siRNA (50 – 300 pmol) was diluted in serum-free Optimem to a final 
volume of 100 µl.  In a separate tube, 2 µl of RNAiMAX was diluted in 98 µl 
serum free Optimem.  The siRNA and RNAiMAX solutions were combined and 
incubated for 20 min at room temperature.  The RNAiMAX-siRNA mixture (200 
µl) was then gently pipetted into each well to ensure an even distribution of the 
siRNA in the medium.  After overnight culture, the medium was removed and the 
cells were washed once with serum-free DMEM.  The medium was replaced with 
1 ml of DMEM containing 10 % FCS and the cells were cultured for 3 days.  After 
3 days in culture, the cells were confluent.  The medium was removed and the 
cells washed with ice-cold PBS.  The cells were lysed with CHAPS buffer [10 mM 
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CHAPS, 20 mM HEPES (pH 7.4), 150 mM NaCl, 2 mM CaCl2], supplemented 
with protease inhibitor cocktail (1:40) and incubated for 5 min on ice.  The cell 
lysate was then scraped into an Eppendorf tube, diluted 1:1 with non-reducing 
sample buffer [0.125 mM Tris-HCl, 0.01 % (w/v) sodium azide, 2 % SDS, 0.1 % 
(w/v) bromophenol blue, 50 % (w/v) glycerol] and briefly sonicated on ice.  Equal 
volumes of each sample were analysed by SDS-PAGE using the Tris-Glycine 
buffer system (6 % acrylamide). 
 
2.8. Microscopy studies 
2.8.1. Protein labeling 
2.8.1.1. Alexa Fluor 488 labeling of ADAMTS4-2  
After purification, 400 µl of a 2.4 µM solution of ADAMTS4-2 was exchanged into 
HEPES-Brij buffer [20 mM HEPES (pH 8.2), 150 mM NaCl, 10 mM CaCl2, 0.02 % 
sodium azide, 0.02 % Brij-35] by dialysis at 4 ºC using a Slide-A-Lyzer dialysis 
casette (MWCO 3500).  Dialysis was necessary to exchange ADAMTS4-2 from 
TNC-Brij into a buffer free from ammonium ions or primary amines as these 
groups react with the fluorophore and reduce the efficiency of the labeling 
reaction.  Alexa Fluor 488 was diluted in DMF (1 mg/ml).  ADAMTS4-2 was 
incubated with Alexa Fluor 488 for 1 h at room temperature.  The amount of 
Alexa Fluor 488 in the final reaction was 110 µg/ml.  After incubation, glycine was 
added to a final concentration of 50 mM to quench the reaction and the solution 
was passed over a PD10 column equilibrated with TNC-Brij to ensure the 
removal of unreacted Alexa Fluor 488 fluorophore.  Alexa Fluor 488-labelled 
ADAMTS4-2 was analysed by SDS-PAGE with silver staining.  The gel was also 
visualized using a Fujifilm FLA-200 phosphoimager (resolution 50, sensitivity 
F1000, Fluor 473, filter 7520).  The fluorescence intensity was also determined 
using a SpectraMax Gemini plate reader (ex. 495 nm, em. 519 nm). 
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2.8.1.2. Alexa Fluor 568 labeling of Concanavalin A  
Concanavalin A was used to visualize the cell surface as it binds specifically to 
mannosyl and glucosyl residues of polysaccharides and glycoproteins (Goldstein 
et al., 1965).  Concanavalin A was diluted to a concentration of 1 mg/ml with 
HEPES-Brij buffer [20 mM HEPES (pH 8.2), 150 mM NaCl, 10 mM CaCl2, 0.02 % 
sodium azide, 0.02 % Brij-35] and Alexa Fluor 568 was diluted in DMF (1 mg/ml).  
Concavalin A (1 ml) was incubated with Alexa Fluor 568 for 1 h at room 
temperature.  The amount of Alexa Fluor 568 in the final reaction was 48 µg/ml.  
After incubation, Alexa Fluor 568-concanavalin A was purified using a PD10 
column as described above for Alexa Fluor 488-ADAMTS4-2.  However, 10 mM 
manganese was added to the TNC-Brij buffer because concanavalin A requires a 
transition metal ion, such as manganese, plus calcium for binding (Sumner and 
Howell, 1936). 
 
2.8.2. Confocal microscopy 
To visualize ADAMTS4-2 within the cell, HTB94 cells were seeded on glass 
coverslips (1x105 cells in 12-well plate), rested overnight and washed thrice in 
phenol red-free, serum-free DMEM.  Cells were then incubated at 37 ºC in 
phenol red-free DMEM containing 0.1 % BSA with or without 250 µg/ml heparin.  
After 1 hour, Alexa Fluor 488-ADAMTS4-2 (15 nM in final volume of 500 µl), with 
a fluorescent reading of ~ 1300 fluorescent units (FU) was added.  As a negative 
control to demonstrate that unbound fluorophore in the Alexa Fluor 488-
ADAMTS4-2 preparation could not be detected, ~ 1300 FU of free Alexa Fluor 
488 diluted in TNC-Brij was added to another well.     
 
Cells were incubated overnight with Alexa Fluor 488-ADAMTS4-2.  The medium 
was then removed and the cells washed thrice with ice-cold PBS.  The cells were 
fixed with 4 % PFA at room temperature for 20 min.  After fixation, the cells were 
washed with PBS and incubated with 35 µg/ml Alexa Fluor 568-concanavalin A in 
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PBS for at room temperature for 10 min.  Following this, the cells were washed 
with PBS before mounting with ProLong Gold reagent.    
 
Each sample was viewed using a Nikon Eclipse TE2000-U confocal laser 
scanning microscope.  To ensure that the intensity of each image could be 
compared, each sample was scanned on the same day with lasers of the same 
intensity and identical exposure times.  The data were collated using Volocity 
software (Improvision). 
 
2.9. Heparin-binding affinity of ADAMTS4-2 and ADAMTS4-1  
The heparin-binding affinity of ADAMTS4-2 and ADAMTS4-1 was analyzed by 
heparin-Sepharose affinity chromatography.  ADAMTS4-2 or ADAMTS4-1 (250 
ng) diluted in TNC-Brij (500 µl) was passed over a column of heparin-Sepharose 
under gravity flow.  The flow-through was collected and bound protein was eluted 
with a step-wise gradient of 0.15-1 M NaCl in 50 mM Tris-HCl (pH 7.5), 10 mM 
CaCl2, 0.02 % sodium azide, 0.02 % Brij-35.  Elutions (500 µl) were TCA-
precipitated (3.3 %) overnight at 4 ºC.  The TCA-soluble fraction was separated 
from the TCA-soluble fraction by centrifugation at 14170 g for 15 min at 4 ºC.  
The TCA-insoluble fraction was resuspended in 50 µl of 2 x SDS-reducing SDS-
PAGE buffer and 15 µl of each sample were analysed by SDS-PAGE (7.5 % 
acrylamide) and Western blotting using the anti-ADAMTS-4-catalytic domain 
antibody.  
 
2.10. α2M preparation 
2.10.1. Azocoll assay 
Azocoll was suspended in 50 mM Tris-HCl (pH 7.8), 1 mM CaCl2, to a 
concentration of 5 mg/ml.  Trypsin was diluted to a concentration of 10 - 100 
µg/ml with TNC-Brij and incubated 1:1 vol with TNC-Brij, α2M or α2M* for 15 min 
at room temperature prior to addition of 490 µl Azocoll suspension.  The samples 
were rotated at room temperature.  At the time intervals indicated, the reaction 
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was stopped by centrifugation at 14170 g for 5 min at 4 ºC.  The supernatant was 
removed and 150 µl aliquots transferred to a 96-well plate.  The absorbance was 
read in triplicate at 550 nm using a FLUOstar Omega (BMG Labtech) plate 
reader.  
 
2.10.2. Methylamine-HCl treatment of α2M  
α2M (6 µM) was incubated with 264 mM methylamine-HCl in 100 mM Tris-HCl 
(pH 8) at room temperature for 1 h.   A separate incubation of α2M in 100 mM 
Tris-HCl (pH 8) served as a negative control.  The samples were exchanged into 
TNC-20 % glycerol buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10 mM 
CaCl2, 0.02 % sodium azide, 20 % glycerol] using a G-50 Sepharose (50 µl Micro 
Column) and activity against trypsin assayed using the Azocoll assay described 
above.  Two µl aliquots of α2M or α2M* were incubated with 8 µl of 10 µg/ml 
trypsin for 15 min prior to the addition of 490 µl Azocoll substrate. 
 
2.10.3. Heat induced fragmentation of α2M.   
α2M or α2M* (2.2 mg/ml) was incubated with 35 µl of 0.05 M Tris-HCl (pH 9.5), 2 
% SDS and 28 mM DTT and heated at 100 ºC for 30 min.  Twenty µl of 75 % 
glycerol/H20/bromophenol blue was added and 40 µl was analysed by SDS-
PAGE (6 % acrylamide) and stained with Coomassie Brilliant Blue R-250. 
 
2.11. Iodination of α2M*  
Iodination of α2M* was performed using iodination beads, according to the 
manufacturer’s instructions.  Two iodination beads were washed with 1000 µl 
PBS to remove any loose particles and then dried on filter paper.  The beads 
were then added to the carrier-free Na125I in PBS (1 mCi/37 MBq in 100 µl).  The 
beads and carrier-free Na125I were incubated at room temperature for 5 min 
before addition of α2M* (100 µg).  The reaction was incubated for 15 min.  The 
reaction was stopped by transferring the solution to a fresh Eppendorf tube so 
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that the protein was no longer in contact with the iodination beads.  Excess 
Na125I or unincorporated 125I was separated from iodinated α2M* by gel filtration 
in TNC-Brij [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10 mM CaCl2, 0.02 % 
sodium azide, 0.02 % Brij-35] using SephadexG-50 (5 ml column).  Elutions (200 
µl) were collected and 5 µl aliquots of each elution was analysed by reducing 
SDS-PAGE (6 % acrylamide) and silver staining. 
 
2.12. Determination of α2M* concentration using α2M standard curve 
To determine the approximate concentration of [125I]-α2M*, the amount of protein 
was estimated using a standard curve constructed relative to known amounts of 
α2M.  Increasing amounts of α2M (ng) and aliquots of [
125I]-α2M* (5 µl and 10 µl) 
were analysed by SDS-PAGE and silver staining.  The gel was scanned and the 
pixel volume of each band was determined using Phoretix software.  The 
concentration of [125I]-α2M* was calculated from the standard curve using the 
equation y = mx + c. 
 
2.13. Statistical analysis 
Experiments were generally conducted in triplicate (n = 3).  Statistical 
significance (P = ≤ 0.05) was determined using GraphPad Prism software 
(GraphPad Software Inc, CA, USA).  Data were analysed by one way ANOVA 
with a Dunnett’s multiple comparison post test. 
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3.1. Introduction 
Our laboratory has recently reported an increase in endogenous TIMP-3 levels in 
cartilage explants and in the conditioned medium of porcine chondrocytes and 
HTB94 chondrosarcoma cells upon treatment with calcium pentosan polysulfate 
or heparin (Troeberg et al., 2008).  In addition, TIMP-3 accumulation was 
observed when cells were treated with cytochalasin D, an agent which blocks 
endocytosis by disrupting actin polymerization (Flanagan and Lin, 1980) and also 
when cells were treated with receptor-associated protein (RAP), a ligand 
antagonist to members of the low-density lipoprotein receptor (LDL-R) family 
(Hussain et al., 1999).  This work suggested that TIMP-3 may be endocytosed 
and raised the hypothesis that TIMP-3-sensitive enzymes such as ADAMTS-4 
and ADAMTS-5 may also be endocytosed.  This is considered because TIMP-1 
and TIMP-2 can be endocytosed alone or in a complex with MMP-9 and MMP-2, 
respectively (Emonard et al., 2004; Hahn-Dantona et al., 2001). 
 
The hypothesis that ADAMTS-4 could be endocytosed by HTB94 cells was 
investigated by: i) monitoring the disappearance of exogenous ADAMTS4-2 from 
the conditioned medium by Western blot analysis and ii) detecting the 
appearance of Alexa Fluor488-labeled ADAMTS4-2 within the cell using confocal 
microscopy.   
    
3.2. Results 
3.2.1. Monitoring ADAMTS-4 disappearance from the medium of HTB94 
cells by Western blot analysis 
3.2.1.1. Expression of ADAMTS4-2 by HEK-293/EBNA cells 
To study ADAMTS-4 disappearance, a truncated form of full-length ADAMTS-4 
lacking the C-terminal spacer domain (ADAMTS4-2) was used.  Full-length 
ADAMTS-4 (ADAMTS4-1) was not used in this study because the spacer domain 
mediates binding to the ECM and cell surface (Kashiwagi et al., 2004) and the 
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purification of ADAMTS4-1 requires the addition of heparin to the medium in 
order to release the enzyme from the matrix.  Additionally, about 80 % of the 
protein is also C-terminally processed in culture and does not bind to the anti-
FLAG M2-column (Kashiwagi et al., 2004). This makes the purification of 
sufficient quantities of ADAMTS4-1 for experimental purposes problematic.  
Although ADAMTS4-1 is 18-fold more active against the Glu373-Ala374 bond of 
aggrecan than ADAMTS4-2 and is 20-fold more active against the CS-2 region of 
aggrecan, ADAMTS4-2 has a higher activity towards general substrates such as 
fibromodulin and carboxymethylated transferrin than ADAMTS4-1 (Fushimi et al., 
2008).   
  
HEK-293/EBNA cells transfected with FLAG-tagged ADAMTS4-2 were grown to 
confluence and incubated in serum-free DMEM.  After 4 days, the conditioned 
medium (200 ml) was collected, aliquotted and 1 ml was TCA-precipitated (3.3 
%).  The TCA-insoluble pellet was re-suspended in 2 x reducing sample buffer 
and the expression of ADAMTS-4-2 was analysed by Western blotting with either 
the anti-ADAMTS-4 catalytic domain antibody or anti-FLAG M2-antibody.  As 
shown in Figure 6, both antibodies were specific, detecting predominantly the 
active form of the enzyme (51 kDa) in the conditioned medium.  The anti-
ADAMTS-4 catalytic domain antibody was used in all further experiments to 
detect ADAMTS-4 in the conditioned medium by Western blotting.  This ensured 
that the protein could still be detected even if the FLAG-tag underwent 
proteolysis during culture.  
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Figure 6: Western blot of conditioned medium containing ADAMTS4-2.   
Conditioned medium (200 ml) from HEK-293/EBNA cells transfected with ADAMTS4-2 
construct was harvested after 4 days of culture in serum-free DMEM.   Conditioned 
medium (1 ml) was precipitated with TCA (3.3 %) and analysed by Western blotting 
using either the anti-FLAG M2-antibody or anti-ADAMTS-4 catalytic domain antibody. 
 
3.2.1.2. Activity of ADAMTS4-2 as determined by GST-IGD-FLAG substrate 
The concentration of active ADAMTS4-2 in the conditioned medium was 
determined by titration with N-TIMP-3, using a recombinant GST-IGD-FLAG 
substrate, designed in-house by Dr Masa Kashiwagi and characterized by Dr 
Ngee Han Lim.  The substrate is composed of the interglobular domain (IGD) of 
aggrecan with a glutathione S-transferase (GST)-tag at the N-terminus and a 
FLAG-tag at the C-terminus.  The substrate contains both the MMP and 
aggrecanase cleavage sites.  N-TIMP-3 inhibits ADAMTSs in a 1: 1 molar ratio 
(Nagase and Brew, 2003) and the cleavage of GST-IGD-FLAG is completely 
inhibited when the number of ADAMTS molecules is equal to the number of 
TIMP-3 molecules (where the line of inhibition intercepts the x-axis).  To 
determine the concentration of ADAMTS4-2 in the conditioned medium, an 
aliquot of conditioned medium was diluted 5-fold with DMEM.  The diluted 
conditioned medium was then incubated with various concentrations of N-TIMP-3 
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for 60 min.  The ADAMTS-4-2/N-TIMP-3 complex was incubated with GST-IGD-
FLAG substrate for 90 min at 37 ºC and the reaction was stopped by addition of 2 
x reducing sample buffer containing 10 mM EDTA.  Samples were analysed by 
SDS-PAGE and Coomassie staining (Figure 7A).  The gel was scanned and the 
pixel volume of the cleaved 21 kDa product was determined using Phoretix 
software. The concentration of N-TIMP-3 was plotted against the pixel volume of 
the cleaved product (Figure 7B).  As the medium was diluted 5-fold with DMEM 
before titration, the concentration of ADAMTS-4-2 in the medium was 200 nM 
(10.3 µg/ml).  The conditioned medium was frozen in aliquots at -20 ºC and used 
as a source of ADAMTS4-2 for all experiments within this chapter unless 
otherwise stated.   
 
 
 
 
Figure 7: N-TIMP-3 titration of conditioned medium containing ADAMTS4-2. 
The concentration of active ADAMTS4-2 in the conditioned medium was determined by 
titration with known concentrations of N-TIMP-3 using GST-IGD-FLAG substrate.  The 
medium containing ADAMTS4-2 was diluted 5-fold with DMEM before titration.  As a 
negative control, conditioned medium collected from non-transfected HEK-293/EBNA 
cells (HEK-293/EBNA c. medium) was incubated with substrate.  A, The samples were 
analysed by reducing SDS-PAGE and stained with Coomassie Brilliant Blue R250.  B, 
Pixel volume of the 21 kDa product band (arrow) was plotted against N-TIMP-3 
concentration.  [N-TIMP-3] on the graph represents the concentration of N-TIMP-3 in the 
final reaction volume (1:4 dilution). To determine the concentration of ADAMTS4-2 in the 
conditioned medium, the value where the line intercepts the x-axis was multiplied by 4, 
then by 5 (dilution factor of conditioned medium).       
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3.2.1.3. Time course of ADAMTS4-2 disappearance from the medium of 
HTB94 cells  
To investigate whether ADAMTS-4 could be endocytosed, the amount of 
recombinant ADAMTS4-2 remaining in the medium of HTB94 cells over 24 h was 
examined.  HTB94 cells were plated overnight (1 x 106 cells/well) in DMEM 
containing 10 % FCS.  The next day, the cells were washed with serum-free 
DMEM and incubated with conditioned medium containing ADAMTS4-2 (1.5 nM).  
Cells were cultured for up to 24 h and the conditioned medium was harvested at 
the time points indicated.  The cells were washed with PBS and subsequently 
lysed with 2 x reducing sample buffer (60 µl).  The conditioned medium and wash 
fractions were precipitated with TCA (3.3 %).  The TCA-soluble fraction was 
separated from the TCA-insoluble fraction by centrifugation at 14170 g for 15 min 
and the TCA-insoluble fraction was re-suspended in 60 µl of 2 x reducing sample 
buffer.  Equal volumes of all samples were analysed by Western blotting using 
the anti-ADAMTS-4 catalytic domain antibody.     
 
Figure 8A shows that the amount of intact ADAMTS4-2 in the medium of HTB94 
cells reduced over a 24 h time period.  To determine the half-life of ADAMTS4-2 
disappearance from the medium of HTB94 cells, the pixel volume of each band 
in Figure 8A was quantified using Phoretix software and the amount of 
ADAMTS4-2 remaining in the medium at each time point was calculated as % of 
the amount of ADAMTS4-2 at 0 h (Figure 8B).  In this experiment, the half-life 
(t½) of ADAMTS4-2 disappearance was 2 h.  However, the enzyme could not be 
detected in either the wash fractions (Figure 8C) or within the cells (Figure 8D).   
 
Time course experiments to determine the amount of ADAMTS4-2 remaining in 
the medium after incubation with HTB94 cells were repeated twice more.  Graphs 
of pixel volume of ADAMTS4-2 in the medium against time are shown in Figure 
9.  The t½ of ADAMTS4-2 disappearance from the medium was 6 h in Figure 9A 
and 8 h in Figure 9B.  
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Figure 8: ADAMTS4-2 disappearance from the medium of HTB94 cells (i). 
Conditioned medium containing ADAMTS4-2 (1.5 nM) was added to HTB94 cells and 
the conditioned medium was harvested at the time points indicated.  The cells were 
washed with PBS and subsequently lysed with 2 x reducing sample buffer.  The 
conditioned medium and wash fractions were precipitated with TCA (3.3 %).  All 
fractions were analysed by Western blotting using the anti-ADAMTS-4 catalytic domain 
antibody.  A, Western blot of TCA-precipitated conditioned medium.  B, The pixel 
volume of each band was quantified using Phoretix software and the amount of 
ADAMTS4-2 remaining in the medium at each time point was calculated as % of the 
amount of ADAMTS4-2 at 0 h.  C, Western blot of TCA-precipitated wash fraction.  D, 
Western blot of lysed cell fraction.   
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Figure 9: ADAMTS4-2 disappearance from the medium of HTB94 cells (ii). 
Conditioned medium containing ADAMTS4-2 (1.5 nM) was added to HTB94 cells and 
the conditioned medium was harvested at the time points indicated.  The conditioned 
medium was precipitated with TCA (3.3 %).  All fractions were analysed by Western 
blotting using the anti-ADAMTS-4 catalytic domain antibody.  The pixel volume of each 
band was quantified using Phoretix software and the amount of ADAMTS4-2 remaining 
in the medium at each time point was calculated as % of the amount of ADAMTS4-2 at 0 
h.  A, Repeat 1.  B, Repeat 2.    
 
3.2.1.4. ADAMTS4-2 is not autodegraded or degraded by soluble 
proteinases during culture 
ADAMTS4-2 was observed to disappear over time from the medium of HTB94 
cells.  The disappearance of ADAMTS4-2 could be due to autodegradation 
during incubation or degradation by proteases produced by HTB94 cells during 
culture.  To investigate these possibilities, conditioned medium containing 
ADAMTS4-2 was diluted in conditioned medium collected from HTB94 cells over 
24 h at 37 ºC.  Alternatively, conditioned medium containing ADAMTS4-2 was 
diluted in serum-free DMEM.  Each sample was incubated for a further 24 h at 37 
ºC.  The mixture was then TCA precipitated (3.3 %) and the TCA-insoluble pellet 
was analysed by Western blotting with anti-ADAMTS4-catalytic domain antibody.   
 
Upon incubation at 37 ºC  for 24 h, ADAMTS4-2 diluted in serum-free DMEM 
showed a minor degradation fragment at approximately 45 kDa whilst 
ADAMTS4-2 diluted in conditioned medium collected from HTB94 cells remained 
intact and does not appear to be significantly reduced (Figure 10).  This 
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suggested that factors in the conditioned medium collected from HTB94 cells 
may even protect against ADAMTS4-2 degradation and shows that the 
disappearance of ADAMTS4-2 from the medium of HTB94 cells (Figure 8 and 
Figure 9) was not a result of autodegradation or proteolysis by soluble 
proteinases during culture.  This result was investigated further in Chapter 4. 
 
Figure 10: Conditioned medium containing ADAMTS4-2 was not autodegraded 
or degraded by soluble proteinases in HTB94 conditioned medium.    
Conditioned medium containing ADAMTS4-2 was diluted to 1.5 nM with serum-free 
DMEM or with conditioned medium collected from HTB94 cells (C.M).  The medium was 
precipitated with TCA (3.3. %) at 0 h or incubated at 37 ºC for 24 h before TCA-
precipitation.  The TCA-insoluble pellet was analysed by Western blotting using the anti-
ADAMTS4-catalytic domain antibody.  
 
3.2.1.5. The effect of protease inhibitors on ADAMTS4-2 disappearance 
from the medium of HTB94 cells 
To investigate whether ADAMTS4-2 underwent proteolytic degradation on the 
cell surface, HTB94 cells were incubated with a variety of protease inhibitors or 
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DMSO carrier solution for 1 h prior to the addition of conditioned medium 
containing ADAMTS4-2.  Figure 11 shows that the disappearance of ADAMTS4-
2 from the medium of HTB94 cells was not affected by the cysteine protease 
inhibitor E-64 (10 µM) or the serine protease inhibitor AEBSF (100 µM) but was 
partially blocked by the metalloproteinase inhibitor GM6001 (10 µM).  This 
indicates that some metalloproteinase-mediated breakdown of ADAMTS4-2 may 
occur on the cell surface.  These results are investigated in further detail in 
Chapter 4. 
 
Figure  11: The effect of protease inhibitors on ADAMTS4-2 disappearance from 
the medium of HTB94 cells.    
HTB94 cells were incubated at 37 ºC in DMEM containing 0.1 % BSA with or without 
protease inhibitors:  E-64 (10 µM), AEBSF (100 µM), GM6001 (10 µM) or DMSO carrier 
(1/1000).  After 1 h, conditioned medium containing ADAMTS4-2 (1.5 nM) was added.  
After 24 h, the conditioned medium was TCA-precipitated and analysed by Western 
blotting using the anti-ADAMTS-4 catalytic domain antibody.   
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3.2.1.6. Linearity of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) assay 
To determine whether the protection against ADAMTS4-2 disappearance in the 
presence of GM6001 was due to compromised cell viability, the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was used to 
examine cell viability in the presence of this agent.  The MTT assay, first 
described by Mosman (1983) is based on the cleavage of the water-soluble 
tetrazolium salt MTT into insoluble formazan crystals by metabolically active 
cells.  The formazan is then solubilised and the concentration of formazan is 
measured by optical density at 574 nm.   
  
To first demonstrate the dependence of the MTT assay on cell number, HTB94 
cells were seeded at various densities (0-3x106 cells) in a 6-well plate and grown 
overnight.  Cells were then incubated with DMEM containing 0.1 % BSA with or 
without 2 mM sodium nitroprusside (SNP) for 24 h at 37 ºC.   The medium was 
replaced with phenol red-free DMEM and MTT reagent was added for 10 min 
before the addition of 10 % SDS in 10 mM HCl to stop the reaction.  As shown in 
Figure 12A, the absorbance reading reached saturation at a density of 1x106 
cells.  Sodium nitroprusside (SNP) was used at a positive control for cell death 
(Del Carlo and Loeser, 2002) and incubation with SNP (2 mM) reduced cell 
viability at all cell densities.  The assay was subsequently refined so that less 
reagents were required by plating 0.5x106 cells in a 12-well plate and reducing 
the volume of MTT reagent added to each well.  The linearity of the MTT assay 
was determined for HTB94 cells by plotting the time incubated with MTT reagent 
against the absorbance at 574 nm.  Figure 12B shows that under the conditions 
used, the assay was linear up to 0.6 absorbance units.  As a result, MTT reagent 
was added for 45 min before solubilisation of the formazan product to ensure that 
the absorbance obtained fell within the linear range.   
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Figure 12: Linearity of MTT assay. 
A, HTB94 cells were seeded in a 6-well plate at various densities (0 - 3x106 cells), grown 
overnight and treated with SNP for 24 h.  Cells were washed once with phenol red-free 
DMEM before incubation with 900 µl phenol red-free DMEM and 100 µl of MTT reagent 
(5 mg/ml in PBS).  After 10 min, 1 ml of 10 % SDS in 10 mM HCl was added to solubilise 
the formazan crystals. The samples were incubated overnight at 37 ºC and 200 µl of 
each well was transferred to a 96-well plate.  The absorbance was read at 574 nm.  
Results are an average of triplicate wells ± S.D.  B, HTB94 cells were seeded in a 12-
well plate at a density of 0.5x106 cells, grown overnight and washed once with phenol 
red-free DMEM before incubation with 975 µl phenol red-free DMEM and 25 µl of MTT 
reagent (5 mg/ml in PBS).  At the time points indicated, 1 ml of 10 % SDS in 10 mM HCl 
was added to solubilise the formazan crystals. The samples were incubated overnight at 
37 ºC and 200 µl of each well was transferred to a 96-well plate.  The absorbance was 
read at 574 nm.  Results are an average of triplicate wells ± S.D. 
 
3.2.1.7. Viability of HTB94 cells in the presence of GM6001 
HTB94 cells were seeded in a 12-well plate at a density of 0.5x106 cells, grown 
overnight and then incubated with DMSO carrier (1/100), GM6001 (100 µM) or 
SNP (2 mM) for 24 h.  The cells were then assessed for cell viability using MTT.  
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There was no apparent difference in cell viability when cells treated with DMSO 
were compared to cells treated with GM6001 (Figure 13).  SNP caused a 90 % 
reduction in cell viability.   
 
Figure 13: MTT assay of HTB94 cell viability upon incubation with GM6001.  
HTB94 cells were seeded in a 12-well plate at a density of 0.5x106 cells, grown overnight 
and then incubated with DMSO carrier (1/100), GM6001 (100 µM) or SNP (2 mM) for 24 
h.  The medium was removed and the cells were washed once with phenol red-free 
DMEM before incubation with 975 µl phenol red-free DMEM and 25 µl of MTT reagent (5 
mg/ml in PBS).  After 45 min, 1 ml of 10 % SDS in 10 mM HCl was added to solubilise 
the formazan crystals. The samples were incubated overnight at 37 ºC and 200 µl of 
each well was transferred to a 96-well plate.  The absorbance was read at 574 nm.  
Results are an average of triplicate wells ± S.D. 
 
 
3.2.1.8. Heparin protects against ADAMTS4-2 disappearance from the 
medium of HTB94 cells 
TIMP-3 accumulates in the medium of HTB94 cells upon treatment with heparin 
(Troeberg et al., 2008).  To test the effect of heparin on ADAMTS4-2 
disappearance, cells were incubated with or without heparin (250 µg/ml) for 1 h 
before conditioned medium containing ADAMTS4-2 was added.  At the time 
points indicated, the medium was harvested and TCA-precipitated as previously 
described.  Equal volumes of each TCA-insoluble fraction were analysed by 
Western blotting with the anti-ADAMTS4-catalytic domain antibody.  Figure 14 
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shows that the amount of ADAMTS4-2 was reduced in the medium after 24 h 
culture compared to 0 h.    When cells were pre-treated with heparin (250 µg/ml) 
for 1 h prior to the addition of ADAMTS4-2, the amount of intact ADAMTS4-2 in 
the medium after 24 h was increased compared to control cells.  This shows that 
heparin protected against ADAMTS4-2 disappearance from the medium.  
ADAMTS4-2 did not disappear from the medium of cells which had been fixed 
with 4 % PFA (30 min, RT) prior to incubation.  In addition, the TCA-insoluble 
fraction recovered from fixed cells with or without heparin was comparable 
showing that treatment with heparin did not affect the recovery of the TCA-
insoluble fraction of ADAMTS4-2 from the medium.   
 
 
Figure 14: Heparin protects against ADAMTS4-2 disappearance from the 
medium of HTB94 cells. 
Live cells or cells fixed with 4 % PFA were incubated with or without heparin (250 µg/ml) 
for 1 h prior to addition of conditioned medium containing ADAMTS4-2.  After 24 h, the 
conditioned medium was harvested and precipitated with TCA.  Samples were analysed 
by Western blotting using anti-ADAMTS-4 catalytic domain antibody.  The 0 h and 24 h 
samples were loaded on the same blot as the 24 h fixed cell samples.  However, the blot 
was cropped and is shown as 3 separate images. 
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3.2.1.9. Viability of HTB94 cells in the presence of heparin  
HTB94 cells were seeded in a 12-well plate at a density of 0.5x106 cells, grown 
overnight and then incubated with or without heparin (500 µg/ml) for 24 h.  The 
cells were then assessed for cell viability using MTT.  The MTT assay showed 
that there was no significant difference in cell viability when cells were treated 
with heparin compared to control (Figure 15).  SNP reduced cell viability by more 
than 90 %.     
 
Figure 15: MTT assay of HTB94 cell viability upon incubation with heparin.   
HTB94 cells were seeded in a 12-well plate at a density of 0.5x106 cells, grown overnight 
and then incubated with or without heparin (500 µg/ml) or SNP (2 mM) for 24 h.  The 
medium was removed and the cells were washed once with phenol red-free DMEM 
before incubation with 975 µl phenol red-free DMEM and 25 µl of MTT reagent (5 mg/ml 
in PBS).  After 45 min, 1 ml of 10 % SDS in 10 mM HCl was added to solubilise the 
formazan crystals. The samples were incubated overnight at 37 ºC and 200 µl of each 
well was transferred to a 96-well plate.  The absorbance was read at 574 nm.  Results 
are an average of triplicate wells ± S.D. 
 
 
3.2.1.10. Heparin dose-dependently inhibits ADAMTS4-2 disappearance 
from the medium of HTB94 cells 
Since cell viability was not adversely affected by heparin treatment, the protective 
effect of heparin on ADAMTS4-2 disappearance from the medium of HTB94 cells 
was investigated in more detail in a heparin dose-response experiment.  HTB94 
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cells were treated for 1 h with 0 – 400 µg/ml heparin prior to the addition of 
conditioned medium containing ADAMTS4-2 (1.5 nM).  The medium was 
removed and precipitated with TCA as previously described and analysed by 
Western blotting using the anti-ADAMTS-4 catalytic domain antibody (Figure 16).  
The Western blot shows that heparin dose-dependently increased the amount of 
ADAMTS4-2 remaining in the medium during the 24 h incubation with HTB94 
cells.  The pixel volume of each lane was measured using Phoretix software and 
the disappearance of ADAMTS4-2 from the medium was expressed as % of 
ADAMTS4-2 in the medium at 0 h (start material) (Figure 16B).  Fifty percent of 
ADAMTS4-2 remained in the medium when cells were treated with 50 µg/ml 
heparin.  A proportion of the medium was also immunoblotted using the TIMP-3 
antibody (Figure 16C).  There are several non-specific bands at high molecular 
weight (>75 kDa) on the Western blot.  However, two bands are visible at 
approximately 25 and 20 kDa, corresponding to the glycosylated and 
unglycosylated forms of TIMP-3, respectively (Apte et al., 1995).  The pixel 
intensity of these TIMP-3 bands were measured using Phoretix software, added 
together and plotted as TIMP-3 accumulation against heparin concentration 
(Figure 16D).  These data are in agreement with published data from our 
laboratory showing TIMP-3 accumulation in the medium of HTB94 cells upon 
treatment with heparin (Troeberg et al., 2008) 
 
3.2.1.11. The effect of other GAGs on ADAMTS4-2 disappearance from the 
medium of HTB94 cells 
To determine which GAGs other than heparin could protect against ADAMTS4-2 
depletion, cells were treated with other GAGs, including chondroitin-4-sulfate, de-
N-sulfated heparin and dermatan sulfate (all at 100 µg/ml) for 1 h prior to the 
addition of conditioned medium containing ADAMTS4-2 (1.5 nM).  After 24 h, the 
medium was precipitated with TCA and analysed by Western blotting with the 
anti-ADAMTS-4-catalytic domain antibody.  In this experiment, the amount of 
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intact ADAMTS4-2 remaining in the medium was increased by heparin.  
However, the other GAGs tested were not as protective (Figure 17). 
 
Figure 16: Heparin dose-dependently inhibits ADAMTS4-2 disappearance from 
the medium of HTB94 cells.  
HTB94 cells were incubated with heparin (0-400 µg/ml) for 1 h prior to addition of 
conditioned medium containing ADAMTS4-2 (1.5 nM final).  After 24 h, the conditioned 
medium was harvested and precipitated with TCA (3.3 %).  A, Each sample was 
analysed by Western blotting using anti-ADAMTS-4 catalytic domain antibody.  B, The 
pixel volume of each ADAMTS-4 band was measured using Phoretix software and the 
depletion of ADAMTS4-2 from the medium expressed as % of ADAMTS4-2 in the 
medium at 0 h (start material) against concentration of heparin.  C, The sample was 
analysed by Western blotting using anti-TIMP-3 antibody. * denotes glycosylated TIMP-
3.  D, The pixel intensity of each TIMP-3 and TIMP-3* band was measured using 
Phoretix software and expressed as TIMP-3 accumulation against concentration of 
heparin.   
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Figure 17: The effect of GAGs on ADAMTS4-2 disappearance from the medium 
of HTB94 cells.   
HTB94 cells were incubated with or without heparin, chondroitin sulfate, de-N-sulfated 
heparin or dermatan sulfate (100 µg/ml) for 1 h prior to addition of conditioned medium 
containing ADAMTS4-2 (1.5 nM final).  After 24 h, the conditioned medium was 
harvested and precipitated with TCA.  Each sample was analysed by Western blotting 
using anti-ADAMTS-4 catalytic domain antibody.  The start material and control sample 
was loaded on the same blot as the GAG-treated samples.  However, the blot was 
cropped and is shown as 2 separate images. 
 
3.2.2. Monitoring the cellular uptake of ADAMTS4-2 by confocal microscopy 
To support the hypothesis that the disappearance of ADAMTS4-2 from the 
medium was as a result of endocytosis and intracellular degradation, the cell 
fraction was analysed to determine whether ADAMTS4-2 could be detected 
within the cell.  However, Western blot analysis of the cell fraction did not detect 
ADAMTS4-2 within the cell (Figure 8D).  An alternative approach to measure 
internalized ADAMTS4-2 was attempted using fluorescently labeled-ADAMTS4-
2.  This section describes the purification and in vitro labeling of ADAMTS4-2 
with Alexa Fluor 488 fluorophore and the detection of intracellular Alexa Fluor 
488-ADAMTS4-2 by confocal microscopy.    
Chapter 3                                Preliminary investigation of ADAMTS4-2 clearance                                             
 
 93 
3.2.2.1. Purification of ADAMTS4-2 by anti-FLAG M2 chromatography and 
gel filtration 
Conditioned medium from ADAMTS4-2-transfected HEK-293/EBNA cells was 
collected over a 7 day culture and centrifuged to remove cell debris.  The 
conditioned medium was applied to a column of anti-FLAG M2-agarose (1.5 ml 
bed volume) in 2 batches of 500 ml.  The column was washed with 1 M NaCl 
buffer [50 mM Tris-HCl (pH 7.5), 1 M NaCl, 10 mM CaCl2, 0.02 % sodium azide 
and 0.02 % Brij-35], followed by TBS and the bound material was eluted with 200 
µg/ml FLAG peptide diluted in TNC-Brij [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 
10 mM CaCl2, 0.02 % sodium azide and 0.02 % Brij-35].  Figure 18A shows a 
silver stain of aliquots of each elution.  Elutions 1-3 from each column purification 
contained ADAMTS4-2.   These fractions were pooled (~ 18 ml) and diluted to 25 
ml with TNC-Brij.  The eluate was then concentrated to 2.5 ml using a Vivaspin 
ultrafiltration spin column (MWCO 3000).  The concentrated sample was further 
purified by gel filtration using Sephacryl S-200 equilibrated with TNC-Brij.  One 
ml fractions were collected in 96-well plate format (plate 1 A1-H12, plate 2 A1-
E12) and samples from wells spanning this range were analysed by SDS-PAGE 
and silver staining (Figure 18B).   The protein was eluted in fractions H3-H12 
(plate 1) and A1-A7 (plate 2).  These fractions were pooled and stored in aliquots 
at -80 ºC until further use.  The concentration of active ADAMTS4-2 was 
determined by titration with N-TIMP-3 GST-IGD-FLAG substrate as described in 
section 3.2.1.2.  The concentration of ADAMTS4-2 was 2.4 µM (123 µg/ml).  The 
yield of ADAMTS4-2 was 410 µg/L of conditioned medium, comparable with a 
yield of 520 µg/L reported by Kashiwagi et al (2004).   
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Figure 18: Purification of ADAMTS4-2.   
Conditioned medium (1L) from HEK-293/EBNA cells transfected with ADAMTS4-2-FLAG 
was applied to a column of anti-FLAG M2-agarose (1 ml) in batches of 500 ml (column 1 
and column 2).  After washing with 1 M NaCl buffer [50 mM Tris-HCl (pH 7.5), 1 M NaCl, 
10 mM CaCl2, 0.02 % sodium azide, 0.02 % Brij-35] (30 ml) and TBS (30 ml), the 
material bound to the column was eluted (E1-E4) with 3 ml of 200 µg/ml FLAG peptide in 
TNV-Brij [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10 mM CaCl2, 0.02 % sodium azide, 
0.02 % Brij-35.  A, Aliquots (7.5 µl) were analysed by reducing SDS-PAGE and silver 
staining.  Elutions 1-3 from each column (25 ml) were pooled and concentrated 10-fold 
using a Vivaspin ultrafiltration spin column (MWCO 3000).  The sample was then loaded 
on to a Sephacryl S-200 column equilibrated with TNC-Brij.  One ml fractions were 
collected in 96-well plate format (plate 1 A1-H12, plate 2 A1-E12).  B, Aliquots (7.5 µl) 
were analysed by reducing SDS-PAGE and silver staining. 
 
 
3.2.2.2. Labeling ADAMTS4-2 with Alexa Fluor 488 fluorophore 
After purification, 400 µl of a 2.4 µM solution of ADAMTS4-2 was exchanged into 
HEPES-Brij buffer [20 mM HEPES (pH 8.2), 150 mM NaCl, 10 mM CaCl2, 0.02 % 
sodium azide, 0.02 % Brij-35] by dialysis at 4 ºC using a Slide-A-Lyzer dialysis 
cassette (MWCO 3500).  Dialysis was necessary to exchange ADAMTS4-2 from 
TNC-Brij into a buffer free from ammonium ions or primary amines as these 
groups react with the fluorophore and reduce the efficiency of the labeling 
reaction.  Alexa Fluor 488 was diluted in DMF (1 mg/ml).  ADAMTS4-2 was 
incubated with Alexa Fluor 488 for 1 h at room temperature.  The amount of 
Alexa Fluor 488 in the final reaction was 110 µg/ml.  After incubation, glycine was 
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added to a final concentration of 50 mM to quench the reaction and the solution 
was passed over a PD10 column equilibrated with TNC-Brij to ensure the 
removal of unreacted Alexa Fluor 488 fluorophore.  As shown in Figure 19, the 
extent by which ADAMTS4-2 was labeled with the fluorophore was determined 
by SDS-PAGE and silver staining coupled with fluorescence visualization using a 
Fujifilm FLA-200 phosphoimager (resolution 50, sensitivity F1000, Fluor 473, 
filter 7520).  An aliquot of Alexa Fluor 488-labeled ADAMTS4-2 was diluted 3-fold 
with TNC-Brij and the concentration of active enzyme was determined by titration 
with N-TIMP-3 using the GST-IGD-FLAG substrate.  The concentration of Alexa 
Fluor 488-labeled ADAMTS4-2 was 150 nM (7.7 µg/ml). 
 
The fluorescence intensity of an aliquot of Alexa Fluor 488-ADAMTS4-2 was 
measured using a SpectraMax Gemini plate reader (ex. 495 nm, em. 519 nm).  
The enzyme was labeled with ~3200 fluorescent units (FU)/µg ADAMTS4-2.   
 
Figure 19: Labeling ADAMTS4-2 with Alexa Fluor 488. 
A, Purified ADAMTS4-2 was labeled with Alexa Fluor 488 fluorophore and visualized by 
reducing SDS-PAGE combined with silver staining (i) and phosphoimaging (ii).  B, The 
active concentration of Alexa Fluor 488-labeled ADAMTS4-2 was determined by titration 
with N-TIMP-3 using GST-IGD-FLAG substrate, as previously described.  [N-TIMP-3] on 
the graph represents the concentration of N-TIMP-3 in the final reaction volume (1:4 
dilution). To determine the concentration of Alexa Fluor488-ADAMTS4-2, the value 
where the line intercepts the x-axis was multiplied by 4, then by 3 (dilution factor of Alexa 
Fluor488-ADAMTS4-2).       
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3.2.2.3. Alexa Fluor 488-ADAMTS4-2 is internalized into HTB94 cells 
To determine if ADAMTS4-2 was internalized into cells, HTB94 cells were 
seeded on glass coverslips (1 x 105 cells in a 12-well plate), grown overnight and 
washed thrice in phenol red-free, serum-free DMEM.  Cells were then incubated 
at 37 ºC in phenol red-free DMEM containing 0.1 % BSA either with or without 
250 µg/ml heparin.  After 1 h, Alexa Fluor 488-ADAMTS4-2 (15 nM), with a 
fluorescent reading of ~ 1300 FU was added.  As a negative control to 
demonstrate that unbound fluorophore in the Alexa Fluor 488-ADAMTS4-2 
preparation could not be detected, ~ 1300 FU of free Alexa Fluor 488 diluted in 
TNC-Brij was added to another well.     
 
Cells were incubated overnight.  The medium was removed and the cell layer 
was washed with PBS.  The cell layer was then fixed with 4 % PFA (20 min, RT) 
and the cell surface was stained using Alexa Fluor 568-labeled concanavalin A.      
 
Figure 20 shows 2 representative images taken from each treatment.  Sections 
through the cell (0.2 µm) were scanned and collated in one image using Volocity 
software.  No fluorescence was detected in the negative control where an 
equivalent amount of free Alexa Fluor 488 fluorescence was added (Figure 20 A, 
B).  Fluorescent-labeled ADAMTS4-2 was detected within the cell (Figure 20 C, 
D), indicating that Alexa Fluor 488-ADAMTS4-2 could indeed be internalized by 
HTB94 cells.  Heparin reduced the amount of Alexa Fluor 488-ADAMTS4-2 
within the cell (Figure 20 E, F), in agreement with its effects on the amount of 
ADAMTS4-2 remaining in the conditioned medium previously shown in section 
3.2.1.6.       
 
Figure 21 shows a representative section through control and heparin-treated 
cells in higher magnification.   In cells incubated with Alexa Fluor 488-ADAMTS4-
2, clusters of fluorescence were detected underneath the plasma membrane.  In 
agreement with Figure 20, cells treated with heparin have less fluorescence 
detectable within the cell.   
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Figure 20: Detection of Alexa Fluor 488-ADAMTS4-2 within the cell.     
HTB94 cells were pre-treated for 1 h with phenol red-free DMEM containing 0.1 % BSA 
with or without 250 µg/ml heparin before addition of Alexa Fluor 488-ADAMTS4-2 (15 
nM).  After overnight incubation, the medium was removed and the cells were fixed with 
4 % PFA.  The cell surface was visualized by incubation with Alexa Fluor 568-labeled 
concanavalin A.  Sections through the cell (0.2 µm) were scanned and collated in one 
image using Volocity software.  Shown are 2 representative fields of view per treatment.  
A & B, Negative control containing ~1300 units of Alexa Fluor 488.  C & D, Alexa Fluor 
488-ADAMTS4-2.  E & F, Alexa Fluor 488-ADAMTS4-2 plus heparin (250 µg/ml).  
Fluorescent-labeled ADAMTS4-2 (green), fluorescent-labeled concanavalin A (red).  
Scale bar = 20 µm.  
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Figure 21: Detection of Alexa Fluor 488-ADAMTS4-2 within the cell.     
HTB94 cells were pre-treated for 1 h with phenol red-free DMEM containing 0.1 % BSA 
with or without 250 µg/ml heparin before addition of Alexa Fluor 488-ADAMTS4-2 (15 
nM).  After overnight incubation, the medium was removed and the cells were fixed with 
4 % PFA.  The cell surface was visualized by incubation with Alexa Fluor 568-labeled 
concanavalin A.  Sections of 0.1 µm were imaged and processed in the XYZ plane using 
Volocity software.  A, section through a cell incubated with Alexa Fluor 488-ADAMTS4-
2.  B, section through a cell incubated with Alexa Fluor 488-ADAMTS4-2 plus heparin 
(250 µg/ml).  Fluorescent-labeled ADAMTS4-2 (green), fluorescent labeled concanavalin 
A (red).  The white lines indicate the focus point of the image.  Scale bar = 20 µm.   
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3.2.3. Heparin-binding affinity of ADAMTS4-2 
Next, the mechanism by which heparin protects against ADAMTS4-2 
disappearance was investigated.  One possibility is that ADAMTS4-2 binds to 
HSPGs on the cell surface and that heparin displaces cell surface binding of 
ADAMTS4-2.  Therefore, the heparin-binding affinity of ADAMTS4-2 was 
analysed by heparin-Sepharose affinity chromatography.  ADAMTS4-2 (250 ng) 
diluted in TNC-Brij (500 µl) was loaded on a column of heparin-Sepharose under 
gravity flow.  The flow-through was collected and bound protein was eluted with a 
step-wise gradient of 0.15-1M NaCl in 50 mM Tris-HCl (pH 7.5), 10 mM CaCl2, 
0.02 % sodium azide, 0.02 % Brij-35.  Elutions (500 µl) were precipitated with 
TCA (3.3 %) and analysed by reducing SDS-PAGE and Western blotting using 
the anti-ADAMTS-4-catalytic domain antibody.   Figure 22A shows that 
ADAMTS4-2 did not bind to the heparin-Sepharose column.  However, in a 
similar experiment, full-length ADAMTS4-1 (250 ng) bound to heparin-Sepharose 
and was eluted with 0.5 -0.75 M NaCl (Figure 22B).   
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Figure 22: ADAMTS4-2, unlike ADAMTS4-1 does not bind heparin-Sepharose.   
A, ADAMTS4-2 or B, ADAMTS4-1 (250 ng) diluted in TNC-Brij (500 µl) were loaded on a 
column of heparin-Sepharose (100 µl bed volume) under gravity flow.  The flow-through 
was collected and the column was eluted with a step-wise gradient of 0.15-1 M NaCl in 
50 mM Tris-HCl (pH 7.5), 10 mM CaCl2, 0.02 % sodium azide, 0.02 % Brij-35.  Elutions 
(500 µl) were precipitated with TCA (3.3 %) and analysed by reducing SDS-PAGE (7.5 
% acrylamide) and Western blotting using the anti-ADAMTS-4-catalytic domain antibody. 
 
 
3.3. Discussion 
In this chapter, the possibility that ADAMTS-4 activity is regulated by endocytosis 
was examined by monitoring the disappearance of exogenous ADAMTS4-2 from 
the medium of HTB94 cells by Western blotting and visualizing the appearance 
of fluorescently labeled ADAMTS4-2 within the cell by confocal microscopy.    
 
HTB94 cells were chosen as a model system to study ADAMTS-4 endocytosis 
because previous work in our laboratory has shown that TIMP-3, the 
endogenous inhibitor of ADAMTS-4, accumulates in the medium of HTB94 cells 
upon treatment with heparin (Troeberg et al., 2008).  TIMP-3 also accumulates in 
these cells in the presence of the LDL-R family antagonist, RAP (Troeberg et al., 
2008).  These results suggest that endocytic mechanisms exist within this cell 
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type.  Furthermore, HTB94 cells are derived from human chondrocytes and 
chondrocytes are the only cell-type found in cartilage.  Several studies report that 
IL-1 stimulation can induce the expression of ADAMTS-4 in human, porcine and 
bovine chondrocytes (Bau et al., 2002; Curtis et al., 2000; Little et al., 2002; 
Tortorella et al., 2001) and we hypothesised that endocytosis of ADAMTS-4 may 
be an important regulatory mechanism in these cells.   
 
The Western blotting data demonstrated that when added to HTB94 cells, 
ADAMTS4-2, a truncated form of full-length ADAMTS-4 lacking the C-terminal 
spacer domain, disappeared from the medium over time.  However, the half-life 
for disappearance was not reproducible, ranging from 2 – 8h.  One reason for 
this could be that monitoring ADAMTS4-2 disappearance by Western blot 
analysis relies on developing the blot within its linear range.  In addition, 
internalised ADAMTS4-2 could not be detected by Western blot analysis of the 
cell lysate.  However, if the enzyme was internalized and rapidly degraded by 
lysosomes, only a very low amount of enzyme or its degradation products would 
be present within the cell at any one time and the sensitivity limits of Western 
blotting may be too low for the enzyme to be detected. Therefore, to study the 
kinetics of ADAMTS4-2 disappearance in further detail and to detect intact 
ADAMTS4-2 or its degradation products within the cells, it was necessary to 
develop a more sensitive and quantitative assay.  This is the subject of Chapter 
4.   
 
The disappearance of ADAMTS4-2 was not due to autodegradation or 
proteolysis by soluble proteinases.  However, the broad-spectrum 
metalloproteinase inhibitor, GM6001, protected against ADAMTS4-2 
disappearance.  Cell viability, assessed by the MTT assay was not reduced upon 
incubation with GM6001.  Therefore, the protective effect of GM6001 could 
indicate that the disappearance of ADAMTS4-2 from the medium was due to 
metalloproteinase-mediated proteolysis of the enzyme at the cell surface.  This 
will be further investigated in Chapter 4.   
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The disappearance of ADAMTS4-2 could be inhibited when the cells were pre-
treated with heparin but less well when cells were pre-treated with de-N-sulfated 
heparin or other less sulfated GAGs such as chondroitin sulfate or dermatan 
sulfate.  This suggests that cell surface sulfation is an essential requirement for 
ADAMTS4-2 disappearance in HTB94 cells and is similar to the effect of each 
GAG on TIMP-3 accumulation (Troeberg et al., 2008).  Cell viability, assessed by 
the MTT assay was not reduced by treatment with heparin and the protective 
effect of heparin could indicate that the mechanism by which ADAMTS4-2 
disappears is the same as that proposed for TIMP-3 (Troeberg et al., 2008).  This 
study hypothesised that a member of the LDL-R family could be a candidate 
TIMP-3-endocytic receptor, with HSPGs acting as a co-receptor in this cell type 
(Troeberg et al., 2008).   
 
To show that the disappearance of ADAMTS4-2 from the medium was a result of 
endocytosis and intracellular degradation, a fluorescent-based assay was 
developed.  When labeled with Alexa Fluor 488, ADAMTS4-2 retained its activity 
against GST-IGD-FLAG substrate.  Furthermore, when Alexa Fluor 488-
ADAMTS4-2 was added to HTB94 cells and incubated at 37 ºC overnight, 
clusters of fluorescence were detected underneath the plasma membrane of the 
cell.  These data indicated that ADAMTS4-2 was taken into the cell.  The discrete 
packages of fluorescence detected within the cell may represent intracellular 
vesicles.  Heparin reduced the fluorescence detectable within the cell, supporting 
the Western blotting results showing that heparin protects against ADAMTS4-2 
disappearance from the medium of HTB94 cells.  As a negative control, the same 
amount of free Alexa Fluor488 was added to other wells and was not detected in 
the cell.  This shows that the uptake of Alexa Fluor 488-ADAMTS4-2 was specific 
compared to free Alexa Fluor488.  Additionally, as the free Alexa Fluor 488 was 
diluted in TNC-Brij, this shows that the uptake of Alexa Fluor488-ADAMTS4-2 
within the cell was not due to permeabilisation of the plasma membrane by the 
detergent in the buffer.  Although detected within the cell, Alexa Fluor 488-
ADAMTS4-2 was not detected on the cell surface.  The binding of enzyme to the 
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cell surface could have been displaced by washing with PBS.  Alternatively, the 
enzyme may be bound to the cell surface but the amount of fluorescence emitted 
may be below the level of detection.  Further work would be to analyse surface-
bound ADAMTS4-2 by immunostaining with the ADAMTS4-catalytic domain 
antibody and Alexa Fluor 647-conjugated secondary antibody.  It would also be 
informative to determine the exact location of ADAMTS-4 within the cell by co-
staining with an endosomal marker, for example.  Co-localisation with lysosomes 
would provide further evidence of ADAMTS4-2 internalisation and intracellular 
degradation.  Together with the Western blotting results, the confocal data 
suggest that ADAMTS4-2 is endocytosed by HTB94 cells and that this process 
can be blocked by heparin.   
 
To investigate the mechanism of heparin protection, the hypothesis that heparin 
binds to ADAMTS4-2, preventing the binding of the enzyme to HSPGs on the cell 
surface was considered.   Although ADAMTS-4 contains 2 consensus GAG 
binding sites in the spacer domain (692F-R-K-F-R-Y697) and (829R-R-R-P-W-A-G-
R-K837) (Flannery et al., 2002), the spacer domain is completely deleted in the 
ADAMTS4-2 construct used in this study.  However, ADAMTS4-2 retains the 
cysteine rich domain which has also been reported to contain a GAG binding 
motif (668S-K-K-K-F-D-K-C675) (Flannery et al., 2002).  However, ADAMTS4-2 did 
not bind to heparin-Sepharose.  Additionally, recent work by Dr Linda Troeberg in 
our laboratory has also shown that ADAMTS4-1 but not ADAMTS4-2 binds to 
heparin-coated plates (personal communication), suggesting that the major GAG 
binding sites of ADAMTS-4 are within the spacer domain. These results differ 
from work by Flannery et al (2002) who reported that both the p68 form of 
ADAMTS-4, containing the spacer domain (similar to ADAMTS4-1) and the p53 
form of ADAMTS-4 (similar to ADAMTS4-2) bound heparin-Sepharose and were 
eluted with 0.8 M NaCl and 0.5 M NaCl, respectively.  However, the p53 form 
retains a small portion of the spacer domain, including part of a consensus GAG 
binding site (692F-R-K694) (Flannery et al., 2002).  This could account for the 
differences in heparin-binding between the study of Flannery et al and the data 
Chapter 3                                Preliminary investigation of ADAMTS4-2 clearance                                             
 
 104 
presented herein.  However, the data presented in this chapter are in agreement 
with previous work in our laboratory (Kashiwagi et al., 2004).  This work showed 
that in HTB94 cells transfected with ADAMTS4-1, the enzyme was localised to 
the pericellular space and required heparin for its release into the medium, whilst 
the enzyme was spontaneously released into the medium when the spacer 
domain was removed.  These results show that the spacer domain plays a major 
role in localizing ADAMTS-4 to the cell layer.  For these reasons, the mechanism 
of how heparin inhibits the clearance of ADAMTS4-2 from the medium of HTB94 
cells is at present unclear.  It is speculated that ADAMTS4-2 may bind heparin 
very weakly.  Alternatively, TIMP-3, the endogenous inhibitor of ADAMTS-4, 
contains heparin-binding domains and binds sulfated GAGs of the ECM (Yu et 
al., 2000).  It is possible that ADAMTS4-2 could be internalized in a complex with 
TIMP-3 in a similar mechanism as that reported for either MMP-2 and MMP-9 
which can be internalised in a complex with TIMP-2 or TIMP-1, respectively 
(Emonard et al., 2004; Hahn-Dantona et al., 2001).  Heparin could inhibit the 
endocytosis of a TIMP-3-ADAMTS4-2 complex by disrupting the interaction 
between TIMP-3 and its endocytic receptor.  This hypothesis will be considered 
in future chapters.   
 
The results of this chapter show that ADAMTS-4-2 disappears from the medium 
of HTB94 cells and can be detected within the cell by fluorescent microscopy.  
This indicates that ADAMTS4-2 clearance from the medium may be due to 
endocytosis and intracellular degradation.  Both GM6001 and heparin protected 
against ADAMTS4-2 clearance and, in agreement with this hypothesis, heparin 
also reduced the amount of Alexa Fluor 488-ADAMTS4-2 detected within the 
cell.  The cellular uptake of ADAMTS-4 by HTB94 cells could have significance in 
the regulation of ADAMTS-4 activity and localization in normal and/or 
pathological conditions such as OA.  Chapter 4 will describe the development 
and use of a radioactivity-based assay to study the mechanism of ADAMTS-4 
cellular uptake and degradation.    
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Chapter 4 
Development and use of a radioactivity-based assay to 
study the mechanism of ADAMTS-4 clearance  
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4.1. Introduction 
In Chapter 3, Western blotting was used to demonstrate that ADAMTS4-2 
disappeared from the medium of HTB94 cells.  In addition, confocal microscopy 
techniques demonstrated that fluorescent-labeled ADAMTS4-2 could be detected 
within the cell.  The aim of this chapter was to develop a radioactivity-based 
assay using [35S]-labeled ADAMTS4-2 to investigate the mechanism of 
ADAMTS4-2 clearance by HTB94 cells.       
 
4.2. Results 
4.2.1. Purification of [35S]-labeled ADAMTS-4-2 
HEK-293/EBNA cells stably transfected with FLAG-tagged ADAMTS4-2 were 
grown to confluence.  They were metabolically labeled with [35S]Met/[35S]Cys by 
incubation for 4 days in serum-free DMEM without L-glutamine, cysteine, 
methionine or cystine, containing 0.2 % lactalbumin enzymatic hydrolysate and 
[35S]Met/[35S]Cys (25 µCi/ml).  [35S]ADAMTS-4-2 was purified from the 
conditioned medium by anti-FLAG M2 affinity chromatography and FLAG peptide 
elution.  Aliquots of each sample were analysed by SDS-PAGE and silver 
staining.  As the silver stain shows in Figure 23, elution 1 contained a single 
protein band at a molecular weight of approximately 51 kDa.  Similarly, exposure 
to autoradiographic film indicated that the protein was labeled with [35S] and that 
there were no other radioactive contaminants in the preparation.   The purified 
protein was verified to be ADAMTS4-2 by Western blot analysis with both anti-
FLAG M2- and anti-ADAMTS4-catalytic domain antibodies.  
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Figure 23: Purification of [35S]ADAMTS4-2 by anti-FLAG M2 affinity 
chromatography.   
HEK-293/EBNA cells transfected with ADAMTS4-2-FLAG construct were metabolically 
labeled with [35S]Met/[35S]Cys for 4 days.  The resulting conditioned medium (40 ml) was 
loaded onto an anti-FLAG M2-agarose column (2 ml).  After washing with 1 M NaCl 
buffer [50 mM Tris-HCl (pH 7.5), 1 M NaCl, 10 mM CaCl2, 0.02 % sodium azide, 0.02 % 
Brij-35] (20 ml) and TBS (20 ml), the bound material was eluted with 200 µg/ml FLAG 
peptide in TNC-Brij [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10 mM CaCl2, 0.02 % 
sodium azide, 0.02 % Brij-35] in 3 ml fractions.  A, Aliquots were analysed by SDS-
PAGE and silver staining.  B, The gel was dried and exposed to autoradiographic film 
overnight.  C, Western blot of [35S]ADAMTS4-2 using anti-FLAG M2-antibody or anti-
ADAMTS-4 catalytic domain antibody. 
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4.2.2. Activity of [35S]ADAMTS4-2 as determined by GST-IGD-FLAG 
substrate 
After purification, an aliquot of [35S]ADAMTS-4-2 elution 1 was diluted with an 
equal volume of TNC-Brij.  The concentration of active [35S]ADAMTS-4-2 was 
determined by titration with N-TIMP-3, using the GST-IGD-FLAG substrate as 
described in section 3.2.1.2.  Samples were analysed by SDS-PAGE and 
Coomassie Brilliant Blue R250 staining.  The gel was scanned and the pixel 
volume of the cleaved 21 kDa product was determined using Phoretix software. 
The concentration of N-TIMP-3 was plotted against the pixel volume of the 
cleaved product (Figure 24). The concentration of active [35S]ADAMTS-4-2 in 
elution 1 was 200 nM (10.3 µg/ml).   
 
 
Figure 24: N-TIMP-3 titration of [35S]ADAMTS4-2.   
The concentration of active [35S]ADAMTS4-2 in elution 1 was determined by titration with 
known concentrations of N-TIMP-3 using GST-IGD-FLAG substrate.  [35S]ADAMTS4-2 
elution 1 (2.5 µl) was diluted with equal volume of TNC-Brij and then incubated with 2.5 
µl of N-TIMP-3 (0-360 nM) for 60 min prior to the addition of GST-IGD-FLAG substrate 
(5 µl) for 90 min at 37 ºC.  Reactions were stopped by addition of 2 x reducing SDS-
sample buffer containing 10 mM EDTA (10 µl).  The samples were run on reducing SDS-
PAGE and stained with Coomassie Brilliant Blue R250.  Pixel volume of the 21 kDa 
product band was plotted against N-TIMP-3 concentration.  [N-TIMP-3] on the graph 
represents the concentration of N-TIMP-3 in the final reaction volume (1:4 dilution). To 
determine the concentration of elution 1, the value where the line intercepts the x-axis 
was multiplied by 4, then by 2 (dilution factor of [35S]ADAMTS4-2).       
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4.2.3. Detection limits of scintillation counting 
In order to use scintillation counting as a read out, it was necessary to determine 
the linear range of scintillation counting.  To achieve this, both [35S]ADAMTS4-2 
and [35S]-labeled flow-through material were serially diluted 1:1 with TNC-Brij and 
the dilutions were counted. The detection limit of [35S]ADAMTS4-2 against 
background was 50 dpm (Figure 25A).  The highest radioactivity counted in the 
flow-through material was 500,000 dpm and the readings were within linear 
range until 50 dpm (Figure 25B).  All samples were therefore required to be 
greater than 50 dpm to be detectable against background.   
 
When measured by scintillation counting, the amount of [35S]Met/[35S]Cys 
incorporation in this batch was 55000 dpm/µg of [35S]ADAMTS-4-2.  Other 
batches of [35S]ADAMTS-4-2 purifed contained comparable [35S]Met/[35S]Cys 
incorporation.   
 
Figure 25: Linearity of scintillation counting. 
[35S]ADAMTS4-2 or [35S]-labeled flow-through (FT) was serially diluted with TNC Brij and 
the radioactivity was determined by scintillation counting using a Wallac 1410 Liquid 
Scintillation Counter (Pharmacia).  A, [35S]ADAMTS4-2 (single reading).  B, [35S]-labeled  
flow-through (triplicate readings).   
 
 
4.2.4. [35S]ADAMTS4-2 clearance by HTB94 cells  
To determine whether [35S]ADAMTS4-2 was cleared by HTB94 cells, cells were 
plated in a 6-well plate at a density of 1x106cells/well and grown overnight before 
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incubation with DMEM containing 0.1 % BSA.  After 1 h, [35S]ADAMTS4-2 (1.5 
nM) was added to each well.  [35S]ADAMTS4-2 was also added to a 6-well plate 
in DMEM containing 0.1 % BSA without HTB94 cells.  The conditioned medium 
was removed after 24 h and precipitated with TCA (3.3 %) overnight at 4 ºC.   
After precipitation the samples were centrifuged at 14170 g for 15 min 4 ºC to 
separate TCA-soluble material (degradation products) from TCA-insoluble 
material (intact enzyme).  The TCA-soluble fraction was pipetted directly into a 
scintillation vial.  The TCA-insoluble fraction was dissolved in 1 M NaOH prior to 
transfer into a scintillation vial.  After removal of the conditioned medium, the 
cells were placed on ice and washed thrice with ice-cold PBS and the wash 
fractions were transferred to scintillation vials for counting.  The cell layer was 
treated with 0.1 % pronase solution on ice to degrade surface ligands and detach 
cells from the plate.  In wells without cells, the well was treated with pronase to 
remove radioactivity bound to the plate.  After 10 min, the cells readily detached 
from the plate and were pipetted into an Eppendorf tube.  The wells were washed 
once with ice-cold PBS and this was pooled with the cell/pronase suspension 
before centrifugation at 755 g for 5 min to separate the surface-bound (pronase-
sensitive) fraction from the intracellular (pronase-resistant) fraction.  The 
pronase-sensitive fraction was pipetted directly into a scintillation vial and the 
pronase-resistant fraction was dissolved in 1 M NaOH prior to scintillation 
counting.   
 
After 24 h incubation with cells, the amount of [35S]ADAMTS4-2 in the 
conditioned medium decreased and the TCA-soluble fraction increased 
compared to incubation in the absence of cells (Figure 26).  In addition, 
radioactivity was detected on the cell surface and within the cell.  The 
radioactivity detected on the surface of the plate incubated without cells reflects 
the binding of [35S]ADAMTS4-2 to the plasticware and the intracellular fraction is 
absent because there were no cells to harvest.  The wash fractions from wells 
incubated with [35S]ADAMTS4-2 in the presence or absence of cells were 
counted and found to be negligible.   Additionally, the recovery of the total 
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number of counts from the surface-bound, intracellular, TCA-soluble and TCA-
insoluble counts was similar (Figure 26E).  These results also show that the 
enzyme was stable upon incubation in the absence of cells and confirms results 
presented in Chapter 3.   
 
Figure 26: [35S]ADAMTS4-2 clearance by HTB94 cells.     
HTB94 cells were seeded in a 6-well plate at a density of 1x106 cells, rested overnight 
and washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM containing 
0.1 % BSA.  After 1 h, [35S]ADAMTS4-2 (1.5 nM) was added.   [35S]ADAMTS4-2 was 
also added to a 6-well plate in DMEM containing 0.1 % BSA without HTB94 cells.  After 
24 h, the conditioned medium was removed and surface-bound, intracellular, TCA-
soluble and TCA-insoluble fractions were harvested as described in section 2.5.2.  
Results are an average of 3 wells ± S.D.  A, Surface-bound counts.  B, Intracellular 
counts.  C, TCA-soluble counts.  D, TCA-insoluble counts.  E, Total surface-bound, 
intracellular, TCA-soluble and TCA-insoluble counts.  The wash fractions were counted 
and found to be negligible. 
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4.2.5. Time course of [35S]ADAMTS4-2 clearance 
To investigate the kinetics of ADAMTS-4-2 clearance, a time course experiment 
was undertaken in order to determine the half-life (t½) of the disappearance of 
intact TCA-insoluble [35S]ADAMTS4-2 from the medium of HTB94 cells.    The 
cells were plated at a density of 1x106cells/well and grown overnight before 
incubation with DMEM containing 0.1 % BSA.  After 1 h, [35S]ADAMTS4-2 (1.5 
nM) was added to each well.  The conditioned medium was removed at 0, 2, 4, 6, 
8 and 24 h and precipitated with TCA (3.3 %) overnight at 4 ºC.   Fractions were 
harvested as described in section 2.5.2.   
 
Figure 27 shows that the amount of intact TCA-insoluble [35S]ADAMTS4-2 in the 
conditioned medium decreased over time in accordance with the Western 
blotting data presented in Chapter 3.  The half-life of disappearance was 8 h.  
Radioactivity was detected within the cell and on the cell surface and the TCA-
soluble degraded protein increased in the medium over time.  The wash fractions 
were counted and found to be negligible and the recovery of the total number of 
counts from the surface-bound, intracellular, TCA-soluble and TCA-insoluble 
counts was similar at each time point tested (Figure 27C).   
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Figure 27: Time course of [35S]ADAMTS4-2 clearance by HTB94 cells. 
HTB94 cells were seeded in a 6-well plate at a density of 1x106 cells, rested overnight 
and washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM containing 
0.1 % BSA.  After 1 h, [35S]ADAMTS4-2 (1.5 nM) was added.  At the time points 
indicated, the conditioned medium was removed and the surface-bound, intracellular, 
TCA-soluble and TCA-insoluble fractions were harvested as detailed in section 2.5.2.  
Each time point is an average of 3 wells ± S.D.  A, Graph of [35S]ADAMTS4-2 
disappearance 0-24 h.  B, Enlargement of 0-10 h time points, showing the surface-
bound and intracellular fractions only.  C, Total surface-bound, intracellular, TCA-
insoluble and TCA-soluble counts.  The wash fractions were counted and found to be 
negligible. 
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4.2.6. Concentration-dependent clearance of [35S]ADAMTS4-2  
To investigate the concentration-dependence of [35S]ADAMTS4-2 clearance,  
[35S]ADAMTS4-2 was added at a range of concentrations (0.5 - 2 nM) and the 
medium was harvested at various time points.  The TCA-insoluble fraction 
remaining at each concentration was plotted against time of incubation (Figure 
28A).  The TCA-insoluble fraction was expressed as % of the TCA-insoluble 
fraction at 0 h (Figure 28B).  At each of the concentrations tested, 
[35S]ADAMTS4-2 disappeared from the medium at a similar rate.     The TCA-
soluble fraction also increased in the medium but was only proportional to the 
concentration of [35S]ADAMTS4-2 added at earlier time points (Figure 28C). 
 
4.2.7. Competition at 4 ºC show specificity of binding  
The amount of non-specific binding was determined by competition with 
increasing concentrations of non-radioactive ADAMTS4-2 or BSA.   HTB94 cells 
were seeded in a 6-well plate at a density of 1x106 cells, rested overnight and 
washed thrice in serum-free DMEM before incubation at 4 ºC in DMEM 
containing 0.1 % BSA for 30 min.  HTB94 cells were then incubated with 
[35S]ADAMTS4-2 (3 nM) at 4 °C in the presence of ADAMTS4-2 (0 - 300 nM) or 
BSA (0 – 44 µM).  After 2 h the medium was removed.  The cells were washed 
thrice with PBS and the cell layer was harvested with 500 µl of 1 M NaOH and 
the radioactivity bound to the cells was measured by scintillation counting.   As 
Figure 29 shows, the binding of [35S]ADAMTS4-2 was inhibited by addition of 
increasing concentrations of ADAMTS4-2 but not by BSA.   
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Figure 28: Concentration-dependent [35S]ADAMTS4-2 clearance by HTB94 
cells. 
HTB94 cells were seeded in a 6-well plate at a density of 1x106 cells, rested overnight 
and washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM containing 
0.1 % BSA.  After 1 h, [35S]ADAMTS4-2 (2 nM, 1 nM or 0.5 nM) was added.  At the time 
points indicated, the conditioned medium was removed and the TCA-soluble and TCA-
insoluble fractions were harvested as detailed in section 2.5.2.  Each point represents a 
single reading.  A, TCA-insoluble fraction.  B, TCA-insoluble fraction taking dpm at 0 h 
as 100 %.  C, TCA-soluble fraction.   
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Figure 29: Competition of [35S]ADAMTS4-2 binding to HTB94 cells at 4ºC.   
HTB94 cells were seeded in a 6-well plate at a density of 1x106 cells, rested overnight 
and washed thrice in serum-free DMEM before incubation at 4 ºC in DMEM containing 
0.1 % BSA for 30 min.  HTB94 cells were then incubated with [35S]ADAMTS4-2 (3 nM) at 
4 °C for 2 h in the presence of ADAMTS4-2 (0 - 300 nM) or BSA (0 – 44 µM).  Surface-
bound material was harvested as detailed in section 2.5.2.  Data is combined from 2 
independent experiments.  Each replicate is plotted separately. 
 
4.2.8. The effect of protease inhibitors on [35S]ADAMTS4-2 clearance  
To discount the possibility that the clearance of [35S]ADAMTS4-2 from the 
medium and the appearance of TCA-soluble radioactivity was due to degradation 
by proteases during culture, HTB94 cells were incubated for 1 h with a variety of 
protease inhibitors or DMSO carrier control prior to the addition of 
[35S]ADAMTS4-2 (1.5 nM) for 24 h.  The fractions were harvested as described in 
section 2.5.2. As shown in Figure 30, DMSO did not inhibit [35S]ADAMTS4-2 
clearance by HTB94 cells.  Of the inhibitors tested, only GM6001 inhibited 
[35S]ADAMTS4-2 clearance  from the medium.  GM6001 did not affect the 
amount of radioactivity bound to the cell surface or the amount detected within 
the cell.  GM6001 reduced the amount of TCA-soluble radioactivity by 
approximately 50 % compared to untreated cells and the TCA-insoluble fraction 
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was similarly protected.  In this experiment, the recovery of the total number of 
counts from the surface-bound, intracellular, TCA-soluble and TCA-insoluble 
counts was similar across each treatment.      
 
This experiment shows that whilst phosphoramidon, E-64 and AEBSF did not 
affect the clearance of [35S]ADAMTS4-2 from the medium, GM6001 was 
protective, supporting the Western blot data presented in Chapter 3.  In addition, 
cell viability, as determined by the MTT assay was not adversely affected by 
GM6001 (Chapter 3).  To investigate these results further, a dose experiment 
was performed with GM6001 and another hydroxamate-based inhibitor, CT1746.  
Both GM6001 and CT1746 dose-dependently inhibited [35S]ADAMTS4-2 
clearance by HTB94 cells but had no dose-dependent effect on the surface-
bound fraction, although the intracellular fraction was significantly reduced at 
higher doses (Figure 31).    
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Figure 30: The effect of protease inhibitors on [35S]ADAMTS4-2 clearance by 
HTB94 cells.   
HTB94 cells were seeded in a 6-well plate at a density of 1x106 cells, rested overnight 
and washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM containing 
0.1 % BSA with or without protease inhibitors (E-64 (10 µM), AEBSF (100 µM), 
phosphoramidon (10 µM), GM6001 (10 µM) or 1/1000 dilution of DMSO carrier solution.  
After 1 h, [35S]ADAMTS4-2 (1.5 nM) was added.  After 24 h, the conditioned medium 
was removed and the surface-bound, intracellular, TCA-soluble and TCA-insoluble 
fractions were harvested as detailed in section 2.5.2.  Results are an average of 2 wells 
± range.  A, Surface-bound counts.  B, Intracellular counts.  C, TCA-soluble counts 
(corrected for TCA-soluble counts in start material).  D, TCA-insoluble counts.  E, Total 
surface-bound, intracellular, TCA-soluble and TCA-insoluble counts.  The wash fractions 
were counted and found to be negligible. 
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Figure 31: The dose-dependent effect of GM6001 and CT1746 inhibitors on 
[35S]ADAMTS4-2 clearance by HTB94 cells.   
HTB94 cells were seeded in a 6-well plate at a density of 1x106 cells, rested overnight 
and washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM containing 
0.1 % BSA with or without GM6001 (1-20 µM) or CT1746 (1-20 µM).  After 1 h, 
[35S]ADAMTS4-2 (1.5 nM) was added.  The control well contained 1/500 dilution of 
DMSO carrier solution.  After 24 h, the conditioned medium was removed and the 
surface-bound, intracellular, TCA-soluble and TCA-insoluble fractions were harvested as 
detailed in section 2.5.2.   Results are an average of 3 wells ± S.D. * = P ≤ 0.05 as 
compared to control.  A, Surface-bound counts.  B, Intracellular counts.  C, TCA-soluble 
counts (corrected for TCA-soluble counts in start material).  D, TCA-insoluble counts.  E, 
Total surface-bound, intracellular, TCA-soluble and TCA-insoluble counts.  The wash 
fractions were counted and found to be negligible. 
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4.2.9. The effect of cytochalasin D on [35S]ADAMTS4-2 clearance  
4.2.9.1. Assessment of HTB94 cell viability upon cytochalasin D treatment 
Cytochalasin D blocks endocytosis by inhibiting actin polymerization (Flanagan 
and Lin, 1980).  However, prolonged incubation with cytochalasin D is toxic.  
Therefore, in order to determine an appropriate length of incubation of cells with 
cytochalasin D, the viability of HTB94 cells in the presence of cytochalasin D (10 
µM) was assessed using the MTT assay as previously characterized in section 
3.2.1.6.  HTB94 cells contracted within 30 min of cytochalasin D treatment.  As 
shown in Figure 32, cell viability was not affected after 6 h incubation with 
cytochalasin D although a 50 % decrease in cell viability was detected when 
HTB94 cells were incubated in the presence of cytochalasin D for 24 h.  Sodium 
nitroprusside (SNP) caused a 20 % reduction in cell viability at 6 h and a 90 % 
reduction in cell viability at 24 h.  As a result of this experiment, cells were treated 
with cytochalasin D for a maximum of 6 h. 
 
Figure 32: MTT assay of HTB94 cell viability upon incubation with cytochalasin 
D.  
HTB94 cells were seeded in a 6-well plate at a density of 1x106 cells, rested overnight 
and then treated with cytochalasin D (10 µM), 1/1000 dilution of DMSO carrier solution 
or SNP (2 mM) for 6 h (A) or 24 h (B).  The medium was removed and the cells were 
washed once with phenol red-free DMEM before incubation with 975 µl phenol red-free 
DMEM and 25 µl of MTT reagent (5 mg/ml in PBS).  After 45 min, 1 ml of 10 % SDS in 
10 mM HCl was added to solubilise the formazan crystals. The samples were incubated 
overnight at 37 ºC and 200 µl of each well was transferred to a 96-well plate.  The 
absorbance was read at 574 nm.  A, Average of triplicate wells ± S.D.  B, Average of 
duplicate wells ± range.   
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4.2.9.2. Cytochalasin D inhibits the appearance of TCA-soluble fraction 
To test the effect of cytochalasin D on [35S]ADAMTS4-2 clearance from the 
medium of HTB94 cells, cells were treated with 10 µM cytochalasin D or 1/1000 
dilution of DMSO carrier solution for 1 h before the addition of [35S]ADAMTS4-2 
(1.5 nM).  After 5 h, the medium was removed and the TCA-soluble and TCA-
insoluble fractions were harvested as previously described.  In this experiment, 
individual surface-bound and intracellular fractions were not harvested, rather the 
cell layer, after washing with PBS was treated with 1 M NaOH.  This gave both 
surface-bound and intracellular fractions in a single sample (cell-associated 
fraction).  As shown in Figure 33, DMSO did not affect the clearance of 
[35S]ADAMTS4-2 or the appearance of the TCA-soluble degraded fraction.  
Although cytochalasin D had no effect on the cell-associated fraction, it reduced 
the appearance of the TCA-soluble fraction by 50 % and significantly increased 
the TCA-insoluble fraction compared to control.  The recovery of the total number 
of counts from the cell-associated, TCA-soluble and TCA-insoluble counts was 
similar across all treatments. 
 
4.2.10. The effect of heparin on [35S]ADAMTS4-2 clearance by HTB94 cells 
4.2.10.1. Heparin inhibits [35S]ADAMTS4-2 clearance 
Cells were treated with heparin (250 µg/ml) for 1 h before the addition of 
[35S]ADAMTS4-2 (1.5 nM).  Heparin (250 µg/ml) was sufficient to completely 
protect against the disappearance of the TCA-insoluble fraction of 
[35S]ADAMTS4-2 (Figure 34).  These data support the Western blotting data 
presented in Chapter 3 and additionally shows that heparin reduced both the 
surface-bound and intracellular fractions.  Data presented in Chapter 3 show that 
cell viability was not adversely affected by incubation with heparin for 24 h, even 
at a concentration of 500 µg/ml (section 3.2.1.9).  The recovery of the total 
number of counts from the surface-bound, intracellular, TCA-soluble and TCA-
insoluble counts was similar across all treatments. 
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Figure 33: The effect of cytochalasin D on [35S]ADAMTS4-2 clearance by HTB94 
cells.  
HTB94 cells were seeded in a 6-well plate at a density of 1x106 cells, rested overnight 
and washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM containing 
0.1 % BSA with or without cytochalasin D (10 µM) or 1/1000 dilution of DMSO carrier 
solution.  After 1 h, [35S]ADAMTS4-2 (1.5 nM) was added.  After 5 h, the conditioned 
medium was removed and the cell-associated, TCA-soluble and TCA-insoluble fractions 
were harvested as detailed in section 2.5.2.   Results are an average of 3 ± S.D.  * = P ≤ 
0.05 as compared to control.  A, Cell-associated counts.  B, TCA-soluble counts 
(corrected for TCA-soluble counts in start material).  C, TCA-insoluble counts.  D, Total 
cell-associated, TCA-soluble and TCA-insoluble counts.  The wash fractions were 
counted and found to be negligible. 
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Figure 34: Heparin inhibits [35S]ADAMTS4-2 clearance by HTB94 cells.  
HTB94 cells were seeded in a 6-well plate at a density of 1x106 cells, rested overnight 
and washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM containing 
0.1 % BSA with or without heparin (250 µg/ml).  After 1 h, [35S]ADAMTS4-2 (1.5 nM) was 
added.  After 24 h, the conditioned medium was removed and surface-bound, 
intracellular, TCA-soluble and TCA-insoluble fractions were harvested as described in 
section 2.5.2.  Results are an average of 3 wells ± S.D. A, Surface-bound counts.  B, 
Intracellular counts.  C, TCA-soluble counts (corrected for TCA-soluble counts in start 
material).  D, TCA-insoluble counts.  E, Total surface-bound, intracellular, TCA-soluble 
and TCA-insoluble counts.  The wash fractions were counted and found to be negligible. 
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4.2.10.2. Heparin inhibits surface-binding of [35S]ADAMTS4-2 at 4 ºC 
To examine the effect of heparin on [35S]ADAMTS4-2 binding at 4 ºC, cells were 
plated as previously described in a 6-well plate and washed thrice with ice-cold 
PBS prior to incubation at 4 ºC for 30 min in 0.1 % BSA with or without heparin 
(500 µg/ml).  After the incubation period, [35S]ADAMTS4-2 (1.5 nM) was added to 
the cells and incubated at 4 ºC.  After 2 h incubation, the medium was removed 
and the cells were washed once with ice-cold PBS.  The cells were treated with 
0.1 % pronase for 10 min on ice and the surface-bound (pronase-sensitive) 
fraction was separated from the intracellular (pronase-resistant) fraction, as 
previously described.  The amount of radioactivity in each fraction was 
determined by scintillation counting.  Figure 35A shows that heparin inhibited the 
binding of [35S]ADAMTS4-2 to the cell surface by 63 %.  Figure 35B shows that 
when incubated at 4 ºC, the amount of radioactivity detectable intracellularly was 
negligible.  The recovery of the total number of counts from either control or 
heparin treatment were similar.     
 
Figure 35: Heparin inhibits surface-binding of [35S]ADAMTS4-2 at 4 ºC.    
HTB94 cells were seeded in a 6-well plate at a density of 1x106 cells, rested overnight 
and washed thrice in serum-free DMEM before incubation at 4 ºC in DMEM containing 
0.1 % BSA with or without heparin (500 µg/ml).  After 30 min, [35S]ADAMTS4-2 (1.5 nM) 
was added.  After incubation for 2 h at 4 ºC the medium was removed and the surface-
bound, intracellular, wash and unbound fractions were harvested as detailed in section 
2.5.2.  A, surface-bound fraction.  B, Total surface-bound, intracellular and unbound 
counts. The wash fractions were counted and found to be negligible.  Results are an 
average of 2 wells ± range.  
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4.2.10.3. Heparin dose-dependently inhibits [35S]ADAMTS4-2 clearance  
To investigate the effect of heparin on [35S]ADAMTS4-2 clearance in further 
detail, a dose-response experiment was performed using 0 – 500 µg/ml heparin.  
Figure 36 shows that heparin resulted in a dose-dependent decrease in both 
intracellular and surface-bound [35S]ADAMTS4-2.  Additionally, treatment of 
HTB94 cells with heparin dose-dependently inhibited the clearance of 
[35S]ADAMTS4-2 and the appearance of the TCA-soluble fraction.  The recovery 
of the total number of counts from the surface-bound, intracellular, TCA-soluble 
and TCA-insoluble counts was similar across all treatments.  These data are 
consistent with the Western blot data presented in Chapter 3.   
 
4.2.10.4. The effect of other GAGs on [35S]ADAMTS4-2 clearance  
To determine whether other GAGs aside from heparin were protective against 
[35S]ADAMTS4-2 clearance, HTB94 cells were treated with a variety of GAGs at 
a concentration of 250 µg/ml for 1 h prior to the addition of [35S]ADAMTS4-2 in a 
24 h assay.  
 
Figure 37 shows that CaPPS, a calcium salt form of chemically sulfated 
beechwood xylosan, inhibited the appearance of the TCA-soluble fraction as 
effectively as heparin (>80 %), whereas dermatan sulfate inhibited by 65 % and 
both chondroitin sulfate and de-N-sulfated heparin inhibited by 30 %.  
Hyaluronan had no marked effect on the clearance of [35S]ADAMTS4-2 from the 
medium.  The recovery of the total number of counts from the surface-bound, 
intracellular, TCA-soluble and TCA-insoluble counts was similar across all 
treatments.  These data are consistent with the Western blotting data shown in 
Chapter 3.   
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Figure 36: Heparin dose-dependently inhibits [35S]ADAMTS4-2 clearance by 
HTB94 cells.   
HTB94 cells were seeded in a 6-well plate at a density of 1x106 cells, rested overnight 
and washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM containing 
0.1 % BSA with or without heparin (0.5 – 500 µg/ml).  After 1 h, [35S]ADAMTS4-2 (1.5 
nM) was added.  After 24 h, the conditioned medium was removed and surface-bound, 
intracellular, TCA-soluble and TCA-insoluble fractions were harvested as described in 
section 2.5.2.  Results are an average of 3 wells ± S.D.  A, Surface-bound counts.  B, 
Intracellular counts.  C, TCA-soluble counts (corrected for TCA-soluble counts in start 
material).  D, TCA-insoluble counts.  E, Total surface-bound, intracellular, TCA-soluble 
and TCA-insoluble counts.  The wash fractions were counted and found to be negligible. 
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Figure 37: The effect of other GAGs on [35S]ADAMTS4-2 clearance by HTB94 
cells.   
HTB94 cells were seeded in a 6-well plate at a density of 1x106 cells, rested overnight 
and washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM containing 
0.1 % BSA with or without various GAGs (250 µg/ml).  After 1 h, [35S]ADAMTS4-2 (1.5 
nM) was added.  After 24 h, the conditioned medium was removed and surface-bound, 
intracellular, TCA-soluble and TCA-insoluble fractions were harvested as described in 
section 2.5.2. Results are an average of 3 wells ± S.D.  A, Surface-bound counts.  B, 
Intracellular counts.  C, TCA-soluble counts (corrected for TCA-soluble counts in start 
material).  D, TCA-insoluble counts.  E, Total surface-bound, intracellular, TCA-soluble 
and TCA-insoluble counts.  The wash fractions were counted and found to be negligible. 
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4.2.11. Heparin inhibits [35S]ADAMTS4-2 clearance by porcine and human 
chondrocytes 
The effect of heparin on the clearance of [35S]ADAMTS4-2 by either porcine or 
human chondrocytes was also investigated.  Similar to its effect in HTB94 cells, 
heparin protected against [35S]ADAMTS4-2 clearance in both porcine and human 
chondrocytes (Figure 38 and Figure 39, respectively).  The recovery of the total 
number of counts from the surface-bound, intracellular, TCA-soluble and TCA-
insoluble counts was similar across all treatments.     
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Figure 38: Heparin inhibits [35S]ADAMTS4-2 clearance by porcine chondrocytes.   
Porcine chondrocytes were seeded in a 12-well plate at a density of 1x106 cells, rested 
for 3 days and washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM 
containing 0.1 % BSA with or without heparin (250 µg/ml).  After 1 h, [35S]ADAMTS4-2 
(0.75 nM) was added.  After 24 h, the conditioned medium was removed and surface-
bound, intracellular, TCA-soluble and TCA-insoluble fractions were harvested as 
described in section 2.5.2.  Results are an average of 3 wells ± S.D.  A, Surface-bound 
counts.  B, Intracellular counts.  C, TCA-soluble counts (corrected for TCA-soluble 
counts in start material).  D, TCA-insoluble counts.  E, Total surface-bound, intracellular, 
TCA-soluble and TCA-insoluble counts.  The wash fractions were counted and found to 
be negligible. 
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Figure 39: Heparin inhibits [35S]ADAMTS4-2 clearance by human chondrocytes.   
Human chondrocytes from a healthy 12 year old male were seeded in a 12-well plate at 
a density of 0.5x106 cells, rested for 3 days and washed thrice in serum-free DMEM 
before incubation at 37 ºC in DMEM containing 0.1 % BSA with or without heparin (250 
µg/ml).  After 1 h, [35S]ADAMTS4-2 (0.75 nM) was added.  After 24 h, the conditioned 
medium was removed and surface-bound, intracellular, TCA-soluble and TCA-insoluble 
fractions were harvested as described in section 2.5.2.  Results are an average of 3 
wells ± S.D.  A, Surface-bound counts.  B, Intracellular counts.  C, TCA-soluble counts 
(corrected for TCA-soluble counts in start material).  D, TCA-insoluble counts.  E, Total 
surface-bound, intracellular, TCA-soluble and TCA-insoluble counts.  The wash fractions 
were counted and found to be negligible. 
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4.2.12. Assessment of [35S]ADAMTS4-2 clearance by CHO-K1 cells and 
pgsA-745 CHO cells 
To investigate whether the cellular uptake of [35S]ADAMTS4-2 required the 
presence of cell surface GAGs, the clearance of [35S]ADAMTS4-2 from the 
medium of CHO-K1 cells and pgsA-745 CHO cells was assessed.  pgsA-745 
CHO cells are deficient in xylosyltransferase, the enzyme which catalyses the 
attachment of xylose to a serine residue of a core protein.  As a result, pgsA-745 
CHO cells are deficient in both CS- and HS- proteoglycans (Esko et al., 1985).  
  
4.2.12.1. Surface binding of [35S]ADAMTS4-2 at 4 ºC 
In a binding experiment similar to that described in section 4.2.10.2., CHO-K1 
cells and pgsA-745 CHO cells were incubated for 30 min at 4 ºC  with or without 
heparin (250 µg/ml) prior to the addition of [35S]ADAMTS4-2 (1.5 nM) for 2 h at 4 
ºC.  The data in Figure 40 show that under these conditions, CHO-K1 cells bound 
approximately three times the amount of [35S]ADAMTS4-2 than pgsA-745 CHO 
cells.   Surface binding of [35S]ADAMTS4-2 to CHO-K1 cells but not pgsA-745 
CHO cells was sensitive to heparin and incubation with heparin reduced the 
surface binding in CHO-K1 cells to the background level seen in pgsA-745 CHO 
cells. 
 
4.2.12.2. [35S]ADAMTS4-2 clearance at 37 ºC  
To determine the effect of HSPGs on [35S]ADAMTS4-2 cellular uptake and 
degradation, CHO-K1 and psgA-745 CHO cells were incubated with 
[35S]ADAMTS4-2 at 37 ºC for 24 h.  The surface-bound fraction from both CHO-
K1 cells and psgA-745 cells were similar in the absence of heparin (Figure 41).  
In the presence of heparin, surface-bound radioactivity was also reduced in both 
cell types.  However, the intracellular fraction of radioactivity in psgA-745 CHO 
cells was approximately 80 % less than that of CHO-K1 cells and heparin 
reduced the intracellular fraction in CHO-K1 cells by approximately 70 % but had 
no effect on the intracellular fraction of psgA-745 CHO cells.  Heparin reduced 
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the TCA-soluble fraction in CHO-K1 cells by 50 % compared to control.  This 
resulted in a similar level of counts as was detected from the TCA-soluble 
fraction harvested from psgA-745 CHO cells.  Heparin treatment had no marked 
effect on the TCA-soluble fraction of psgA-745 CHO cells.  In CHO-K1 cells, 
heparin increased the TCA-insoluble fraction compared to untreated CHO-K1 
cells.  In addition, the TCA-insoluble fraction was increased in psgA-745 CHO 
cells compared to CHO-K1 cells.  However, the TCA-insoluble fraction harvested 
from heparin-treated psgA-745 CHO cells was not significantly different to the 
TCA-insoluble fraction of untreated CHO-K1 cells, although there was a trend 
towards an increase.  The recovery of the total number of counts from the 
surface-bound, intracellular, TCA-soluble and TCA-insoluble counts was similar 
across all treatments. 
 
 
 
Figure 40: [35S]ADAMTS4-2 binding to the surface of CHO-K1 cells and psgA-
745 CHO cells.   
Cells were seeded in a 6-well plate at a density of 1x106 cells, rested overnight and 
washed thrice in serum-free Ham’s F12 medium before incubation at 4 ºC in Ham’s F12 
medium containing 0.1 % BSA with or without heparin (250 µg/ml).  After 30 min, 
[35S]ADAMTS4-2 (1.5 nM) was added.  The cells were incubated for 2 h at 4 ºC.  The 
medium was removed and the cells were washed with ice-cold PBS.  The cell layer was 
harvested with 1 M NaOH and the radioactivity counted.  Results are an average of 3 
wells ± S.D.  
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Figure 41: [35S]ADAMTS4-2 uptake and degradation by CHO-K1 and psgA-745 
CHO cells.  
Cells were seeded in a 6-well plate at a density of 1x106 cells, rested overnight and 
washed thrice in serum-free Ham’s F12 medium before incubation at 37 ºC in Ham’s F12 
medium containing 0.1 % BSA with or without heparin (250 µg/ml).  After 1 h, 
[35S]ADAMTS4-2 (1.5 nM) was added.  After 24 h, the conditioned medium was removed 
and surface-bound, intracellular, TCA-soluble and TCA-insoluble fractions were 
harvested as described in section 2.5.2.  Results are an average of 3 wells ± S.D. * = P 
≤ 0.05 as compared to CHO-K1 cells.  A, Surface-bound counts.  B, Intracellular counts.  
C, TCA-soluble counts.  D, TCA-insoluble counts.  E, Total surface-bound, intracellular, 
TCA-soluble and TCA-insoluble counts.  The wash fractions were counted and found to 
be negligible. 
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4.2.13. Uptake and degradation of [35S]ADAMTS4-5 by HTB94 cells 
4.2.13.1 Purification of [35S]ADAMTS4-5  
To determine whether the ancillary domains of ADAMTS-4 were required for 
ADAMTS-4 clearance, the catalytic domain of ADAMTS-4 (ADAMTS4-5) was 
tested for its ability to clear from the medium of HTB94 cells.  HEK-293/EBNA 
cells expressing ADAMTS4-5 were metabolically labeled with [35S]Met/[35S]Cys 
as described in section 4.2.1. [35S]ADAMTS-4-5 was purified from the 
conditioned medium by anti-FLAG M2 affinity chromatography and FLAG peptide 
elution.  Aliquots of each sample were analysed by SDS-PAGE and silver 
staining (Figure 42A).  The gel was also exposed to autoradiographic film (Figure 
42B).  [35S]ADAMTS4-5 was collected in elutions 1 & 2, running at a molecular 
weight slightly higher than the predicted molecular weight of 24 kDa (Figure 
42B).   This observation is in agreement with Gendron et al (2007).  In addition, 
there was a protein band at approximately 50 kDa and at the top of the gel, 
although the band at the top of the gel appeared to be non-radioactive.  
ADAMTS4-5 has essentially no aggrecanase activity (Kashiwagi et al., 2004).  
Therefore, to determine the approximate concentration of [35S]ADAMTS4-5, the 
amount of protein was determined by standard curve against BSA.  Figure 42C 
shows a silver stain of increasing amounts of BSA (ng) and an aliquot of 
[35S]ADAMTS4-5 (5 µl).  The gel was scanned and the pixel volume of each band 
was determined using Phoretix software.  Figure 42D shows a standard curve of 
pixel volume of the BSA band against amount of BSA (ng) added.  Using the 
equation y = mx + c, the concentration of [35S]ADAMTS4-5 was calculated to be 
50 nM (1.2 µg/ml) based on a molecular weight of 24 kDa. 
 
4.2.13.2. [35S]ADAMTS4-5 uptake by HTB94 cells 
When added to HTB94 cells, [35S]ADAMTS4-5 (1.5 nM) was cleared from the 
medium over 24 h (Figure 43).  Similar to their effect on [35S]ADAMTS4-2 (1.5 
nM), heparin and GM6001 reduced the amount of radioactivity associated with 
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the surface-bound and intracellular fractions and also inhibited the appearance of 
the TCA-soluble fraction by >90 % and 50 %, respectively.   
 
 
 
Figure 42: Purification of [35S]ADAMTS4-5 and determination of concentration 
using BSA standard curve. 
HEK-293/EBNA cells transfected with ADAMTS4-5-FLAG construct were metabolically 
labeled with [35S]Met/[35S]Cys for 4 days and purified as described in section 4.2.1.  A, 
Aliquots were analysed by reducing SDS-PAGE and silver staining.  B, The gel was 
exposed to autoradiographic film overnight.  C, The amount of [35S]ADAMTS4-5 in  
elution 1 was determined by SDS-PAGE analysis of 5 µl of elution 1 and known amounts 
of BSA (100-2.5 ng).  The gel was developed by silver staining and scanned.  The pixel 
volume of each band was determined using Phoretix software.  D, Standard curve of 
pixel volume of [35S]ADAMTS4-5 band against amount of BSA (ng) added.   
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Figure 43: The effect of GM6001 and heparin on the clearance of 
[35S]ADAMTS4-5 by HTB94 cells.    
HTB94 cells were seeded in a 6-well plate at a density of 1x106 cells, rested overnight 
and washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM containing 
0.1 % BSA with or without either GM6001 (10 µM), heparin (250 µg/ml) or 1/1000 
dilution of DMSO carrier solution.  After 1 h, [35S]ADAMTS4-2 (1.5 nM) was added.  After 
24 h, the conditioned medium was removed and the surface-bound, intracellular, TCA-
soluble and TCA-insoluble fractions were harvested as described in section 2.5.2.   
Results are an average of 2 wells ± range.  A, Surface-bound counts.  B, Intracellular 
counts.  C, TCA-soluble counts (corrected for TCA-soluble counts in start material).  D, 
TCA-insoluble counts.  E, Total surface-bound, intracellular, TCA-soluble and TCA-
insoluble counts.  The wash fractions were counted and found to be negligible. 
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4.2.14. [35S]ADAMTS4-2 clearance by wild-type and Timp-3-null dermal 
fibroblasts  
In view of the results of Chapter 3, where ADAMTS4-2 did not bind heparin-
Sepharose, I considered the hypothesis that ADAMTS4-2 could be internalized in 
a complex with TIMP-3 and that GM6001 inhibited ADAMTS4-2 clearance by 
disrupting the interaction between TIMP-3 and ADAMTS4-2.  In addition, heparin 
may inhibit ADAMTS4-2 clearance by blocking the interaction between TIMP-3 
and GAGs of the ECM.  Wild-type and Timp-3-null dermal fibroblasts were 
incubated for 1 h with GM6001 (50 µM) or heparin (250 µg/ml) prior to the 
addition of [35S]ADAMTS4-2 (1.5 nM) for 24 h. The TCA-insoluble fraction at the 
start of the experiment (0 h) was 5378 dpm ± 244.  As shown in Figure 44, very 
little [35S]ADAMTS4-2 was cleared from the medium of either wild-type or Timp-
3-null mouse dermal fibroblasts over 24 h.  Additionally, the amount of TCA-
soluble radioactivity detected in the medium after 24 h was comparable between 
wild-type and Timp-3-null fibroblasts.  Heparin reduced the TCA-soluble fraction 
by more than 95 % in either cell type.  GM6001 reduced the TCA-soluble fraction 
by 68 % ± 7 in wild-type cells and by 40 % ± 10 in Timp-3-null cells.  The cell-
associated fraction was increased in control wild-type cells compared to control 
Timp-3-null cells.  Heparin and GM6001 reduced the amount of cell-associated 
radioactivity in wild-type fibroblasts but had little effect on the cell-associated 
fraction from Timp-3-null fibroblasts.    The recovery of the total number of counts 
from the cell-associated, TCA-soluble and TCA-insoluble counts was similar 
across all treatments.   
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Figure 44:  [35S]ADAMTS4-2 clearance by Timp-3 wild-type (+/+) and null  (-/-) 
mouse dermal fibroblasts.     
Cells  were seeded in a 12-well plate at a density of 0.5x106 cells, grown overnight and 
washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM containing 0.1 
% BSA and 0.5 % DMSO with or without heparin (250 µg/ml) or GM6001 (50 µM).  After 
1 hour, [35S]ADAMTS4-2 (1.5 nM) was added.  After 24 h, the conditioned medium was 
removed and cell-associated, TCA-soluble and TCA-insoluble fractions were harvested 
as described in section 2.5.2.  Results are an average of 2 wells ± range.  A, Cell-
associated counts.  B, TCA-soluble counts (corrected for TCA-soluble counts in start 
material). C, TCA-insoluble counts.  D, Total cell-associated, TCA-soluble and TCA-
insoluble counts.  The wash fractions were counted and found to be negligible. 
 
 
4.3. Discussion 
This chapter describes the development of a radioactive protein-based assay 
and its use to investigate the clearance of ADAMTS4-2 by HTB94 cells and 
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chondrocytes.  A radioactive protein-based approach offers increased sensitivity 
over the Western blotting methods described in Chapter 3 and also gives a 
quantitative read-out.   
 
Time course experiments using [35S]ADAMTS4-2 verified the Western blotting 
data presented in Chapter 3 because the TCA-insoluble fraction of 
[35S]ADAMTS4-2 disappeared from the medium upon incubation with HTB94 
cells over time.  Moreover, radioactivity was detected on the surface and within 
the cell, supporting the hypothesis that ADAMTS4-2 binds to the cell surface and 
is endocytosed by HTB94 cells.  These data are in contrast with the microscopy 
data presented in Chapter 3, where although Alexa Fluor 488-ADAMTS4-2 was 
detected within the cell, it was not detected on the cell surface. The possible 
reason for not detecting Alexa Fluor 488-ADAMTS4-2 on the cell surface may be 
due to reduced sensitivity of fluorescence detection as discussed in Chapter 3.  
However, along with a decrease in the TCA-insoluble fraction over time, there 
was an increase in the TCA-soluble fraction of the medium upon addition of 
[35S]ADAMTS4-2.  This observation is consistent with the hypothesis that 
degraded remnants of [35S]ADAMTS4-2 are released into the medium following 
endocytosis and degradation within the cell.   
 
When a range of [35S]ADAMTS4-2 concentrations were added to HTB94 cells, 
the TCA-insoluble [35S]ADAMTS4-2 disappeared from the medium at the same 
rate, regardless of the concentration.  This shows that the mechanism by which 
[35S]ADAMTS4-2 was cleared from the medium was non-saturable under these 
conditions.  This observation is not consistent with a receptor-mediated endocytic 
process because at high concentrations of ligand, it would be expected that all 
endocytic receptors become occupied and the clearance of ligand would be 
dependent on the turnover of the receptor and/or its level of expression on the 
cell surface. Non-saturable binding of thrombospondin to CHO cells defective in 
GAG synthesis has been previously described (Murphy-Ullrich et al., 1988).  In 
this study, the authors hypothesised that there may be a second binding phase 
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that could be saturated when higher concentrations of ligand are added or that 
binding is non-saturable due to thrombospondin self-aggregation.  To investigate 
the non-saturable binding of [35S]ADAMTS4-2 further, the concentration of 
[35S]ADAMTS4-2 added to the cells should be increased by at least 100-fold.  
However, this was not feasible in the present study due to limited reagents.  
Furthermore, although, there have been no reports that ADAMTS-4 can self-
aggregate, ADAMTS4-2 contains a thrombospondin type I-like domain.  The 
thrombospondin type 1-like domain of ADAMTS-4 may mediate adhesion to the 
cell membrane and/or the ECM, as has been shown for ADAMTS-1 (Kuno et al., 
1999).   
 
The binding experiments at 4 ºC showed that non-radiolabeled ADAMTS4-2 
dose-dependently competed with [35S]ADAMTS4-2 for binding to HTB94 cells.  
Non-specific binding determined by addition of 100-fold excess of ADAMTS4-2 
was less than 20 %.  The addition of 10,000-fold excess BSA did not compete 
with [35S]ADAMTS4-2 binding, showing that the binding to the cell surface was 
specific.    
 
The Western blotting data presented in Chapter 3 showed that the 
metalloproteinase inhibitor, GM6001 inhibited ADAMTS4-2 disappearance from 
the medium of HTB94 cells whilst serine and cysteine protease inhibitors had no 
effect.  In this chapter, the effect of these protease inhibitors was confirmed using 
[35S]ADAMTS4-2.  In addition to GM6001, another metalloprotease inhibitor 
CT1746 dose-dependently inhibited the clearance of [35S]ADAMTS4-2, further 
suggesting that cell surface metalloproteinases may degrade [35S]ADAMTS4-2.  
However, [35S]ADAMTS4-2 proteolysis would likely fragment the intact protein 
into smaller TCA-insoluble fragments and no fragments of ADAMTS-4 were 
detected when the TCA-insoluble fraction of the medium was analysed by 
Western blotting using the anti-ADAMTS4-catalytic antibody (Chapter 3).  
Proteolysis within the catalytic domain could destroy the antibody binding 
epitope, resulting in the failure to detect any proteolysed fragments.  To further 
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investigate the possibility of [35S]ADAMTS4-2 fragmentation, it would be 
informative to analyse the TCA-insoluble fraction of the medium by 
autoradiography after SDS-PAGE.   
 
Since the effect of metalloproteinase inhibitors on the clearance of 
[35S]ADAMTS4-2 by HTB94 cells suggests that some cell surface 
metalloproteinase-mediated degradation of [35S]ADAMTS4-2 may occur, future 
work would be to identify which cell surface metalloproteinases are expressed by 
HTB94 cells.  The expression of these metalloproteinases could be knocked 
down using siRNA and the effect of each metalloprotease on the clearance of 
[35S]ADAMTS4-2 assessed.  In this regard, MMP-17 is reportedly expressed in 
JJ012 chondrosarcoma cells and has been shown to cleave full-length ADAMTS-
4 (68 kDa), generating a protein with a molecular weight of 40 kDa in addition to 
protein of 53 kDa in size (Gao et al., 2004).  This suggests that MMP-17 is a 
candidate metalloproteinase responsible for cell surface cleavage of ADAMTS4-2 
into a 40 kDa protein.       
 
Another approach would be to assess the clearance of [35S]ADAMTS4-2 in the 
presence of 100-fold excess of either TIMP-1, TIMP-2 or TIMP-3.  This would 
narrow down a candidate metalloproteinase as MT-MMPs are inhibited by TIMP-
2, not TIMP-1 and only TIMP-3 inhibits ADAMTSs.  However, it may be difficult to 
interpret the results because HTB94 cells express LRP-1 and both TIMP-1 and 
TIMP-2 are endocytosed via LRP-1 (Emonard et al., 2004; Hahn-Dantona et al., 
2001). Additionally, TIMP-3 also accumulates in the medium of HTB94 cells 
when treated with heparin or the LDL-R family antagonist RAP (Troeberg et al., 
2008).  However, in HTB94 cells, heparin and CaPPS did not affect the levels of 
TIMP-1 or TIMP-2 in the medium (Troeberg et al., 2008) suggesting that at least 
in HTB94 cells TIMP-1 and TIMP-2 are not endocytosed by a heparin-sensitive 
mechanism.   
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The effect of cytochalasin D, which block endocytosis by inhibiting actin 
polymerization (Flanagan and Lin, 1980) was also examined.  This treatment 
reduced the amount of TCA-soluble radioactivity in the medium, suggesting that 
ADAMTS4-2 is endocytosed by an actin-dependent mechanism.  The 
endocytosis of many ligands requires an intact actin cytoskeleton.  For example, 
cytochalasin D treatment inhibits CD-14-dependent LPS endocytosis in THP-1 
cells (Poussin et al., 1998).  Additionally, entry of Kaposi's sarcoma-associated 
herpesvirus (KSHV) into HUVEC cells was blocked by approximately 40 % upon 
treatment with cytochalasin D (Raghu et al., 2009).  In HTB94 cells, cytochalasin 
D causes TIMP-3 accumulation (Troeberg et al., 2008) which suggests that it 
blocks actin-dependent endocytosis of TIMP-3 in these cells.     
   
The production of the TCA-soluble fraction was not completely blocked by 
treatment with cytochalasin D suggesting that other processes aside from actin-
dependent endocytosis may mediate ADAMTS4-2 clearance by HTB94 cells.  As 
discussed above, the TCA-soluble radioactivity produced in the presence of 
cytochalasin D could be due to metalloprotease-mediated breakdown on the cell 
surface.  Further work would be to investigate the effect of cytochalasin D in 
combination with GM6001 on the clearance of [35S]ADAMTS4-2 by HTB94 cells.  
Alternatively, a cytochalasin D-independent mechanism of [35S]ADAMTS4-2 
endocytosis may exist.  A cytochalasin D-independent but tyrosine kinase-
dependent mechanism of endocytosis has been reported for LpL-enriched LDL 
(Fuki et al., 2000a).  To further investigate this, a first step would be to determine 
the effect of the tyrosine kinase inhibitor genistein on the clearance of 
[35S]ADAMTS4-2 by HTB94 cells.   
 
Another approach would be to determine the effect of lysosomotropic agents 
such as monensin or chloroquine on the clearance of [35S]ADAMTS4-2 by 
HTB94 cells and their effect on the amount of intracellular radioactivity.  
Monensin and chloroquine neutralize the lysosome and inhibit lysosomal activity 
causing an accumulation of endocytosed ligand within the cell.  The 
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accumulation of [35S]ADAMTS4-2 within the intracellular fraction would support 
the hypothesis that [35S]ADAMTS4-2 is endocytosed and degraded by lysosomal 
hydrolases prior to the release of TCA-soluble amino acids from the cell into the 
medium.    
 
In this chapter, I showed that treatment of HTB94 cells with heparin prior to the 
addition of [35S]ADAMTS4-2 reduced the surface-bound, intracellular and TCA-
soluble fraction and protected against the clearance of [35S]ADAMTS4-2.  In 
addition, binding studies at 4 ºC also demonstrated that heparin reduced the 
binding of [35S]ADAMTS4-2 to the cell surface.    This experiment showed that 
treatment of the cell layer with pronase for 10 min on ice was sufficient to remove 
cell surface proteins because pronase was able to effectively separate 
intracellular from surface-bound [35S]ADAMTS4-2.   It also showed that 
incubation at 4 ºC prevents intracellular uptake so in binding studies at 4 ºC it 
was not necessary to discriminate between surface-bound and intracellular 
fractions meaning that the surface-bound radioactivity could be recovered by 
harvesting the cell layer with 1 M NaOH.  The correlation between the amount of 
radioactivity within the cell and the amount of TCA-soluble radioactivity in the 
medium in experiments conducted at 37 ºC suggests that [35S]ADAMTS4-2 is 
endocytosed and degraded within the cell.  
 
The investigation of the effect of different GAGs on the clearance of 
[35S]ADAMTS4-2 by HTB94 cells yielded similar results to that reported by 
Western blot analysis in Chapter 3.  GAGs with low levels of sulfation 
(chondroitin or dermatan sulfate) or no sulfation (hyaluronan) were not as 
effective as heparin or CaPPS, both of which are highly sulfated.  Furthermore, 
N-desulfated heparin was less protective than heparin.  This indicates that the 
clearance of [35S]ADAMTS4-2 by HTB94 cells depends on the level of sulfation.      
 
[35S]ADAMTS4-5 was also cleared by HTB94 cells over 24 h.  This indicates that 
the cysteine-rich, thrombospondin type-1 and disintegrin domains of ADAMTS-4 
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are not essential for ADAMTS-4 clearance by HTB94 cells.  In addition to 
heparin, the metalloprotease inhibitor GM6001 also inhibited the clearance of 
[35S]ADAMTS4-5.  The inhibitory effect of heparin was greater than that of 
GM6001 for both [35S]ADAMTS4-2 and [35S]ADAMTS4-5, suggesting that the 
heparin-sensitive mechanism of clearance by HTB94 cells is more dominant than 
the GM6001-sensitive mechanism.  Similar to ADAMTS4-2, ADAMTS4-5 does 
not bind heparin-coated plates (Dr Linda Troeberg, personal communication).  
Together, these data indicate that the mechanisms of both [35S]ADAMTS4-2 and 
[35S]ADAMTS4-5 clearance are the same.  However, the rate of clearance may 
differ between these proteins and should be the subject of future study.   
 
It would also be informative to determine whether full-length ADAMTS-4 is 
cleared by HTB94 cells.  During the course of this study, the purification of 
[35S]ADAMTS4-1 in a manner similar to that described for [35S]ADAMTS4-2 was 
attempted several times.  However, ADAMTS4-1 loses about 80 % of its FLAG-
tag during culture (Kashiwagi et al., 2004) and sufficient quantities of 
[35S]ADAMTS4-1 were unattainable for use in this study.  As discussed in 
Chapter 3, ADAMTS4-1 binds to the ECM and cell surface via interaction of the 
spacer domain (Kashiwagi et al., 2004).  Therefore, ADAMTS4-1 would likely 
bind with greater affinity to the ECM and cell surface of HTB94 cells.  It would be 
informative to see whether ADAMTS4-1 clearance by HTB94 cells proceeded at 
the same rate as ADAMTS4-2.   One approach to the successful purification of 
ADAMTS4-1 may be to purify the protein and then radiolabel the purified protein 
with 125Iodine.  Alternatively, a new construct with the FLAG-tag at the N-
terminus could be created to determine whether this improves the yield of intact 
ADAMTS4-1. 
 
In addition, heparin prevented the clearance of [35S]ADAMTS4-2  by both porcine 
and human chondrocytes, showing that the cellular uptake of [35S]ADAMTS4-2 
also occurs in primary cells.  It would be of further interest to investigate the rate 
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of [35S]ADAMTS4-2 clearance by normal chondrocytes compared to OA 
chondrocytes to determine if the mechanism is altered in disease.  
The experiments using CHO-K1 and pgsA-745 CHO cells demonstrated that cell 
surface HSPGs are required for the internalisation of [35S]ADAMTS4-2 although 
similar amounts of radioactivity were detected on the surface of both CHO-K1 
cells and psgA-745 CHO cells.   This could be due to non-specific binding of 
[35S]ADAMTS4-2 at the cell surface during the 24 h culture.  However, the 
amount of enzyme detected within the cell correlated with the amount of TCA-
soluble radioactivity detected in the medium suggesting that HSPGs mediate the 
binding, internalisation and lysosomal degradation of ADAMTS4-2.  These 
observations support the hypothesis that ADAMTS-4 clearance is dependent on 
the cellular level of sulfation.  Heparin inhibited the appearance of the TCA-
soluble fraction of CHO-K1 cells compared to psgA-745 CHO cells.  However, 
heparin treatment did not completely block the appearance of the TCA-soluble 
fraction in either CHO-K1 cells and psgA-745 CHO cells, suggesting that other 
mechanisms of degradation may exist.  To eliminate the possibility of 
metalloproteinase-mediated degradation at the cell surface, future work would be 
to repeat these experiments in the presence of GM6001.    
 
Similar studies have shown that HSPGs mediate the catabolism of 
thrombospondin by CHO-K1 cells (Murphy-Ullrich et al., 1988).  Comparable to 
the results presented for [35S]ADAMTS4-2, cell surface binding and degradation 
of thrombospondin by CHO-K1 cells was inhibited by heparin, whereas heparin 
had little effect in pgsA-745 CHO cells (Murphy-Ullrich et al., 1988).  In addition, 
Yang et al showed that LRP-1-mediated endocytosis of MMP2-thrombospondin-2 
complex was inhibited by heparin (Yang et al., 2001), suggesting that a HSPG 
co-receptor is involved.  However, it has been suggested that HSPG binding is 
not necessary for thrombospondin-1 to bind LRP-1 at the cell surface but that 
subsequent endocytosis requires high affinity heparin binding (Wang et al., 
2004b).  
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To further characterize the dependence of cell surface HSPGs on the 
mechanism of [35S]ADAMTS4-2 clearance, future studies would also include 
using other strains of CHO cells defective in GAG synthesis:  CHO-761 cells are 
deficient in galactosyltransferase, CHO-803 cells are defective in heparan sulfate 
but have normal levels of chondroitin sulfate and CHO-677 cells are defective in 
heparan sulfate but have elevated levels of chondroitin sulfate (Murphy-Ullrich et 
al., 1988).  Additionally, heparitinase and/or chondroitinase treatment of wild-type 
CHO-K1 cells prior to the addition of [35S]ADAMTS4-2 would be informative.    To 
further characterize the effect of HSPGs on the clearance of ADAMTS4-2 by 
HTB94 cells, future work would be to identify which HSPGs are expressed by 
HTB94 cells.  The expression of these HSPGs could be knocked-down using 
siRNA and the effect of each HSPG on the clearance of [35S]ADAMTS4-2 
assessed.   
 
In view of the results of Chapter 3, where ADAMTS4-2 did not bind heparin-
Sepharose, I considered the hypothesis that ADAMTS4-2 could be internalized in 
a complex with TIMP-3.  This hypothesis was considered because of reports that 
the LRP-1 ligands MMP-2 and -9 can be internalized alone or in complex with 
TIMP-2 or TIMP-1, respectively (Emonard et al., 2004; Hahn-Dantona et al., 
2001).  I also hypothesised that GM6001 may inhibit endocytosis by disrupting 
the interaction between TIMP-3 and [35S]ADAMTS4-2.  In addition, since TIMP-3 
contains heparin-binding domains and binds sulfated GAGs of the ECM (Yu et 
al., 2000), heparin could inhibit the internalization of [35S]ADAMTS4-2 from the 
medium by blocking the interaction between TIMP-3 and cell surface HSPGs, 
with HSPGs acting as co-receptors for TIMP-3 endocytosis.  Potential HSPG co-
receptor candidates include perlecan, syndecans and glypicans.  Perlecan may 
be the HSPG involved in TIMP-3 binding to the matrix since, in a review article, 
Knox and Whitelock quote an unpublished study where TIMP-3 reportedly binds 
perlecan and is localized pericellulary (Knox and Whitelock, 2006). However, 
preliminary experiments showed that very little [35S]ADAMTS4-2 was cleared by 
either wild-type or Timp-3-null mouse dermal fibroblasts after 24 h.  Additionally, 
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the amount of TCA-soluble radioactivity detected in the medium after 24 h was 
comparable between wild-type and Timp-3-null fibroblasts.  Although heparin had 
a greater inhibitory effect than GM6001, reducing the TCA-soluble fraction by 
more than 95 %, GM6001 reduced the TCA-soluble fraction by 68 % in wild-type 
cells and by 40 % in Timp-3-null cells.  The differential effect of GM6001 between 
wild-type and Timp-3-null cells suggests that a mechanism whereby ADAMTS-4 
is endocytosed as a complex with TIMP-3 may exist.  The cell-associated fraction 
was increased in control wild-type cells compared to control Timp-3-null cells.  
Heparin and GM6001 reduced the amount of cell-associated radioactivity in wild-
type fibroblasts but had little effect on the cell-associated fraction from Timp-3-
null fibroblasts.  This suggests that [35S]ADAMTS4-2 may interact with cell 
surface TIMP-3.  However, the cells used in this experiment were thawed from 
liquid nitrogen stocks and were originally isolated from mice which were culled 
due to infection.  The infection may be the reason why very little ADAMTS4-2 
was cleared by either wild-type or Timp-3-null fibroblasts.  To confirm that the 
results are reproducible, the above experiment needs to be repeated using 
freshly isolated fibroblasts from healthy mice or in HTB94 cells where TIMP-3 
expression is silenced by siRNA.    
 
In summary, this chapter describes the development and use of a radioactivity-
based assay to monitor the clearance of ADAMTS-4 by HTB94 cells and 
chondrocytes.  The results indicate that both ADAMTS-4-2 and ADAMTS4-5 are 
cleared by HTB94 cells, showing that this process is not dependent on sites 
within the ancillary domains of ADAMTS-4.  Degradation at the cell surface may 
account for some of the observations.  However, preliminary studies using Timp-
3-null fibroblasts have indicated that ADAMTS-4 may be endocytosed in a 
complex with TIMP-3.  It is possible that GM6001 may disrupt this interaction.  
The clearance of ADAMTS-4 is also heparin-sensitive, indicating that the 
mechanism requires cell surface HSPGs.  In the case of ADAMTS4-2, this 
requirement has been confirmed because cells deficient in HSPGs accumulated 
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50 % less TCA-soluble degradation products of [35S]ADAMTS4-2 in the medium 
than wild-type cells and less radioactivity was detected within the cell.   
 
Numerous studies report the requirement of HSPGs for endocytosis of some 
LRP-1 ligands.  With this in mind, the aim of Chapter 5 is to investigate whether 
LRP-1 plays a role in the clearance of ADAMTS4-2 by HTB94 cells.            
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Chapter 5 
Investigating the role of LDL-R family in the clearance of 
ADAMTS4-2  
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5.1. Introduction 
In the previous chapter, a radioactive-based assay was developed and used to 
characterize the clearance of ADAMTS-4 by HTB94 cells.   It was shown that 
ADAMTS-4 clearance may be due in part to proteolysis at the cell surface.  
However, the protein was detectable within the cell, suggesting endocytosis may 
also occur.  The cellular uptake and clearance of ADAMTS-4 was also shown to 
be dependent on cell surface HSPGs and preliminary work indicated that 
ADAMTS-4 may be endocytosed in a complex with TIMP-3.  In view of previous 
work in our laboratory showing that TIMP-3 accumulates in the conditioned 
medium of HTB94 cells upon treatment with either heparin or RAP, a ligand 
antagonist of the LDL-R family (Troeberg et al., 2008), I tested whether 
ADAMTS-4 clearance was also RAP-sensitive.  Therefore, the aims of this 
chapter were to:  i) determine whether RAP inhibits ADAMTS-4 clearance and ii) 
compare the clearance of ADAMTS-4 to that of methylamine-activated α2M 
(α2M*), the endocytosis of which is characteristic of LRP-1 (Strickland et al., 
1990).   
 
5.2. Results 
5.2.1. Assessing the effect of RAP on [35S]ADAMTS4-2 clearance 
5.2.1.1. SDS-PAGE analysis of recombinant RAP 
Recombinant RAP protein was a kind gift from Dr Hervé Emonard (Christian de 
Duve Institute of Cellular Pathology and Université Catholique de Louvain, 
Brussels, Belgium).  Before using RAP in cell experiments, the purity of the 
protein was confirmed by SDS-PAGE and staining with Coomassie Brilliant Blue 
R-250.  As shown in Figure 45, the protein ran at a molecular weight of 
approximately 39 kDa with minor fragments of a lower molecular weight.       
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Figure 45: Purified recombinant RAP.   
Recombinant RAP was a kind gift from Dr Hervé Emonard (Christian de Duve Institute of 
Cellular Pathology and Université Catholique de Louvain, Brussels, Belgium).  RAP (20 
µg) was run on SDS-PAGE (10 % acrylamide) and the protein was stained using 
Coomassie Brilliant Blue R-250.    
 
 
 
5.2.1.2. RAP inhibits [35S]ADAMTS4-2 clearance by HTB94 cells 
HTB94 cells were incubated with RAP (500 nM) or heparin (250 µg/ml) for 1 h 
before addition of [35S]ADAMTS4-2 (1.5 nM).  After 24 h, the fractions were 
harvested as previously described.  Figure 46 shows that incubation with RAP 
did not significantly affect the amount of radioactivity bound to the cell surface or 
within the cell.  However, the TCA-soluble fraction was reduced by approximately 
50 % by RAP.  Although the TCA-insoluble fraction showed a slight increase 
compared to control, this was not statistically significant.  In addition, heparin was 
more protective than RAP.  The recovery of the total number of counts from the 
surface-bound, intracellular, TCA-soluble and TCA-insoluble counts was similar 
across all treatments.    
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Figure 46: RAP inhibits clearance of [35S]ADAMTS4-2 by HTB94 cells.    
Cells were seeded in a 6-well plate at a density of 1x106 cells, grown overnight and 
washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM containing 0.1 
% BSA with or without heparin (250 µg/ml) or RAP (500 nM).  After 1 hour, 
[35S]ADAMTS4-2 (1.5 nM) was added.  After 24 h, the conditioned medium was removed 
and surface bound, intracellular, TCA-soluble and TCA-insoluble fractions were 
harvested as described in section 2.5.2.  Results are an average of 3 wells ± S.D. * = P 
≤ 0.05 as compared to control.  A, Surface-bound counts.  B, Intracellular counts.  C, 
TCA-soluble counts.  D, TCA-insoluble counts.  E, Total surface-bound, intracellular, 
TCA-soluble and TCA-insoluble counts.  The wash fractions were counted and found to 
be negligible. 
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5.2.1.3. RAP inhibits clearance of [35S]ADAMTS4-5 by HTB94 cells 
In order to determine whether the clearance of [35S]ADAMTS4-5 (catalytic 
domain) was RAP-sensitive, HTB94 cells were incubated with RAP (500 nM) or 
heparin (250 µg/ml) for 1 h before addition of [35S]ADAMTS4-5 (1.5 nM) in a 24 h 
assay.  As shown in Figure 47, RAP had no effect on the surface-bound fraction 
but reduced the intracellular fraction by approximately 40 %.  RAP also 
significantly protected against the clearance of the TCA-insoluble fraction and 
protected against the appearance of the TCA-soluble fraction by 80 % compared 
to control.  However, the protective effect of RAP was not as pronounced as 
heparin.  The recovery of the total number of counts from the surface-bound, 
intracellular, TCA-soluble and TCA-insoluble counts was similar across all 
treatments.  These data indicate that the appearance of the TCA-soluble fraction 
upon incubation of HTB94 cells with either ADAMTS4-2 or ADAMTS4-5 was 
inhibited by RAP.  However, the amount by which RAP protected against the 
appearance of the TCA-soluble fraction differed between experiments.    
 
5.2.1.4. RAP does not inhibit surface binding of [35S]ADAMTS4-2 at 4 ºC  
To determine whether RAP affected the binding of [35S]ADAMTS4-2 to the 
surface of HTB94 cells, cells were equilibrated at 4 ºC for 30 min with either 
heparin (500 µg/ml) or RAP (500 nM) before addition of [35S]ADAMTS4-2 (1.5 
nM) for 2 h.  The surface bound fraction was determined as described in section 
2.5.2.  Figure 48 shows that whilst incubation with heparin reduced the binding of 
[35S]ADAMTS4-2 to the cell surface by 60 %, RAP had no effect.   
 
5.2.1.5. Viability of HTB94 cells in the presence of RAP 
Figure 49 shows that treatment of HTB94 cells with RAP (500 nM) for 24 h did 
not affect cell viability as assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) assay.  As a positive control for cell death, 
treatment with sodium nitroprusside (2mM) inhibited cell viability by 93 %.   
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Figure 47: RAP inhibits clearance of [35S]ADAMTS4-5 by HTB94 cells.   
HTB94 cells were seeded in a 6-well plate at a density of 1x106 cells, grown overnight 
and washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM containing 
0.1 % BSA with or without heparin (250 µg/ml) or RAP (500 nM). After 1 hour, 
[35S]ADAMTS4-5 (1.5 nM) was added.  After 24 h, the conditioned medium was removed 
and surface bound, intracellular, TCA-soluble and TCA-insoluble fractions were 
harvested as described in section 2.5.2.  Results are an average of 3 wells ± S.D. * = P 
≤ 0.05 as compared to control.  A, Surface-bound counts.  B, Intracellular counts.  C, 
TCA-soluble counts (corrected for TCA-soluble counts in start material).  D, TCA-
insoluble counts.  E, Total surface-bound, intracellular, wash, TCA-soluble and TCA-
insoluble counts.  The wash fractions were counted and found to be negligible. 
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Figure 48: RAP does not inhibit surface binding of [35S]ADAMTS4-2 at 4 ºC.  
HTB94 cells were seeded in a 6-well plate at a density of 1x106 cells, grown overnight 
and washed thrice in serum-free DMEM before incubation at 4 ºC in DMEM containing 
0.1 % BSA with or without heparin (250 µg/ml) or RAP (500 nM).  After 30 min, 
[35S]ADAMTS4-2 (1.5 nM) was added.  After incubation for 2 h at 4 ºC the medium was 
removed and the surface bound fractions were harvested as described in section 2.5.2.  
Results are an average of 2 wells ± range.   
 
 
 
Figure 49: MTT assay of HTB94 cell viability upon incubation with RAP.   
HTB94 cells were seeded in a 12-well plate at a density of 0.5 x 106 cells, grown 
overnight and then treated with RAP (500 nM) or sodium nitroprusside (SNP) (2 mM) for 
24 h.  The medium was removed and the cells were washed once with phenol red-free 
DMEM before incubation with 975 µl phenol red-free DMEM and 25 µl of MTT reagent (5 
mg/ml in PBS).  After 45 min, 1 ml of 10 % SDS in 10 mM HCl was added to solubilise 
the formazan crystals. The samples were incubated overnight at 37 ºC and 200 µl of 
each well was transferred to a 96-well plate.  The absorbance was read at 574 nm.  
Results are an average of triplicate wells ± S.D.   
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5.2.1.6. RAP inhibits clearance of [35S]ADAMTS4-2 by porcine and human 
chondrocytes 
Whilst heparin reduced the surface-bound and intracellular fractions isolated from 
porcine chondrocytes, in this experiment, RAP significantly increased both the 
surface bound fraction and intracellular fraction (Figure 50).  However, RAP 
protected against the clearance of the TCA-insoluble fraction of [35S]ADAMTS4-2 
and the appearance of the TCA-soluble fraction was reduced by 60 % compared 
to control.  Similar to its effect on porcine chondrocytes, RAP inhibited the 
clearance of the TCA-insoluble fraction of [35S]ADAMTS4-2 from the medium of 
chondrocytes isolated from a young normal human donor (male, 12-year old) 
(Figure 51).  RAP also inhibited the appearance of the TCA-soluble fraction by 70 
%.  In this experiment, RAP reduced the TCA-soluble fraction by as much as 
heparin treatment.  Figure 52 shows that RAP had no effect on the surface-
bound fraction but decreased the intracellular fraction isolated from another 
young normal human donor (male, 17-year old).  The TCA-soluble fraction was 
reduced by 75 % compared to control and again RAP was as protective as 
heparin.  The recovery of the total number of counts from the surface-bound, 
intracellular, TCA-soluble and TCA-insoluble counts was similar across all 
treatments within each experiment.  Although RAP consistently reduced the 
TCA-soluble fraction, the amount of protection was variable and requires further 
investigation.  However, these data show RAP-dependent mechanisms of 
ADAMTS4-2 clearance by both primary porcine and human chondrocytes.    
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Figure 50: RAP inhibits clearance of [35S]ADAMTS4-2 by porcine chondrocytes.   
Porcine chondrocytes were seeded in a 12-well plate at a density of 1x106 cells, grown 
for 3 days and washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM 
containing 0.1 % BSA with or without heparin (250 µg/ml) or RAP (500 nM).  After 1 
hour, [35S]ADAMTS4-2 (1.5 nM) was added.  After 24 h, the conditioned medium was 
removed and surface bound, intracellular, TCA-soluble and TCA-insoluble fractions were 
harvested as described in section 2.5.2.  Results are an average of 3 wells ± S.D. * = P 
≤ 0.05 as compared to control.  A, Surface-bound counts.  B, Intracellular counts.  C, 
TCA-soluble counts (corrected for TCA-soluble counts in start material).  D, TCA-
insoluble counts.  E, Total surface-bound, intracellular, wash, TCA-soluble and TCA-
insoluble counts.  The wash fractions were counted and found to be negligible. 
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Figure 51: RAP inhibits clearance of [35S]ADAMTS4-2 by human chondrocytes.   
Human chondrocytes from a healthy 12 year old male were seeded in a 12-well plate at 
a density of 0.5x106 cells, grown for 3 days and washed thrice in serum-free DMEM 
before incubation at 37 ºC in DMEM containing 0.1 % BSA with or without heparin (250 
µg/ml) or RAP (500 nM).  After 1 hour, [35S]ADAMTS4-2 (1.5 nM) was added.  After 24 
h, the conditioned medium was removed and surface bound, intracellular, TCA-soluble 
and TCA-insoluble fractions were harvested as described in section 2.5.2.  Results are 
an average of 3 wells ± S.D. * = P ≤ 0.05 as compared to control.  A, Surface-bound 
counts.  B, Intracellular counts.  C, TCA-soluble counts (corrected for TCA-soluble 
counts in start material).  D, TCA-insoluble counts.  E, Total surface-bound, intracellular, 
TCA-soluble and TCA-insoluble counts.  The wash fractions were counted and found to 
be negligible. 
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Figure 52: RAP inhibits clearance of [35S]ADAMTS4-2 by human chondrocytes.   
Human chondrocytes from a healthy 17 year old male were seeded in a 6-well plate at a 
density of 1x106 cells, grown for 3 days and washed thrice in serum-free DMEM before 
incubation at 37 ºC in DMEM containing 0.1 % BSA with or without heparin (250 µg/ml) 
or RAP (500 nM).  After 1 hour, [35S]ADAMTS4-2 (1.5 nM) was added.  After 24 h, the 
conditioned medium was removed and surface bound, intracellular, TCA-soluble and 
TCA-insoluble fractions were harvested as described in section 2.5.2.  Results are an 
average of 2 wells +/- range.  A, Surface-bound counts.  B, Intracellular counts.  C, TCA-
soluble counts (corrected for TCA-soluble counts in start material).  D, TCA-insoluble 
counts.  E, Total surface-bound, intracellular, TCA-soluble and TCA-insoluble counts.  
The wash fractions were counted and found to be negligible. 
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5.2.2. Investigating the role of LRP-1 in the clearance of [35S]ADAMTS4-2  
5.2.2.1. siRNA knockdown of LRP-1 in HTB94 cells 
The reduction in the TCA-soluble fraction upon incubation of HTB94 cells and 
primary chondrocytes with RAP suggested a RAP-sensitive mechanism of 
[35S]ADAMTS4-2 clearance by these cell types.  The most studied member of the 
LDL-R family with respect to endocytosis of proteolytic enzymes and their 
inhibition is LRP-1.  Therefore, the effect of knockdown of LRP-1 by siRNA on 
[35S]ADAMTS4-2 clearance was investigated, using previously validated LRP-1 
primers (Dedieu et al., 2008).   
 
Firstly, to establish the conditions for LRP-1 knockdown, HTB94 cells were 
transfected overnight in a 12-well plate with 0-300 pmol of control siRNA or LRP-
1 siRNA using Lipofectamine RNAiMAX reagents.  After transfection, the medium 
was replaced with DMEM containing 10 % FCS.  After 3 days in culture, whole 
cell lysates were harvested in CHAPS buffer [10 mM CHAPS, 20 mM HEPES 
(pH 7.4), 150 mM NaCl, 2 mM CaCl2], supplemented with protease inhibitor 
cocktail (1:40) and samples were analysed by non-reducing SDS-PAGE (5 % 
Tris glycine) and Western blotting with anti-LRP-1 (8G1) antibody.  As a loading 
control, equal volumes of each sample were analysed by non-reducing SDS-
PAGE (7.5 % acrylamide) and Western blotting with an anti-α-tubulin antibody.    
 
Figure 53 shows that LRP-1 ran with a molecular weight of approximately 515 
kDa whilst the α-tubulin ran with a molecular weight of approximately 45 kDa as 
expected.  The blots were scanned and the pixel volume of the LRP-1 specific 
band (~515 kDa) and the α-tubulin band (~45 kDa) were determined using 
Phoretix software.  Under the transfection conditions used, 50 pmol of LRP-1 
siRNA was sufficient to attenuate LRP-1 expression in HTB94 cells by 73 %.  
Transfection with control siRNA had no effect on the expression of LRP-1 
compared to untransfected cells (control) or transfection with Lipofectamine 
RNAimax reagent alone.  Transfection also had no effect on the expression of α-
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tubulin.  These results validate the specific siRNA knockdown of LRP-1 in HTB94 
cells. 
 
Figure 53: siRNA knockdown of LRP-1 in HTB94 cells.    
HTB94 cells were seeded in a 12-well plate at a density of 1.5 x 104 cells and grown 
overnight.  Cells were left untransfected (control) or transfected with either Lipofectamine 
RNAimax reagent alone, or Lipofectamine RNAimax containing control siRNA or LRP-1 
siRNA (300 pmol, 100 pmol or 50 pmol) for 24 h.  Cells were then grown for 3 days in 
DMEM containing 10 % FCS.  Cells were the lysed with CHAPS buffer (10 mM CHAPS, 
20 mM HEPES (pH 7.4), 150 mM NaCl, 2 mM CaCl2), supplemented with protease 
inhibitor cocktail (1:40).  Samples were then diluted 1:1 with non-reducing SDS-loading 
buffer and equal volumes of each sample were analysed by A, non-reducing SDS-PAGE 
(5 % Tris glycine) and Western blotting with anti-LRP-1 (8G1) antibody.  B, As a loading 
control, equal volumes of each sample were analysed by non-reducing SDS-PAGE (7.5 
% acrylamide) and Western blotting with an anti-α-tubulin antibody.   
 
5.2.2.2. The effect of attenuated LRP-1 expression on clearance of 
[35S]ADAMTS4-2  
The effect of LRP-1 knockdown on the clearance of [35S]ADAMTS4-2 was 
investigated in duplicate so that 1 set of cells were used for Western blot analysis 
to confirm the knockdown of LRP-1 expression whilst [35S]ADAMTS4-2 was 
added to the other set of cells to determine LRP-1-dependent [35S]ADAMTS4-2 
clearance.    HTB94 cells were transfected with 50 pmol of either control siRNA 
or LRP-1 siRNA overnight and allowed to grow in DMEM containing 10 % FCS 
for 3 days.  After 3 days in culture, cell lysates were either harvested with 
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CHAPS buffer and frozen at -20 ºC (0 h) or incubated at 37 ºC in DMEM 
containing 0.1 % BSA with or without heparin (250 µg/ml).   After 24 h, the cell 
lysates were harvested as previously described.  Equal volumes of each sample 
were analysed by non-reducing SDS-PAGE (5 % Tris glycine) and Western 
blotting with anti-LRP-1 (2629) antibody.  As a loading control, equal volumes of 
each sample were analysed by non-reducing SDS-PAGE (7.5 % acrylamide) and 
Western blotting with an anti-α-tubulin antibody.   The blots were scanned and 
the pixel volume of the LRP-1 specific band (~515 kDa) and the α-tubulin band 
(~45 kDa) were determined using Phoretix software.  The other set of transfected 
cells was incubated at 37 ºC in DMEM containing 0.1 % BSA with or without 
heparin (250 µg/ml) for 1 h prior to the addition of [35S]ADAMTS4-2 (1.5 nM).  
After 24 h, the conditioned medium was removed and surface bound, 
intracellular, TCA-soluble and TCA-insoluble fractions were harvested as 
previously described.     
 
Compared to untransfected cells, the cells transfected with either control siRNA 
or LRP-1 siRNA did not grow as well because the expression of α-tubulin is 
greater in untransfected cells than the cells transfected with either LRP-1 or 
control siRNA (Figure 54).  Transfection with LRP-1 siRNA knocked down the 
expression of LRP-1 at 0 h by 81 %.    However, the expression of LRP-1 in the 
LRP-1 siRNA treated cells was reduced by only 56 % compared to control siRNA 
treated cells at the 24 h time point.  The specificity of the LRP-1 antibody (2629) 
was confirmed by Western blotting using the secondary antibody alone (Figure 
54B).  Expression of α-tubulin in control and LRP-1 siRNA transfected cells was 
comparable throughout the experiment.  Similarly, treatment with heparin did not 
affect the expression of either LRP-1 or α-tubulin in control and LRP-1 siRNA 
transfected cells.   
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Figure 54: siRNA knockdown of LRP-1 in HTB94 cells.    
HTB94 cells were seeded in a 12-well plate at a density of 2.5 x 104 cells and grown 
overnight.  Cells were transfected with control siRNA or LRP-1 siRNA (50 pmol) using 
Lipofectamine RNAi max reagent for 24 h.  Cells were then grown for 3 days in DMEM 
containing 10 % FCS.  Cells were either lysed immediately (0 h) with CHAPS buffer (10 
mM CHAPS, 20 mM HEPES (pH 7.4), 150 mM NaCl, 2 mM CaCl2), supplemented with 
protease inhibitor cocktail (1:40) or incubated in DMEM containing 0.1 % BSA for 24 h 
with or without heparin (250 µg/ml) before lysis.  Samples were then diluted 1:1 with 
non-reducing SDS-loading buffer and equal volumes of each sample analysed by A, 
non-reducing SDS-PAGE (5 % Tris glycine) and Western blotting with anti-LRP-1 (2629) 
antibody.  B, Non-reducing SDS-PAGE (5 % Tris glycine) and Western blotting with 
secondary antibody and no primary antibody.  C, As a loading control, equal volumes of 
each sample were analysed by non-reducing SDS-PAGE (7.5 % acrylamide) and 
Western blotting with an anti-α-tubulin antibody.  C = control, H = heparin treated (250 
µg/ml).  Each treatment was performed in duplicate.   
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Figure 55 shows the effect of LRP-1 attenuation on the clearance of 
[35S]ADAMTS4-2 by HTB94 cells.  In accordance with the Western blotting data, 
untransfected cells produced more TCA-soluble [35S] degradation products than 
transfected cells because there was greater cell growth in untransfected cells 
than cells transfected with either control siRNA or LRP-1 siRNA.  The amount of 
radioactivity in surface-bound, intracellular, TCA-soluble and TCA-insoluble 
fractions were comparable between control siRNA-transfected and LRP-1 siRNA-
transfected cells.  Additionally, heparin protected against the clearance of 
[35S]ADAMTS4-2 by control siRNA- or LRP-1 siRNA-transfected cells to the 
same extent.  Although the expression of LRP-1 was increased at 24 h compared 
to 0 h, these data indicate that under the conditions of the experiment, LRP-1 
knockdown of at least 50 % compared to control transfection had no effect on the 
uptake of [35S]ADAMTS4-2.    The recovery of the total number of counts from 
the surface-bound, intracellular, TCA-soluble and TCA-insoluble counts was 
similar across all treatments. 
 
5.2.2.3. [35S]ADAMTS4-2 clearance by wild-type and LRP-1-null mouse 
embryonic fibroblasts  
To further investigate whether LRP-1 plays a role in ADAMTS4-2 clearance, the 
uptake of [35S]ADAMTS4-2 (1.5 nM) from the medium by wild-type mouse 
embryonic fibroblasts (MEF-1) and LRP-1-deficient mouse embryonic fibroblasts 
(PEA-13) were compared.  As shown in Figure 56, the disappearance of 
[35S]ADAMTS4-2 and the appearance of the TCA-soluble fraction were similar in 
both cell types.  The surface-bound fraction was less in the MEF-1 cells 
compared to PEA-13 cells although the intracellular fraction was similar in both 
cell types. 
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Figure 55: The effect of attenuated LRP-1 expression on clearance of 
[35S]ADAMTS4-2 by HTB94 cells.   
HTB94 cells were transfected as shown in Figure 5.9 and washed thrice in serum-free 
DMEM before incubation at 37 ºC in DMEM containing 0.1 % BSA with or without 
heparin (250 µg/ml).  After 1 hour, [35S]ADAMTS4-2 (1.5 nM) was added.  After 24 h, the 
conditioned medium was removed and surface bound, intracellular, TCA-soluble and 
TCA-insoluble fractions were harvested as described in section 2.5.2.  Results are an 
average of 2 wells ± range.  A, Surface-bound counts.  B, Intracellular counts.  C, TCA-
soluble counts (corrected for TCA-soluble counts in start material).  D, TCA-insoluble 
counts.  E, Total surface-bound, intracellular, TCA-soluble and TCA-insoluble counts.  
The wash fractions were counted and found to be negligible. 
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Figure 56: Clearance of [35S]ADAMTS4-2 by MEF-1 and PEA-13 cells.   
MEF-1 and PEA-13 cells were seeded in a 12-well plate at a density of 0.5x106 cells, 
grown overnight and washed thrice in serum-free DMEM before incubation at 37 ºC in 
DMEM containing 0.1 % BSA.  After 1 hour, [35S]ADAMTS4-2 (1.5 nM) was added.  At 
the time points indicated, the conditioned medium was removed and surface-bound, 
intracellular, TCA-soluble and TCA-insoluble fractions were harvested as described in 
section 2.5.2.  Results are an average of 2 wells ± range.  A, Surface-bound counts, B, 
Intracellular counts, C, TCA-soluble counts (corrected for TCA-soluble counts in start 
material). D, TCA-insoluble counts.  E & F, Total surface-bound, intracellular, TCA-
soluble and TCA-insoluble counts from MEF-1 and PEA-13 cells, respectively.  The 
wash fractions were counted and found to be negligible. 
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5.2.2.4. Heparin more effectively inhibits the clearance of [35S]ADAMTS4-2 
from the medium of HTB94 cells than of MEF-1 cells   
Next, the clearance of [35S]ADAMTS4-2 by MEF-1 cells and HTB94 cells was 
compared.  MEF-1 and HTB94 cells were plated at a density of 0.5x106 
cells/well, grown overnight and incubated with heparin (250 µg/ml) for 1 h before 
addition of [35S]ADAMTS4-2 (1.5 nM).  The surface-bound and intracellular 
fractions isolated from HTB94 cells were more radioactive than those isolated 
from MEF-1 cells, although both surface-bound and intracellular fractions upon 
heparin treatment were similar in either cell type (Figure 57 A, B).  Although the 
TCA-soluble fraction was significantly different between MEF-1 and HTB94 cells, 
the TCA-insoluble fraction was comparable in either cell type.  However, heparin 
was more protective against the appearance of the TCA-soluble fraction in 
HTB94 cells: heparin reduced the TCA-soluble fraction by 83 % in HTB94 cells 
compared to a 28 % reduction in MEF-1 cells.  The recovery of the total number 
of counts from the surface-bound, intracellular, TCA-soluble and TCA-insoluble 
counts was similar across all treatments. 
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Figure 57: Heparin more effectively inhibits the clearance of [35S]ADAMTS4-2 by 
HTB94 cells than by MEF-1 cells.   
MEF-1 and HTB94 cells were seeded in a 12-well plate at a density of 0.5x106 cells, 
grown overnight and washed thrice in serum-free DMEM before incubation at 37 ºC in 
DMEM containing 0.1 % BSA with or without heparin (250 µg/ml).   After 1 hour, 
[35S]ADAMTS4-2 (1.5 nM) was added.  After 24 h, the conditioned medium was removed 
and surface bound, intracellular, TCA-soluble and TCA-insoluble fractions were 
harvested as described in section 2.5.2.  Results are an average of 3 wells ± S.D. * = P 
≤ 0.05 as compared to control.  A, Surface-bound counts.  B, Intracellular counts.  C, 
TCA-soluble counts (corrected for TCA-soluble counts in start material).  D, TCA-
insoluble counts.  E, Total surface-bound, intracellular, TCA-soluble and TCA-insoluble 
counts.  The wash fractions were counted and found to be negligible. 
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5.2.3. Endocytosis of methylamine-treated α2M by MEF-1, PEA-13 and 
HTB94 cells  
The aim of the following section was to compare the clearance of ADAMTS4-2 by 
HTB94 cells to the endocytosis of methylamine-treated α2M (α2M*), a well-
studied ligand of LRP-1.  In order to study α2M* endocytosis, α2M* was prepared 
by reacting α2M with 264 mM methylamine-HCl in 100 mM Tris-HCl (pH 8.0) for 1 
h at room temperature.  Tyrosine residues of α2M* were then labeled with 
125I 
using Iodo-Beads.       
 
5.2.3.1. Use of Azocoll substrate to confirm conversion of α2M to α2M*  
Azocoll is an insoluble protein-dye conjugate which can be hydrolysed by a 
variety of proteinases, giving a soluble coloured product which is proportional to 
enzyme activity (Chavira et al., 1984).  α2M inhibits most proteinases irreversibly 
to form an α2M-proteinase complex.  Any proteinase within an α2M-proteinase 
complex is able to cleave low molecular mass substrates but can not cleave 
large substrates such as Azocoll.  Therefore, the addition of α2M to the reaction 
inhibits proteinase-mediated Azocoll cleavage.    However, α2M* can no longer 
bind to proteinases and so addition of α2M* to the reaction does not inhibit 
proteinase-mediated Azocoll cleavage.  To determine whether α2M was 
converted to α2M* by methylamine-HCl treatment, trypsin-mediated cleavage of 
Azocoll and the inhibition of cleavage by α2M but not α2M* was tested.    
 
5.2.3.1.1. Linearity of Azocoll assay 
Before using the Azocoll assay to measure trypsin activity in the presence of 
either α2M or α2M*, the linearity of the assay was determined.  Azocoll substrate 
(0.15 g) was washed with 50 ml of buffer (50 mM Tris-HCl, 1 mM CaCl2, pH 7.8) 
with rotation for 4 h at room temperature.   The suspension was then centrifuged 
and the pellet was resuspended in 30 ml of buffer to give a 5 mg/ml suspension.   
Azocoll (490 µl) was then incubated with either 10 µl of 50 mM Tris-HCl, 1 mM 
CaCl2 (pH 7.8) or trypsin (4 µM in 50 mM Tris-HCl, 1 mM CaCl2, pH 7.8).   At the 
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time intervals indicated, the reaction was stopped by centrifugation and the 
supernatant was transferred to a 96-well plate.  The absorbance of the soluble 
coloured product was read at 550 nm.  The absorbance reading was plotted 
against the time incubated with 50 mM Tris-HCl, 1 mM CaCl2 (pH 7.8), either with 
or without trypsin.   Figure 58A shows that in the absence of trypsin, Azocoll was 
not cleaved but when trypsin was added to the buffer, the substrate was cleaved 
and the cleavage was linear up to 25 min (enlarged view in Figure 58B).  To 
allow for a greater incubation period before stopping the reaction, the 
concentration of trypsin in the reaction was diluted 10-fold with 50 mM Tris-HCl, 1 
mM CaCl2 (pH 7.8).  Figure 58C shows that under these conditions, the assay 
was linear up to 3.5 h (enlarged view in Figure 58D).    As a consequence of 
these results, future experiments were executed using a stock solution of 400 nM 
trypsin.  The reaction was stopped between 90 min – 2 h after addition of Azocoll 
substrate.   
 
5.2.3.1.2. AEBSF and α2M inhibit trypsin-mediated Azocoll cleavage  
The ability of trypsin to cleave Azocoll substrate could be inhibited by incubation 
of the serine protease inhibitor AEBSF (50 mM) with trypsin for 15 min prior to 
the addition of Azocoll substrate (Figure 59A).  In addition, the proteolytic activity 
of trypsin could also be dose-dependently inhibited by α2M (Figure 59B), 
reaching a maximum level of inhibition at an approximate ratio of 1:1 
(α2M:trypsin).  
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Figure 58: Linearity of the Azocoll assay. 
Azocoll was suspended in 0.05 M Tris-HCl, 1 mM CaCl2 (pH 7.8) to give a 5 mg/ml slurry 
whereas trypsin was diluted to either 4 µM or 400 nM in 50 mM Tris-HCl, 1 mM CaCl2 
(pH 7.8).  A, Azocoll (490 µl) was incubated at room temperature with 10 µl of trypsin (4 
µM) or buffer alone (10 µl).  Results are an average of 3 ± S.D.  B, Enlargement of 0 - 25 
min time points.  C, Azocoll (490 µl) was incubated at room temperature with 10 µl of 
trypsin (400 nM).  D, Enlargement of 0 - 3.5 h time points.  At the time intervals 
indicated, the reaction was stopped by centrifugation at 14170 g for 5 min at 4 ºC and 
transfer of the supernatant (150 µl aliquot) to a 96-well plate.  The absorbance was read 
at 550 nm using a FLUOstar Omega (BMG Labtech) plate reader.   
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Figure 59: AEBSF and α2M inhibit trypsin-mediated cleavage of Azocoll.  
Azocoll was suspended in 0.05 M Tris-HCl, 1 mM CaCl2 (pH 7.8) to give a 5 mg/ml slurry 
and trypsin was diluted to 400 nM in 50 M Tris-HCl, 1 mM CaCl2 (pH 7.8).  A, Trypsin 
(10 µl) was incubated with 10 µl of TNC-Brij [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10 
mM CaCl2, 0.02 % sodium azide, 0.02 % Brij-35] or AEBSF (10 µl of 100 mM stock) for 
15 min at room temperature prior to the addition of Azocoll (490 µl).  TNC-Brij (20 µl) 
was the negative control.  The reaction was incubated at room temperature with rotation 
for 90 min before centrifugation at 14170 g for 5 min at 4 ºC and transfer of the 
supernatant (150 µl aliquot) to a 96-well plate.  Results are an average of 3 ± S.D.  B, 
Trypsin (10 µl) was incubated with 10 µl of TNC-Brij or α2M (50 nM, 100 nM, 200 nM, 
300 nM, 600 nM, 1 µM or 2 µM, diluted in TNC-Brij) for 15 min at room temperature prior 
to the addition of Azocoll (490 µl).   The reaction was incubated at room temperature 
with rotation for 2 h before centrifugation at 14170 g for 5 min at 4 ºC and transfer of the 
supernatant (150 µl aliquot) to a 96-well plate.   The absorbance was read at 550 nm 
using a FLUOstar Omega (BMG Labtech) plate reader.  The absorbance was plotted 
against the ratio of α2M:trypsin in the assay.  Results are an average of 2 readings ± 
range.  
 
 
 
5.2.3.1.3. α2M* does not inhibit trypsin-mediated cleavage of Azocoll 
To test that the buffers used to react with α2M did not cause Azocoll hydrolysis, 
Azocoll substrate was incubated with 50 mM TNC-Brij (pH 7.8) or 100 mM Tris-
HCl (pH 8.0) either with or without 264 mM methylamine-HCl.  Azocoll substrate 
was not hydrolysed by any of the buffers tested.  In addition, trypsin cleavage of 
Azocoll was comparable in 100 mM Tris-HCl (pH 8.0) either with or without the 
addition of 264 mM methylamine-HCl (Figure 60A). 
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α2M was incubated with 100 mM Tris-HCl (pH 8) either with or without the 
addition of 264 mM methylamine-HCl.  The final concentration of α2M was 6 µM.  
After 1 h incubation at room temperature, the samples were exchanged into TNC 
buffer with 20 % glycerol [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10 mM CaCl2, 
0.02 % sodium azide, 20 % glycerol] using G-50 Sepharose.  Aliquots of α2M and 
α2M treated with methylamine-HCl were then incubated with trypsin for 15 min at 
room temperature prior to the addition of Azocoll substrate.  As shown in Figure 
60B, the addition of α2M inhibited Azocoll cleavage whereas α2M treated with 
methylamine-HCl did not inhibit Azocoll cleavage.  These results show that α2M 
was converted to α2M* by treatment with methylamine-HCl. 
 
5.2.3.1.4. Heat-induced fragmentation of α2M but not α2M* 
Heating α2M at pH 9.5 with SDS (2 %) and DTT (28 mM) for 30 min at 100 ºC 
generated bands at 125 kDa and 62 kDa (Figure 61).  In contrast, α2M* did not 
generate either the 125 kDa or the 62 kDa band.  This is in accordance with 
published work (Harpel et al., 1979) and further demonstrated α2M was 
converted to α2M* by reaction with methylamine-HCl.         
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Figure 60: α2M* does not inhibit trypsin-mediated cleavage of Azocoll.     
Azocoll was suspended in 0.05 M Tris-HCl, 1 mM CaCl2 (pH 7.8) to give a 5 mg/ml slurry 
and trypsin was diluted to 400 nM in 0.05 M Tris-HCl, 1 mM CaCl2 (pH 7.8).  A, Trypsin 
(8 µl) was incubated with 2 µl of 100 mM Tris-HCl (pH 8) either with or without 264 mM 
methylamine-HCl for 15 min at room temperature prior to the addition of Azocoll 
substrate (490 µl).  Azocoll was not hydrolyzed by TNC-Brij [50 mM Tris-HCl (pH 7.5), 
150 mM NaCl, 10 mM CaCl2, 0.02 % sodium azide, 0.02 % Brij-35] (10 µl) or 100 mM 
Tris-HCl (pH 8.0) either with or without 264 mM methylamine HCl (10 µl).  The reaction 
was incubated at room temperature with rotation for 2 h before centrifugation at 14170 g 
for 5 min at 4 ºC and transfer of the supernatant (150 µl aliquot) to a 96-well plate.  The 
absorbance was read at 550 nm using a FLUOstar Omega (BMG Labtech) plate reader.  
B, α2M was incubated with 100 mM Tris-HCl (pH 8) either with or without 264 mM 
methylamine-HCl (6 µM α2M final concentration) at room temperature.  The samples 
were exchanged into TNC-20 % glycerol buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 
10 mM CaCl2, 0.02 % sodium azide, 20 % glycerol] using G-50 Sepharose and activity 
against trypsin assayed as follows:  Two µl of α2M or α2M* were incubated with 8 µl of 
trypsin for 15 min prior to the addition of Azocoll substrate (490 µl).  Trypsin (8 µl) with 
TNC-Brij (2 µl) was the positive control.  TNC-Brij (10 µl) was the negative control.  The 
reaction was incubated at room temperature with rotation for 2 h before centrifugation at 
14170 g for 5 min at 4 ºC and transfer of the supernatant (150 µl aliquot) to a 96-well 
plate.   The absorbance was read at 550 nm using a FLUOstar Omega (BMG Labtech) 
plate reader.  Results are an average of 3 readings ± S.D.   
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Figure 61: Heat-induced fragmentation of α2M.   
α2M or α2M* (2.2 mg/ml) was incubated with 35 µl of 0.05 M Tris-HCl (pH 9.5), 2 % SDS, 
28 mM DTT and heated at 100 ºC for 30 min.  The samples were analysed by SDS-
PAGE (6 % acrylamide) and stained with Coomassie Brilliant Blue R-250.      
 
5.2.3.2. Iodination of α2M* 
α2M* (100 µg) was iodinated with 
125I using Iodo-Beads.  Excess Na125I or 
unincorporated 125I was separated from iodinated α2M* by gel filtration in TNC-
Brij [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10 mM CaCl2, 0.02 % sodium 
azide, 0.02 % Brij-35] using SephadexG-50 (5 ml column).  Elutions (200 µl) 
were collected and 5 µl aliquots of each elution was analysed by reducing SDS-
PAGE (6 % acrylamide) and silver staining.   
 
[125I]-α2M*, with a molecular weight of approximately 185 kDa, eluted in fractions 
5 to 7 (Figure 62).  However, there were minor bands at a higher molecular 
weight which became more apparent when the gel was exposed to a 
phosphoimaging plate.  This indicates that the sample was not completely 
reduced when analysed by reducing SDS-PAGE as the samples were not boiled 
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for 5 min prior to SDS-PAGE because of the risk of creating volatile 125I under 
these conditions.  Elution 6 was selected for use in subsequent experiments.   
 
 
 
Figure 62: 125I-labeling of α2M* using Iodo-Beads. 
Two iodination beads were washed with 1000 µl PBS to remove any loose particles and 
dried on filter paper.  The beads were then added to carrier-free Na125I (1 mCi/37 MBq) 
in PBS (100 µl).  The beads and carrier-free Na125I were incubated at room temperature 
for 5 min before addition of α2M* (100 µg) to a final volume of 200 µl.  The reaction was 
incubated for 15 min.  Excess Na125I or unincorporated 125I was separated from iodinated 
α2M* by gel filtration into TNC-Brij [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10 mM 
CaCl2, 0.02 % sodium azide, 0.02 % Brij-35] using G-50 Sepharose (5 ml column).  Two 
hundred µl elutions were collected and aliquots (5 µl) were analysed by A, reducing 
SDS-PAGE (6 % acrylamide) and silver staining.  B, the gel was exposed to a 
phosphoimaging plate for 30 min.  e = elution. 
 
 
5.2.3.2.1. Silver stain of [125I]-α2M* to determine concentration 
To determine the approximate concentration of [125I]-α2M* in elution 6, the 
amount of protein was estimated using a standard curve constructed relative to 
known amounts of α2M.  Figure 63 shows a silver stain of increasing amounts of 
α2M (ng) and aliquots of [
125I]-α2M (5 µl and 10 µl).  The gel was scanned and the 
pixel volume of each band was determined using Phoretix software.  Figure 63B 
shows a standard curve of pixel volume of α2M band against amount of α2M (ng) 
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added.  Using the equation y = mx + c, the concentration of [125I]-α2M* was 
calculated to be 50 nM based on the molecular weight of the tetramer (740 kDa).  
 
 
Figure 63: Determination of approximate [125I]-α2M* concentration using α2M 
standard curve. 
The amount of [125I]-α2M* was determined using a standard curve of known amounts of 
α2M.  A, α2M (60-2.5 ng) was analysed by reducing SDS-PAGE (6 % acrylamide) 
together with 5 µl and 10 µl aliquots of [125I]-α2M* from elution 6.  The gel was developed 
by silver staining and scanned.  The pixel volume of each band was determined using 
Phoretix software.  B, Standard curve of pixel volume of α2M band against amount of 
α2M (ng) added.   
 
5.2.3.2.2. Detection limits of [125I]-α2M* counting 
125I emits gamma radiation which can be measured in the absence of scintillation 
fluid using a gamma counter.  In a similar manner to that described in Chapter 3, 
the linear range of [125I]-α2M* detection was determined. To achieve this, [
125I]-
α2M* was serially diluted 1:1 with TNC-Brij and the dilutions were counted. The 
highest radioactivity counted was 700,000 dpm and the readings were linear 
down to 50 dpm (Figure 64).   The amount of 125I incorporation was 10811 
dpm/µg of [125I]-α2M*. 
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Figure 64: Linearity of [125I]-α2M* counting.  
[125I]-α2M* was serially diluted with TNC Brij and the radioactivity was measured using a 
1282 COMPUGAMMA Universal Gamma Counter (Wallac, Pharmacia). 
 
 
5.2.2.3. [125I]-α2M* endocytosis by wild-type and LRP-1-deficient embryonic 
fibroblasts  
To confirm that [125I]-α2M* and RAP were behaving as expected, the endocytosis 
of [125I]-α2M* by either MEF-1 (wild-type) or PEA-13 (homozygous LRP-1-
deficient) cells was assessed.   
 
MEF-1 or PEA-13 cells were incubated with or without RAP (500 nM) for 1 h 
before the addition of [125I]-α2M* (0.05 nM).  After 6 h, the medium was harvested 
and TCA precipitated (3.3 %).  The cell layer was washed thrice with PBS and 
solubilised with 1 M NaOH.  Radioactivity in each fraction was determined by 
gamma counting.  Figure 65 shows that [125I]-α2M* was endocytosed by MEF-1 
but not PEA-13 fibroblasts since MEF-1 cells showed increased radioactivity in 
both the cell-associated and TCA-soluble fractions as well as decreased 
radioactivity in the TCA-insoluble fraction compared to PEA-13 cells.  In addition, 
when MEF-1 cells were treated with RAP, both the cell-associated and TCA-
soluble fractions harvested from MEF-1 cells were reduced by 60 % and 80 %, 
respectively.  RAP reduced both the cell-associated and TCA-soluble fractions to 
to levels similar to those of PEA-13 cells.  Furthermore, the amount of TCA-
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insoluble radioactivity harvested from RAP-treated MEF-1 cells was similar to the 
TCA-insoluble fraction from PEA-13 cells.  In contrast, treatment with RAP had 
no effect on any of the fractions harvested from PEA-13 cells.  The recovery of 
the total number of counts from the cell-associated, TCA-soluble and TCA-
insoluble counts was similar across all treatments.   
 
5.2.2.4. [125I]-α2M* endocytosis by HTB94 cells and the effect of RAP 
HTB94 cells were incubated with or without RAP (500 nM) for 1 h before the 
addition of [125I]-α2M* (0.025 nM).  After 6 h or 24 h, the medium was harvested 
and TCA precipitated (3.3 %).  The cell layer was washed thrice with PBS and 
solubilised with 1 M NaOH.  Radioactivity in each fraction was determined by 
gamma counting.  Figure 66 shows that upon addition of [125I]-α2M* to HTB94 
cells, the TCA-soluble fraction increased and the TCA-insoluble fraction 
decreased with time.  RAP reduced the amount of cell-associated radioactivity at 
both 6 h and 24 h.  Additionally, RAP reduced the TCA-soluble fraction by 50 % 
at both 6 h and 24 h.  There was no significant change in the TCA-insoluble 
fraction by RAP at 6 h but RAP partially blocked the clearance of TCA-insoluble 
[125I]-α2M* at 24 h.  In addition, RAP did not completely protect against the 
appearance of the TCA-soluble fraction at either 6 h or 24 h.   The recovery of 
the total number of counts from the cell-associated, TCA-soluble and TCA-
insoluble counts was similar across all treatments.   
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Figure 65: [125I]-α2M* endocytosis by MEF-1 and PEA-13 cells.   
MEF-1 and PEA-13 cells were seeded in a 12-well plate at a density of 0.5x106 cells, 
grown overnight and washed thrice in serum-free DMEM before incubation at 37 ºC in 
DMEM containing 0.1 % BSA with or without RAP (500 nM).  After 1 hour, [125I]-α2M* 
(0.05 nM) was added.  After 6 h, the conditioned medium was removed and cell-
associated, TCA-soluble and TCA-insoluble fractions were harvested as described in 
section 2.5.2.  Results are an average of 2 wells ± range.  A, Cell-associated counts.  B, 
TCA-soluble counts (corrected for TCA-soluble counts in start material). C, TCA-
insoluble counts.  D, Total cell-associated, TCA-soluble and TCA-insoluble counts.  The 
wash fractions were counted and found to be negligible. 
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Figure 66: [125I]-α2M* endocytosis by HTB94 cells.   
HTB94 cells  were seeded in a 12-well plate at a density of 0.5x106 cells, grown 
overnight and washed thrice in serum-free DMEM before incubation at 37 ºC in DMEM 
containing 0.1 % BSA with or without RAP (500 nM).  After 1 hour, [125I]-α2M* (0.025 nM) 
was added.  After 6 h or 24 h, the conditioned medium was removed and cell-
associated, TCA-soluble and TCA-insoluble fractions were harvested as described in 
section 2.5.2.  Results are an average of 2 wells ± range.  A, Cell-associated counts.  B, 
TCA-soluble counts (corrected for TCA-soluble counts in start material). C, TCA-
insoluble counts.  D, Total cell-associated, TCA-soluble and TCA-insoluble counts.  The 
wash fractions were counted and found to be negligible. 
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5.3. Discussion 
In this chapter, the role of the LDL-R family in the clearance of ADAMTS-4 by 
HTB94 cells was investigated.  RAP blocked the clearance of [35S]ADAMTS4-2 
from the medium exposed to HTB94 cells and also from the medium exposed to 
both porcine and human chondrocytes.  The clearance of [35S]ADAMTS4-5 by 
HTB94 cells was also inhibited by RAP.  This indicates that neither the cysteine-
rich, thrombospondin type-1 or disintegrin domain of ADAMTS-4 are essential for 
RAP-sensitive ADAMTS-4 clearance by HTB94 cells.  However, RAP showed 
greater protection against the appearance of the TCA-soluble fraction with 
[35S]ADAMTS4-5 than [35S]ADAMTS4-2.  However, the level of protection by 
RAP also varied between HTB94 cells and chondrocytes.  Since there is 
variability in these results, it will be important to investigate the protective effect 
of RAP further by experimental repetition.  Experiments at 4 ºC indicated that 
RAP did not affect surface binding of [35S]ADAMTS4-2.  In this regard, RAP has 
been shown to have no effect on the binding of [125I]-pro-MMP-2:TIMP-2 to 
HT1080 cells.  However, RAP reportedly inhibits endocytosis of the complex 
suggesting that an unknown RAP-insensitive co-receptor may be involved in the 
initial binding to the cells surface, followed by RAP-sensitive endocytosis 
mediated by LRP-1 (Emonard et al., 2004).  Additionally, although internalisation 
of MMP-13 is via the LRP-1 receptor, MMP-13 binds to wild-type (MEF-1) and 
LRP-1-null (MEF-2) cells at equal levels, suggesting that the LRP-1 receptor is 
not involved in the primary binding of MMP-13 to the cell surface (Barmina et al., 
1999).  Ca2+ is necessary for MMP-13 binding to an unidentified 170 kDa 
receptor before transfer to the LRP-1 receptor (Barmina et al., 1999).  Future 
work would be to conduct a binding assay in the presence and absence of Ca2+ 
to investigate whether binding of [35S]ADAMTS4-2 to the surface of HTB94 cells 
is dependent on this ion.   
 
The possibility that RAP inhibited ADAMTS-4 clearance by compromising cell 
viability was ruled out because incubation of HTB94 cells with RAP for 24 h had 
no effect on cell viability assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
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tetrazolium bromide (MTT) assay.  Future work would be to measure the effect of 
RAP and other agent tested in this study on cell apoptosis by staining cells with 
FITC conjugated-annexin V and propidium iodide or by TUNEL staining.  
Additionally, to confirm that ADAMTS-4 clearance is inhibited by a mechanism 
that is absolutely due to the action of RAP, one could test whether the His-tag 
alone has any effect on ADAMTS-4 clearance.   In view of the data presented in 
Chapter 4, where GM6001 was found to block ADAMTS4-2 clearance, the effect 
of RAP in combination with GM6001 on ADAMTS4-2 clearance by HTB94 cells 
should also be assessed.      
 
The role of LRP-1 in the clearance of ADAMTS4-2 was examined because RAP 
blocks the endocytosis of all known LRP-1 ligands (Herz et al., 1991) although it 
also competes for the binding of ligands to several receptors of the LDL-R family 
aside from LRP-1 (Bu, 1998; Herz et al., 1991). The first approach was to 
knockdown the expression of LRP-1 in HTB94 cells using siRNA.  In a 24 h 
experiment, knockdown of LRP-1 expression by more than 50 % had no effect on 
the clearance of [35S]ADAMTS4-2 compared to cells transfected with control 
siRNA.  These data indicate that LRP-1 does not mediate the cellular uptake and 
clearance of ADAMTS4-2 by HTB94 cells.   Future work would be to harvest the 
medium at earlier time points because during the course of the experiment (24 
h), the expression of LRP-1 in cells treated with LRP-1 siRNA increased 
compared to the expression of LRP-1 at the start of the experiment.  
Alternatively, the efficiency of LRP-1 knockdown may be improved using vector-
based short hairpin RNA (shRNA) system.  Dedieu et al (Dedieu et al., 2008) 
reported the efficiency of shRNA knockdown of LRP-1 in FTC133 cells (human 
follicular thyroid carcinoma cells) to be greater than 90 % compared to a 70 % 
efficiency using siRNA.  Nonetheless, it would also be informative to assess the 
effect of RAP on the clearance of ADAMTS4-2 by HTB94 cells where LRP-1 
expression was attenuated by either approach as this may reveal whether an 
LRP-1-independent but RAP-dependent mechanism of ADAMTS4-2 clearance 
exists in HTB94 cells.   
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To further investigate whether LRP-1 mediates ADAMTS4-2 endocytosis, the 
clearance of ADAMTS4-2 by wild-type mouse embryonic fibroblasts (MEF-1) and 
LRP-1-deficient mouse embryonic fibroblasts (PEA-13) was compared.  The 
uptake of ADAMTS4-2 from the medium was found to be similar in both cell 
types.     In contrast, RAP, uPA/PAI-1 complexes or α2M* are not endocytosed by 
PEA-13 cells although they are endocytosed by MEF-1 cells (Willnow and Herz, 
1994).  The results reported herein suggest that ADAMTS4-2 is not a ligand for 
LRP-1.  The effect of RAP on the clearance of ADAMTS4-2 by either MEF-1 cells 
or PEA-13 cells would not yield any additional information since ligand blotting 
experiments have shown that RAP does not bind to any other membrane protein 
in PEA-13 fibroblasts (Willnow and Herz, 1994).  This suggests that LRP-1 is the 
only RAP-binding LDL-R family member expressed in embryonic fibroblasts.   
However, this experiment should be conducted in order to confirm this.    
 
Although a similar amount of intact [35S]ADAMTS4-2 disappeared from the 
medium of MEF-1 cells compared to HTB94, the protective effect of heparin was 
more pronounced in HTB94 cells.  This suggests that the mechanism of 
[35S]ADAMTS4-2 clearance may differ between these cell types and that HTB94 
cells may be more dependent on HSPGs than MEF cells, for example.  It would 
be informative to compare the expression of HSPGs such as perlecan, 
syndecans and glypicans between these cell types.    
 
To confirm that the MEF-1 and PEA-13 cells were behaving as expected and to 
ensure that the preparation of RAP inhibited LRP-1-mediated endocytosis, the 
endocytosis of [125I]-α2M* was assessed.  More [
125I]-α2M* was endocytosed by 
MEF-1 cells compared to PEA-13 cells and RAP inhibited the uptake of [125I]-
α2M* in MEF-1 cells but had no effect in PEA-13 cells.  This shows that the cells 
were behaving as expected and that the preparation of RAP inhibited LRP-1 
mediated endocytosis of [125I]-α2M*.   However, the TCA-soluble fraction of MEF-
1 cells treated with RAP or of PEA-13 cells either with or without RAP increased 
during the course of the experiment compared to the amount of TCA-soluble 
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radioactivity at the start of the experiment.  This suggests that an LRP-1 
independent mechanism of [125I]-α2M* degradation exists.  The results reported 
here are contrary to a study demonstrating that LRP-1 is the only receptor 
mediating the uptake of [125I]-α2M* in mouse embryonic fibroblasts (Willnow and 
Herz, 1994). 
 
 [125I]-α2M* endocytosis by HTB94 cells was also assessed after 6 h and 24 h 
incubation. TCA-soluble radioactivity increased in the medium of HTB94 cells 
with incubation and was in part inhibited by RAP.  The effect of RAP on the TCA-
insoluble fraction was not significant at 6 h but RAP inhibited the TCA-insoluble 
fraction at 24 h.  However, RAP was not fully protective against [125I]-α2M* 
disappearance, supporting the hypothesis that an LRP-1-independent 
mechanism of [125I]-α2M* endocytosis and intracellular degradation may exist in 
HTB94 cells.  This is also contrary to reports that endocytosis of [125I]-α2M* is 
unique to LRP-1 (Willnow and Herz, 1994).   
 
Future work to yield information about the mechanism of ADAMTS4-2 clearance 
would be to compare the rate of ADAMTS4-2 clearance by HTB94 cells to that of 
α2M*.   Since α2M* was labeled with 
125I, preparing [125I]-ADAMTS4-2 would 
ensure that the sensitivity of detection could be comparable between proteins.  
As a first step to this goal, ADAMTS4-2 was subject to iodination following the 
same method used to prepare [125I]-α2M*.  However, iodination of ADAMTS4-2 
yielded an inactive enzyme, possibly due to the harsh oxidation conditions of the 
reaction.  Further attempts to maintain enzyme activity upon iodination, by 
reducing the incubation time of the iodination reaction for example could be 
attempted.   
 
The data presented in this chapter support a RAP-sensitive mechanism of 
ADAMTS-4 clearance by HTB94 cells.  However, RAP only inhibits partially, so 
RAP-insensitive mechanisms also exist. As previously mentioned, pressing work 
will be to test the effect of RAP in combination with GM6001 to determine 
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whether RAP-insensitive, GM6001-insensitive mechanisms of ADAMTS-4 
clearance exist before conducting further studies.  In addition to binding to LRP-
1, RAP binds to other members of the LDL-R family.  For example, RAP also 
binds to megalin (LRP-2) (Kounnas et al., 1992b) and VLDL-R (Battey et al., 
1994) with high affinity although it binds the LDL-R weakly (Medh et al., 1995).  
Given the data suggesting that LRP-1 knockdown in HTB94 cells or genetic 
deficiency of LRP-1 in embryonic fibroblasts does not prevent ADAMTS-4 
clearance, it is hypothesised that RAP may inhibit ADAMTS-4 cellular uptake 
mediated by another member of the LDL-R family.  Additionally, RAP has been 
reported to bind to other receptors, including cubilin (Birn et al., 1997), sortilin   
(Petersen et al., 1997; Tauris et al., 1998) and lipolysis-stimulated receptor 
(Troussard et al., 1995).  Furthermore, the C-terminal domain of RAP also binds 
to heparin (Orlando and Farquhar, 1993, 1994), suggesting that RAP could 
inhibit the clearance of ADAMTS4-2 by HTB94 cells and chondrocytes by binding 
to HSPGs at the cell surface.  
  
To further investigate this hypothesis, the identification of proteins in cell 
membrane extracts capable of binding to ADAMTS-4 would be informative.  Cell 
membrane extracts from HTB94 cells could be separated under conditions of 
non-reducing SDS-PAGE followed by transfer to PVDF membrane.  The 
membrane could then be subjected to ligand binding using [125I]-ADAMTS4-2, 
which would offer increased sensitivity over [35S]ADAMTS4-2.    Potential cell 
surface ADAMTS-4 binding proteins could also be identified by 
immunoprecipitation using an ADAMTS-4 antibody or ADAMTS-4 could be 
immobilized onto a resin and the membrane extract passed over the resin.  Any 
bound proteins could be identified by SDS-PAGE followed by mass 
spectrometry.  Alternatively, cell membrane extracts could be used in ligand 
binding experiments with RAP to determine RAP-binding proteins.  This may 
reveal which proteins RAP interacts with to inhibit [35S]ADAMTS4-2 cellular 
uptake and clearance by HTB94 cells.  Another strategy would be to identify 
which members of the LDL-R family HTB94 cells express and then perform 
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knockdown studies to determine the effect of each receptor on the ADAMTS4-2 
clearance.   
 
In summary, the results reported herein have eliminated the role of LRP-1 in the 
clearance of ADAMTS-4 by HTB94 cells and suggest that other RAP-binding 
proteins such as another member of the LDL-R family may be responsible.   
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As discussed in Chapter 1, ADAMTS-4 is one of several members of the 
ADAMTS family with the ability to cleave the IGD domain of aggrecan at the 
Glu373-Ala374 bond.  Although both ADAMTS-4 and ADAMTS-5 were initially 
purified from IL-1α-stimulated cartilage explants, suggesting that they both may 
be involved in cartilage matrix degradation, studies in knockout mice have 
indicated that ADAMTS-5 may be a more important aggrecanase in the 
progression of osteoarthritis, at least in the mouse (Glasson et al., 2005; Stanton 
et al., 2005).  However, siRNA knockdown of either ADAMTS-4 or ADAMTS-5 
reduced aggrecan degradation in both OA and normal human cartilage 
stimulated with TNFα or oncostatin M (Song et al., 2007).  In addition, a recent 
study using immunohistochemistry techniques showed that ADAMTS-4 was 
detected in human OA chondrocytes and not control cartilage and that the 
expression of ADAMTS-4 was increased with disease severity (Cheung et al., 
2009).  Furthermore, the expression of ADAMTS-4 correlated with de-
methylation of CpG sites within the ADAMTS-4 promoter region, suggesting that 
ADAMTS-4 is epigenetically regulated.  Together, these studies suggest that 
degradation of aggrecan by ADAMTS-4 could contribute to human OA.      
 
Whilst the activity of ADAMTS-4 can be regulated in a number of ways including 
gene expression, prodomain removal, C-terminal processing and inhibition by 
TIMP-3, the focus of this thesis was to assess whether endocytosis of ADAMTS-
4 from the extracellular milieu could be an additional mechanism regulating 
ADAMTS-4 activity in the ECM.  Further research into the mechanisms by which 
ADAMTS-4 activity may be regulated is essential in order to understand the role 
of ADAMTS-4 in the progression of osteoarthritis.  In addition, such work may 
ultimately assist with the development of agents to prevent and/or delay the 
onset of arthritic disease.   
 
To determine whether ADAMTS-4 could be endocytosed, I first assessed 
whether exogenously added ADAMTS4-2, a truncated form of full-length 
ADAMTS-4 lacking the C-terminal spacer domain, could disappear from the 
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medium of HTB94 chondrosarcoma cells (Chapter 3).  I discovered that 
ADAMTS4-2 disappeared from the medium of HTB94 cells over time and 
fluorescent-labeled ADAMTS4-2 could be detected within the cell by confocal 
microscopy.  Further study using a radioactive-based assay (Chapter 4 & 5) 
showed that the clearance of ADAMTS4-2 by HTB94 cells was reduced by 
hydroxamate-based metalloproteinase inhibitors (e.g. GM6001), cytochalasin D 
and sulfated GAGs such as heparin and calcium pentosan polysulfate.  In 
addition, I identified that the clearance of ADAMTS4-2 was partially dependent 
on cell surface HSPGs as well as the LDL receptor family antagonist RAP.  
Although the majority of this work was conducted using ADAMTS4-2, a limited 
number of experiments using the catalytic domain of ADAMTS-4 alone 
(ADAMTS4-5) showed that the clearance of ADAMTS-4 by HTB94 cells is not 
dependent on sites within the ancillary domain.  The uptake of the catalytic 
domain of ADAMTS-4 was also partially inhibited by heparin, GM6001 or RAP.  
As previously discussed in Chapter 4, future work will be to determine whether 
full-length ADAMTS4 (ADAMTS4-1) is endocytosed by HTB94 cells, particularly 
given that ADAMTS4-1 has high affinity for the ECM and cell surface (Kashiwagi 
et al., 2004).   
 
RAP binds to LRP-1, one of several members of the LDL receptor family with 
high affinity, inhibiting the uptake of several LRP-1 ligands (Bu et al., 1992; Herz 
et al., 1992; Nykjaer et al., 1992).  However, the work presented in this thesis 
showed that ADAMTS4-2 clearance was not blocked by LRP-1 deficient cells 
compared to wild-type cells nor by siRNA knockdown of LRP-1 expression in 
HTB94 cells.  This suggests that another member of the LDL receptor family 
aside from LRP-1 may be responsible for mediating the clearance of ADAMTS4-
2 by HTB94 cells.  This is supported by studies in which RAP has been shown to 
bind to other members of the LDL receptor family with high affinity including 
megalin (Kounnas et al., 1992a), VLDL-R (Battey et al., 1994), apoER2 
(Stockinger et al., 1998) and sorLA/LR11 (Jacobsen et al., 1996).  Future work 
would be to determine which members of the LDL receptor family aside from 
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LRP-1 are expressed by HTB94 cells and perform knockdown experiments to 
determine whether any of them mediate ADAMTS4-2 cellular uptake and 
degradation.  RAP, in addition to binding to members of the LDL receptor family 
also binds directly to heparin via residues within the C-terminal domain (Orlando 
and Farquhar, 1993, 1994), suggesting that RAP could inhibit ADAMTS4-2 
cellular uptake by HTB94 cells and chondrocytes by binding to an unidentified 
HSPG receptor at the cell surface, displacing bound ADAMTS4-2.   However, in 
our experiments, RAP did not affect the binding of ADAMTS4-2 to the cell 
surface at 4 ºC suggesting that a RAP-insensitive co-receptor is involved in the 
initial binding of ADAMTS4-2 to the cell surface, followed by RAP-sensitive 
endocytosis, as has been described for MMP-2 (Emonard et al., 2004) and MMP-
13 (Barmina et al., 1999).  Alternatively, the role of other receptors in the cellular 
uptake of ADAMTS-4 should also be considered since RAP also binds to several 
other receptors including lipolysis-stimulated receptor (Troussard et al., 1995), 
cubilin (Birn et al., 1997) and sortilin (Petersen et al., 1997; Tauris et al., 1998), 
for example.   
 
The data presented in this thesis indicate that metalloproteinase-mediated 
degradation of ADAMTS-4 at the cell surface may account for as much as 50 % 
of ADAMTS-4 clearance by HTB94 cells.  Pressing work will be to determine the 
effect of GM6001 on the cellular uptake and degradation of ADAMTS4-2 by 
HSPGs-deficient CHO745 cells compared to wild-type cells, in both the presence 
and absence of RAP.  This experiment may enable the relative contribution of 
each pathway to be assessed and conclusively determine whether the clearance 
of ADAMTS4-2 from the medium of HTB94 cells in the presence of RAP is in fact 
due to metalloproteinase-mediated degradation at the cell surface. 
     
In view of the observation that the clearance of ADAMTS-4 from the medium of 
HTB94 cells can be inhibited by GM6001, published studies investigating LRP-1 
mediated endocytosis have reported that the activity of the LRP-1 receptor can 
be regulated by MT1-MMP in malignant cells (Rozanov et al., 2004).   MT1-MMP 
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proteolysis of LRP-1 was reported to inactivate the ligand binding domain of 
LRP-1 and inhibit the internalisation of LRP-1 ligands whilst GM6001 blocked 
MT1-MMP-mediated proteolysis of LRP-1. Although the effect of GM6001 on 
ligand endocytosis was not directly assessed in the published study, I 
hypothesize that GM6001 would enhance the endocytosis of LRP-1 ligands by 
inhibiting LRP-1 shedding from the cell surface.  This is in contrast with the effect 
of GM6001 on the clearance of ADAMTS-4 by HTB94 cells reported in this thesis 
and further suggests that LRP-1 is not involved in the mechanism of ADAMTS-4 
clearance reported herein.   
 
A RAP-dependent mechanism of MMP-13 endocytosis exists in human 
chondrocytes although the receptor was identified to be LRP-1 since the 
internalisation of MMP-13 from the medium was reduced by LRP-1-deficient cells 
compared to wild type cells (Barmina et al., 1999).  A subsequent study 
demonstrated that MMP-13 internalisation from the medium was reduced by OA 
chondrocytes suggesting that impaired MMP-13 internalisation could contribute 
to cartilage matrix degradation in OA (Walling et al., 2003).  Since the data 
presented herein suggest that ADAMTS-4 is regulated by endocytosis, further 
study would be to determine whether ADAMTS-4 endocytosis is different 
between healthy and OA chondrocytes, as is the case for MMP-13.  If so, it 
would be of interest to determine the relative importance of impaired ADAMTS-4 
internalisation compared to that of MMP-13 internalisation in the development 
and progression of OA.       
 
The HSPG-dependent mechanism of ADAMTS-4 endocytosis will also be the 
subject of future study.  Whilst HSPGs have been suggested to be co-receptors 
for the endocytosis of some LRP-1 ligands, they have also been identified as 
independent receptors mediating the endocytosis of bound ligands as part of the 
normal HSPG turnover on the cell surface.  For example, the HSPG perlecan has 
been shown to mediate the uptake of HIV-1 Tat, a transcriptional transactivator of 
the HIV-1 virus (Argyris et al., 2004).  However, only a small amount of HIV-1 Tat 
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protein was degraded, which suggests that perlecan-mediated internalisation of 
HIV-1 Tat does not deliver HIV-1 Tat to the lysosomes.  Fuki et al reported that 
the syndecan family of proteoglycans internalise lipoprotein lipase (LpL)-enriched 
low density lipoprotein (LDL) via a mechanism independent to the LRP-1 
pathway (Fuki et al., 1997) but dependent on cholesterol-rich membrane rafts 
(Fuki et al., 2000b).  In addition, perlecan has been reported to mediate the 
endocytosis of LpL-enriched LDL independent to either syndecan or LRP-1, via a 
mechanism sensitive to the tyrosine kinase inhibitor genistein (Fuki et al., 2000a).  
Since the chondrocyte pericellular matrix is rich in perlecan (Melrose et al., 
2006), experiments to determine whether perlecan mediates the clearance of 
ADAMTS-4 from the medium of HTB94 cells and chondrocytes will be an 
interesting line of future study.   
 
Our group has recently reported that endogenous TIMP-3 accumulated in HTB94 
cells upon treatment with heparin (Troeberg et al., 2008) and unpublished work 
within our laboratory has also shown that exogenously added TIMP-3 clears from 
the medium of HTB94 cells in a manner similar to that observed with 
exogenously added ADAMTS4-2, with both heparin and RAP also inhibiting 
TIMP-3 clearance.  These findings suggest that ADAMTS4-2 and TIMP-3 may be 
regulated in the same way.  TIMP-3 contains heparin-binding domains and binds 
sulfated GAGs of the ECM (Yu et al., 2000) and also binds to ADAMTS-4 with 
high affinity (Kashiwagi et al., 2001).  As depicted in Figure 67, it is possible that 
ADAMTS4-2 could be internalized in a complex with TIMP-3.  This hypothesis is 
based on the observations that ADAMTS4-2 does not bind heparin-Sepharose 
and the major GAG binding sites of ADAMTS-4 have been mapped to the spacer 
domain, which is absent from ADAMTS4-2.  Without considering the possibility 
that ADAMTS-4 is internalised in a complex with TIMP-3, it is difficult to explain 
why heparin inhibits the clearance of ADAMTS-4 by HTB94 cells.  If internalised 
as a complex, this observation could be explained by the possibility that heparin 
blocks the association between TIMP-3 and cell surface HSPGs.   I also 
considered this hypothesis because the LRP-1 ligands MMP-2 and -9 can be 
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internalized alone or in complex with TIMP-2 or TIMP-1, respectively (Emonard 
et al., 2004; Hahn-Dantona et al., 2001). Thus, I further hypothesize that whilst 
GM6001 may inhibit metalloproteinase-mediated proteolysis of ADAMTS-4 at the 
cell surface, GM6001 may also inhibit endocytosis by disrupting the interaction 
between the ADAMTS-4 and TIMP-3 complex.  RAP may inhibit the clearance of 
ADAMTS-4 by HTB94 cells and chondrocytes by disrupting the interaction of the 
ADAMTS-4-TIMP-3-HSPG complex with a RAP-sensitive, as yet unidentified 
endocytic receptor.  Although I have eliminated LRP-1 as the RAP-sensitive 
receptor in this mechanism, further work to validate the ADAMTS-4-TIMP-3 
complex hypothesis would be to first determine whether exogenous TIMP-3 can 
be endocytosed by LRP-1 using LRP-1 wild-type and knockout cells.  In this 
study, I conducted preliminary experiments to determine whether ADAMTS-4 
could be internalised in the absence of TIMP-3 by investigating the clearance of 
ADAMTS4-2 by wild-type and Timp-3-null mouse dermal fibroblasts.  However, 
these experiments were preliminary and very little intact ADAMTS4-2 
disappeared from the medium during culture.  Heparin had a greater inhibitory 
effect than GM6001, reducing the TCA-soluble fraction by more than 95 %, 
GM6001 reduced the TCA-soluble fraction by 68 % in wild-type cells and by 40 
% in Timp-3-null cells.  However, the differential effect of GM6001 between wild-
type and Timp-3-null cells suggests that a mechanism whereby ADAMTS-4 is 
endocytosed as a complex with TIMP-3 may exist.  The cell-associated fraction 
was increased in control wild-type cells compared to control Timp-3-null cells and 
heparin and GM6001 reduced the amount of cell-associated radioactivity in wild-
type fibroblasts but had no effect on the cell-associated fraction from Timp-3-null 
fibroblasts.  This suggests that [35S]ADAMTS4-2 may interact with cell surface 
TIMP-3.  However, it is clear that more work will be required in order to determine 
whether ADAMTS-4 is actually endocytosed in a complex with TIMP-3.  An 
alternative approach other than using Timp-3-null fibroblasts may be to 
knockdown the expression of TIMP-3 in HTB94 cells by siRNA.    
 
Chapter 6                                                                                                Discussion                                              
 
 195 
Figure 67 summarizes the possible mechanisms by which ADAMTS-4 clearance 
by HTB94 cells and chondrocytes may be inhibited by GM6001, heparin and 
RAP.  However, it is likely that more than one mechanism of ADAMTS-4 
clearance exists and that cell surface metalloproteinase-mediated degradation of 
ADAMTS-4 in addition to RAP-sensitive and/or HSPG-sensitive mechanisms 
each contribute to the cellular uptake and clearance of ADAMTS-4 by HTB94 
cells and chondrocytes reported in this study.  
 
Concluding remarks 
The work described in this thesis has identified a novel mechanism of ADAMTS-
4 regulation by HTB94 cells and chondrocytes.  These results indicate that 
ADAMTS4-2 is cleared from the medium by HTB94 cells and chondrocytes via a 
mechanism that is sensitive to hydroxamate-based metalloproteinase inhibitors, 
HSPGs and the LDL receptor family antagonist RAP.  It will be important to 
investigate whether the endocytosis of ADAMTS-4 changes with age and/or with 
the development of OA as well as extending the study to other aggrecanases, 
notably ADAMTS-5.  Additionally, endocytosis may be a general mechanism 
regulating ADAMTS activity in tissues other than cartilage.  For example, as the 
expression of both ADAMTS-4 and -5 have been reported to be increased in 
human glioblastomas (Held-Feindt et al., 2006; Matthews et al., 2000; Nakada et 
al., 2005), it is tempting to suggest that impaired endocytosis of either/both 
enzymes may contribute to their invasive potential in the brain.  Whilst the results 
reported within this thesis provide the first steps to understanding the regulation 
of ADAMTS-4 activity by endocytosis, studies are required to further understand 
the role of HSPGs in this process.  Further work to characterize the RAP-
sensitive mechanism of ADAMTS4-2 clearance in addition to addressing whether 
impaired endocytosis of ADAMTS-4 contributes significantly to the development 
of osteoarthritis are also important questions worthy of further investigation.      
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Figure 67: Hypothetical mechanism of ADAMTS-4 clearance by HTB94 cells and 
chondrocytes. 
I propose that ADAMTS-4 may be endocytosed in a complex with TIMP-3.  The complex 
first binds to cell surface HSPGs via interaction with TIMP-3 and is then transferred to a 
second receptor which mediates internalisation.  A, GM6001 may inhibit ADAMTS-4 
proteolysis at the cell surface and/or B, disrupt the formation of the ADAMTS-4-TIMP-3 
complex.  This reduces TIMP-3 uptake from the medium and intracellular degradation.  
C, I propose that heparin inhibits internalisation of the complex by preventing the binding 
of TIMP-3 to HSPGs whilst D, RAP inhibits the internalisation of the ADAMTS-4-TIMP-3-
HSPG complex by preventing the interaction between the complex and an unidentified 
RAP-sensitive endocytic receptor.  As depicted here, HSPGs may be endocytosed in a 
complex with receptor x.  Alternatively, they may mediate transfer to receptor x and 
remain on the cell surface.  
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